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DEVELOPMENT  OF  A  SENSITIVE  CELL  CULTURE  SYSTEM  TO  ASSESS 
PRION  INFECTIVITY  AND THE EFFICACY OF  PRION DECONTAMINATION 
TECHNOLOGIES 
by Thomas James Secker 
 
Creutzfeldt-Jakob disease (CJD) can be iatrogenically transmitted during transplants, grafts 
and transfusions from CJD infected donors and also contaminated surgical instruments. A 
variety  of  methods  to  amplify  and  detect  the  presence  of  infectious  prions  as  disease 
markers are available. However, these techniques do not measure the infectivity potentially 
associated with these markers. Currently, animal-bioassays are used to detect infectivity; 
however, they have limitations in detectable prion strains, cost, ethical considerations and 
assay  length.  Novel  cell-based  infectivity  assays  offer  the  potential  to  overcome  these 
limitations, lower the requirements for animal use and the application of different cell lines 
could detect a wider range of prion strains. This project utilised murine neuroblastoma, N2a 
#58 cells infected with 22L-murine scrapie to develop a highly sensitive assay for the in situ 
detection of amyloid-rich prion (PrP
Sc) accumulation as an indication of prion infectivity. 
The autofluorescence quenching properties of Sudan black (SB) were incorporated into a 
novel Thioflavin T (ThT) based protocol for amyloid staining with improved specificity and 
sensitivity.  Cell  passages  were  incorporated  into  the  assay  to  increase  incubation  time, 
improve cell viability and subsequently improve assay sensitivity; thus, demonstrating the 
detection  of  infectivity  from  a  final  10
-10  dilution  of  22L-infected  brain  homogenate. 
Introduction of 22L-inoculated, surgical grade stainless steel wires to the N2a #58 cells 
demonstrated  the  SB/ThT  detection  of  prion  infectivity  pre  and  post  decontamination, 
which  was  comparable  to  animal  bioassay  data.  Furthermore,  preliminary  work  on  the 
incorporation of the SB/ThT detection of prion infectivity within neural stem cells (NSC’s), 
for  prion  propagation  within  a  cell  line  that  did  not  require  genetic  manipulation  for 
increased prion susceptibility, highlighted problems with unspecific fluorescence of dead 
cells  during  NSC  differentiation.  Improvements  in  culture  conditions  of  the  NSC’s 
regarding atmospheric conditions and trophic support were addressed in preparation for 
their use in future prion infectivity assays.         iv
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Chapter 1 
 
General introduction      2 
     3 
1.1 Introduction 
 
Transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob 
disease (CJD) in humans are a group of neurodegenerative diseases characterised by the 
accumulation  of  the  infectious,  misfolded  prion  protein  (Prusiner  1998).  The  prion 
associated “protein only” hypothesis describes the basis of protein aggregation in TSE’s 
as  an  autocatalytic  conversion  of  the  α-helical,  host  encoded  cellular  prion  protein 
(PrP
c)  to  form  the  infectious,  β-pleated  sheet  isoform  (designated  PrP
sc  or  PrP
res) 
(Prusiner 1998, Weissmann et al. 2002).
 The main cause of neurodegeneration in TSE’s 
is  thought  to  be  the  aggregation  of  PrP
Sc  which  accumulates  as  PrP
Sc  rich  amyloid 
fibrillar  plaques  thus  altering  the  normal  morphology  of  the  brain  tissue  leading  to 
degeneration of neuronal pathways, causing the associated symptoms of dementia. Post-
mortem microscopic evaluation of the brains of infected patients typically demonstrates 
several  common  diagnostic  traits  associated  with  protein  aggregation  in  TSE’s 
including spongiform degeneration, caused by cell death leading to degeneration of the 
normal tissue morphology, the accumulation of PrP
Sc and astrocytic gliosis (Prusiner 
1997).   
 
The accumulation of the mis-folded prion protein is implicated in a broad range 
of TSE’s across a number of mammalian species. The range of TSE’s associated with 
PrP
Sc deposition and potentially caused by accumulation of the infectious prion protein 
include;  Creutzfeldt-Jakob  disease  (CJD),  Kuru  and  Gerstmann-Straussler-Scheinker 
syndrome (GSS) affecting humans, Bovine spongiform encephalopathy (BSE) affecting 
cattle, scrapie affecting sheep and chronic wasting disease (CWD) effecting elk and 
deer,  alongside  a  number  of  less  common  TSE  diseases.  All  of  these  TSE’s  have 
varying routes of transmission which are summarised in Table 1.  
   4 
   
 
Table 1 – Transmissible spongiform encephalopathies 
Comparison of Transmissible spongiform encephalopathies (TSE) and their varying mechanisms of transmission (Adapted from Collinge 2001, Prusiner 1997). 
TSE  Species    Mechanism of Transmission 
Kuru  Human 
  Transmission of infectious prions from cannibalistic rituals, thought to be the 
earliest link to CJD. 
Sporadic CJD (sCJD)  Human    The spontaneous formation of infectious PrPSc caused by a mutation in the 
prion protein gene (PRNP gene). 
Familial CJD (fCJD)  Human    A genetic variation of CJD caused by a mutation in the PRNP gene that can 
potentially be passed to offspring. 
Variant CJD (vCJD)  Human    Horizontal transmission of infectious prions from BSE infected matter to 
humans. 
Iatrogenic CJD (iCJD)  Human    Transmission of infectious material via medical accidents including 
neurosurgery and infected tissue transplants. 
Gerstmann-Straussler-Scheinker 
disease (GSS)  Human    A genetic mutation in the PRNP gene, thought to be an atypical CJD. 
Fatal Familial insomnia (FFI)  Human    A genetic mutation in the PRNP gene. 
Bovine  spongiform  encephalopathy 
(BSE)  Cattle    Infection via transmission of contaminated feed, milk or land. 
Scrapie  Sheep    Transmission of PrPSc from infected sheep and contaminated soil. 
Chronic wasting disorder (CWD)   Cervids    Infection via transmission of PrPSc from contaminated feed and soil. 
Feline  spongiform  encephalopathy 
(FSI)   Cats    Infection via transmission of PrPSc from contaminated food. 
Transmissible mink encephalopathy   Mink    Horizontal transmission of prions from BSE and Scrapie infected animals.  
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1.2 Creutzfeldt-Jakob disease 
 
The transmission of PrP
Sc was first discovered from the spread of Kuru, a TSE 
that  affected  the  Fore  tribe  in  Papua  New  Guinea  in  the  early  1950’s  which  was 
established to spread via the tribe’s cannibalistic rituals, reaching total reported deaths 
of ~2500 people (Gajdusek et al. 1957, Lumley 2008). Kuru showed similarities in 
dementia  based  symptoms  as  scrapie  and  subsequently  CJD,  which  lead  to  the 
conclusion that the causes of these diseases evolved from a common infectious unit. 
Furthermore, it was shown that Kuru could be transmitted to chimpanzee models, and 
comparable tests with CJD and GSS followed suggesting the transmission of a related 
or identical infectious unit (Collinge 2001, Gajdusek et al. 1966, Gibbs et al. 1968, 
Masters et al. 1981). 
 
Creutzfeldt-Jakob disease can be divided into three subcategories based on the 
mode  of  acquisition:  inherited,  sporadic  and  acquired.  Sporadic  CJD  was  first 
discovered in a 22 year old woman in the 1920s and is the most common type of CJD, 
affecting around 1 - 2 people per million each year, accounting for around 85% of all 
CJD cases (Belay 1999, Lumley 2008, Wadsworth et al. 2007). It is associated with the 
spontaneous conversion of PrP
c to PrP
Sc which is hypothesised to be a consequence of 
either; a somatic mutation in the gene that encodes the prion protein (PRNP) that is 
associated with increased age, or by a spontaneous conversion of PrP
c to PrP
Sc, caused 
by an error during PRNP gene expression (Belay 1999, Collinge 2001). Familial or 
inherited CJD accounts for around 10 – 15% of all CJD cases and is characterised by a 
dominant autosomal genetic defect of the PRNP gene of which there are around 20 
distinct  mutations  discovered  (Collinge  1997).  The  conformation  of  PrP
Sc  from 
inherited  and  sporadic  CJD  cases  is  thought  to  be  different  from  that  of  acquired 
diseases as the potential of transmission of the sporadic/inherited agent is a lot lower 
than the variant form (Collinge 1997).  
 
The two acquired types of CJD are variant CJD (vCJD) and iatrogenic CJD 
(iCJD). Variant CJD is caused by the horizontal transmission of infectious prions from   6 
BSE infected cattle to humans. The spread and outbreak of BSE was later attributed to 
the cross species transmission of sheep scrapie from the feed produced from rendered 
carcasses (Wilesmith et al. 1991). A further hypothesis was the spread of prions from 
unknown sporadic BSE cases as rendered cattle carcasses had also been used for cattle 
feed (Collinge 2001). The BSE epidemic hit its peak in the UK in 1992 and began to 
decline towards the end of the 1990’s to the mid 2000’s (Figure 1) as a nation-wide 
culling of infected livestock was introduced and the use of meat-and-bone meal (MBM) 
feed was halted (Wilesmith et al. 1992). Over 180,000 cases of BSE were discovered in 
the UK and an estimate of around a million total infected cattle (Anderson et al. 1996). 
Following the UK epidemic, an increase in BSE in non-UK countries was observed, 
most likely caused by the transmission of PrP
Sc from imported contaminated meat or 
MBM feed from the UK (Bradley et al. 2012). The first case of vCJD was recognised in 
1995 and the link between BSE and vCJD established due to the fact that the isolated 
prion protein from both diseases had the same biochemical properties and there was a 
clear correlation regarding timing with the BSE epidemic and vCJD outbreak (Figure 1) 
(Will et al. 1996). Variant CJD is clear evidence of the ability of the infectious prion to 
cross the “species barrier”.  
 
Importantly, there is clearly an established link between disease susceptibility 
and genetic variation of codon 129 of the prion protein gene. There are three genetic 
variations of the PrP
Sc mutation located at codon 129 (typically encoding for methionine 
and  valine)  of  the  PRNP  gene.  These  three  genetic  variations  are  known  as 
methionine/valine  (MV)  heterozygous,  methionine  homozygous  (MM)  and  valine 
homozygous (VV). These account for 50%, 40% and 10% of the Caucasian population, 
respectively  (Lumley  2008,  Owen  et  al.  1990,  Wadsworth  and  Collinge  2007). 
Individuals that are homozygous (both VV and MM) for this polymorphism are more 
susceptible to sCJD, with 95.5% or cases in one study being homozygous for either 
methionine or valine (Belay 1999, Palmer et al. 1991). Furthermore over half of the 
healthy controls were heterozygous (MV) for this polymorphism (Palmer et al. 1991). 
This was also determined to be the case with the susceptibility of acquiring vCJD from 
the BSE outbreak with all cases to date being MM homozygous at codon 129 (Asante et 
al. 2006, Ironside et al. 2006). However, the susceptibility of transmission to VV and 
MV humanised mice has been demonstrated; with an increased asymptomatic state and 
an  increased  incubation  period  which  in  some  cases  outlasted  the  rodent  lifespan   7 
(Bishop  et  al.  2006).  More  recently  a  case  of  transmission  of  vCJD  from  blood 
transfusion  was  observed  in  an  MV  heterozygous  subject,  suggesting  that  the  MV 
polymorphism can be associated with disease transmission (Ironside et al. 2006). This 
also highlights that there is the potential of a second wave of CJD in individuals that are 
VV or MV at codon 129 that are presently asymptomatic carriers of disease with a far 
increased incubation period; this would also increase the unknown risk of iatrogenic 
transmission between/from these unknown cases. In addition, homozygotes, particularly 
with  the  MM  mutation  were  more  susceptible  to  acquiring  iatrogenic  CJD  from 
pituitary hormone inoculation (Collinge et al. 1991, Collinge 1997, Palmer et al. 1991). 
It has also been demonstrated that 12 cases of disease transmission from dura matter 
grafts were all associated with individuals carrying the MM homozygous polymorphism 
(Collinge  et  al.  1991).  Furthermore,  it  has  been  shown  that  a  similar  genetic 
susceptibility is observed in sCJD and iCJD cases (Deslys et al. 1994). These findings 
suggest  that  the  heterozygosity  of  MV  at  codon  129  has  a  protective  effect  on  the 
individual which is also found in inherited TSE’s including GSS and FFI (Baker et al. 
1991, Collinge 2001, Hsiao et al. 1992).  
 
Variant CJD is to this day the most common acquired TSE in humans in the UK; 
however  the  incidence  is  relatively  low  with  176  deaths  recorded  from  the  start  of 
surveillance in 1990 up to the end of August 2012 (Data from the National Creutzfeldt-
Jacob Disease Research and Surveillance Unit (NCJDRSU)). Although the mortality 
rate of vCJD is relatively low, possible future outbreaks of BSE potentially due to the 
discovery of atypical strains alongside our still limited understanding of this unique 
infectious  agent  could  lead  to  a  second  outbreak  of  vCJD  or  an  atypical  vCJD. 
Furthermore,  there  is  still  a  risk  of  the  iatrogenic  transmission  of  CJD  from 
asymptomatic carriers which is discussed in depth later in this report.  
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Figure 1 – Incidences of BSE and vCJD 
The incidences of A) BSE and B) vCJD in both the UK (light grey) and Non-UK countries 
(dark grey), highlighting the correlation between the epidemic of BSE and the onset of vCJD 
especially within the UK (Data obtained from the National CJD Surveillance Unit (NCJDSU, 
Edinburgh). 
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1.3 The prion protein 
 
Neurodegeneration  caused  by  the  accumulation  of  protein  aggregates  which 
precedes  the  breakdown  of  normal  tissue  morphology  seems  to  be  a  common 
occurrence in many diagnosed neurodegenerative diseases. However, different proteins 
or precursor proteins/molecules seem to be the disease-associated agents (Caughey et al. 
2003).  For  example,  Alzheimer’s  disease  (AD)  is  caused  by  the  formation  of  β-
amyloidal (Aβ, amyloid β) plaques produced from aggregation of the amyloid precursor 
protein (APP). More recently it has been observed that an increase in intracellular tau 
and  phosphorylated  tau  leading  to  the  breakdown  of  microtubules  could  also  be  a 
disease mechanism associated with AD. Parkinson’s disease (PD) is associated with the 
formation of lewy bodies produced by α-synuclein. Finally, Huntington’s (Htn) disease 
is caused by a mutation in the huntingtin gene (HTT) which leads to the production of 
fibrillar  Htn  plaques  (Caughey  and  Lansbury  2003).  The  main  difference  of  TSE’s 
compared to other neurodegenerative diseases is that PrP
Sc can transmit between hosts, 
whereas none of the other mentioned protein precursors have currently demonstrated 
any host to host transmission (Caughey and Lansbury 2003). However, within the last 
12 years it has been shown that AD can be induced in APP transgenic mice (Kane et al. 
2000, Meyer-Luehmann et al. 2006) and APP transgenic rats (Rosen et al. 2012) after 
the introduction of AD infected human brain homogenate. More recently the de novo 
formation of Aβ deposits has been demonstrated in mice expressing wild-type human 
APP  (Morales  et  al.  2011).  Although  there  is  currently  no  evidence  that  AD  is 
transmissible, these recent studies have shown that the disease can be induced under 
certain conditions.  
 
The  mechanisms  in  which  these  infectious  protein  precursors  lead  to  the 
formation of protein aggregates in many of these diseases is unknown, especially in 
TSE’s where various potential mechanisms have been thoroughly studied and will be 
discussed further in this report (Collinge 2001, Moore et al. 2009, Prusiner et al. 1981, 
Prusiner 1997, Redecke et al. 2009). The protein that causes TSE’s is characterised by a 
stoichiometric transformation of the host cellular glycoprotein precursor PrP
c to form 
the partial Proteinase K (PK) resistant, infective isoform known as PrP
Sc (Aguzzi et al. 
2008).    10 
 
The human cellular prion protein is encoded by a single copy gene, denoted the 
PRNP gene, located on the short arm of chromosome 20 (Oesch et al. 1985, Robakis et 
al.  1986). PrP
c  is a monomeric glycoprotein  attached to  cell membrane surfaces  by 
commonly  occurring  glycophosphatidylinositol  (GPI)  anchors,  and  is  thought  to  be 
transported out of the  cell by  an  endocytic pathway  (Caughey  et  al. 2006). PrP
c  is 
around 231 amino acids in length, with a molecular mass of 35-36 kDa (Figure 2). 
Structurally  it  is  largely  α-helical  and  found  ubiquitously  in  the  body,  but  more 
predominantly on cells of the CNS (Moore et al. 2009). PrP
c is
 characterised by N-
linked glycosylation at two sites of the protein and is modified post-transcriptionally 
with a GPI anchor in the endoplasmic reticulum (Figure 2). Followed by attachment to 
the  cell  surface  by  binding  of  the  C-terminal  end  with  the  cell  surface 
phosphatidylinositol group anchor associated with the GPI proteins. The cellular prion 
protein  contains  two  highly  conserved  regions  at  the  N-terminal  side;  one  region 
comprising the 5 octapeptide repeats, consisting of 5 repeats of an octameric amino acid 
structure with the sequence; Proline, Histidine, Glycine, Glycine, Glycine, Tryptophan, 
Glycine  and  Glutamine  (PHGGGWGQ)  and  a  charged  cluster  also  known  as  the 
hydrophilic  region  sitting  next  to  the  hydrophobic  core.  The  C-terminal  end  of  the 
protein primarily consists of the Proteinase K (PK) resistant core which is associated 
with  the  infectious  misfolded  isoform.  In  addition,  it  contains  the  two  N-linked 
glycosylation regions situated at asparagines 181 and 197, a single disulphide bridge 
between cysteines 179 and 214 and the GPI anchor region at the far C-terminal end. The 
number of glycosylation sites present on each PrP molecule can be determined by the 
number of glycosylation bands present during Western blot analysis. The position of PK 
cleavage  is  speculated  to  be  around  the  hydrophobic  core  of  the  N-terminal  region 
(Figure 2) (Aguzzi et al. 2008, Caughey and Lansbury 2003, Charvériat et al. 2009).   
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Figure 2 – The primary structure of PrP
c 
A  diagrammatic  representation  of  PrP
c  structure  highlighting  the  octapeptide-repeat  region 
(OR), hydrophobic core (HC), two N-Linked glycosylation sites (N-181 and N-197), the GPI 
anchor at the C-terminal end and the membrane attachment region (MA), the PK-resistant core 
fragment  which is  associated  with  PrP
Sc  and the  area  of  PK cleavage  (Aguzzi  et  al.  2008, 
Harrison et al. 1997). 
 
 
  The use of nuclear magnetic resonance spectroscopy (NMR) to determine the 
secondary structure of natural PrP
c has not been possible due to difficulty in producing 
an adequate amount of purified PrP
c (Riesner 2003). Consequently, the structure has 
been determined using recombinant mouse PrP
c (Riek et al. 1997).  The cellular isoform 
of the prion protein has been demonstrated to be predominantly α-helical, comprising 
three α-helixes; one spanning residues 144-154, one at residues 175-193 and the third 
spanning residues 200-219. Two small β-strands forming an anti-parallel β-sheet are 
found between residues 128-131 and 161-164. The remaining N-terminal region from 
residues  23-121,  containing  the  octapeptide  repeats  has  been  observed  to  be 
considerably unstructured and flexible (Figure 3) (Riesner 2003).   
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Figure 3 – Secondary structure of PrP
c 
A diagrammatic representation of the proposed secondary structure of PrP
c, highlighting the α-
helix and β-sheet positions and the unstructured N-terminal region. (adapted from Riek et al. 
1997).  
 
 
1.3.1 The suggested functions of PrP
c 
 
  The  role  of  PrP
c  is  not  fully  understood,  due  in  part  to  the  fact  that  PrP
c 
knockout mice (PrP
0/0), which have been genetically modified to inhibit PRNP gene 
expression, do not display any overt clinical symptoms. Initial studies using knockout 
mice showed normal development and behaviour (Bueler et al. 1992), with no obvious 
change in physiology other than a resistance to infection from scrapie  (Büeler et al. 
1993). However, more recently studies have shown that PrP
c is believed to be involved 
in a number of cellular pathways. Research has demonstrated certain subtle changes in 
the normal neurological processes observed in the knockout mice, including pathways 
within the central nervous system controlling synaptic function and neuronal neurite   13 
outgrowth. It has been demonstrated that PrP
c can act as a ligand for laminin binding, 
instigating an increase in neurite growth and outreach in primary neurons of rodents 
(Graner et al. 2000). PrP null mice confirm that
 the cellular prion protein is not essential 
to maintain the important synaptic functions required for normal life. In mice devoid of 
PrP
c it has been observed that there is no change in a number of synaptic functions apart 
from a partial increase in locomotor activity when in a novel environment (Roesler et al. 
1999). However, in stark contrast, other studies have shown that the loss of PrP
c can 
instigate neurological changes. The loss of PrP
c has shown to effect circadian activity 
rhythm, resulting in an altered sleep pattern in PrP null mice (Tobler et al. 1996). Mice 
devoid  of  PrP
c  also  have  weakened  GABAA  (γ-aminobutyric  acid  type  A)  receptor 
mediated fast inhibition and impaired long term potentiation, demonstrating reduced 
long term learning and memory (Collinge et al. 1994).  
 
  PrP
c has also demonstrated involvement in functional activities and acts as a 
ligand for various molecules in a diverse number of cells, including neurons, T-cells, 
leukocytes, neural stem cells and haematopoietic stem cells (Caughey and Baron 2006, 
Isaacs et al. 2006). The binding of copper and zinc to the OR region of PrP
c could be a 
clue to its potential role in redox control (Aguzzi et al. 2008, Caughey and Baron 2006). 
Cu
2+ ions bind to 5 or 6 binding sites situated in the 4 to 5 octapeptide repeats found 
within  the  N-terminal  side  of  PrP
c.  The  relationship  between  PrP
c  and  copper  was 
confirmed when it was established that PrP null mice contained 50% lower levels of 
synaptosomal copper than wild-type mice suggesting a role of PrP
c in synaptic copper 
homeostasis (Herms et al. 1999). The decreased activity of copper-dependant enzyme 
superoxide  dismutase-1  (SOD-1)  in  PrP  null  mice  suggest  that  PrP
c  may  act  as  a 
chaperone for the delivery of Cu
2+ to SOD-1 (Brown et al. 1998). It is unknown if PrP
c 
is the principle Cu
2+ binding molecule in the brain, however the use of PI-PLC (an 
enzyme that digests GPI anchors) causes a release of Cu
2+ ions from cerebellar cells 
suggesting  that  the  principle  molecule  contains  a  GPI  anchor,  as  is  found  in  PrP
c 
(Brown et al. 1997). It has also been suggested that PrP
c itself has SOD like activity. 
Increased levels of PrP
c located at the synapse of neurons suggests PrP
c mimics SOD 
and controls the levels of Cu
2+ ions at this location as SOD has been shown to cause 
detrimental  neurological  effects  in  the  presence  of  synapses  (Brown  et  al.  1999). 
However, further research has suggested this is not the case as no PrP
c dependant SOD-
1 or SOD-2 activity has been observed in vivo in the heart, spleen or brain (Hutter et al.   14 
2003). This also excludes the possibility that PrP
c may act as a chaperone to deliver 
excess Cu
2+ to SOD-1. A more likely hypothesis is that the high levels of PrP
c situated 
on the pre-synaptic membrane and the high affinity binding of Cu
2+ ions to PrP
c could 
be involved in buffering the increased levels of copper released during synaptic vesicle 
fusion and the fact that nerve endings release copper during depolarization (Vassallo et 
al. 2003). The affinity of PrP
c for copper binding correlates with the Cu
2+ concentrations 
observed at the synapse, thus further supporting this hypothesis (Millhauser 2007). This 
would also relate to findings discussed earlier regarding the impaired synaptic ability in 
PrP null mice that could be caused by the toxicity of excess copper and the lack of the 
previously hypothesised neuroprotective capabilities of PrP
c (Collinge et al. 1994). This 
is supported by the fact that wild-type neurons and glial cells are much more resistant to 
oxidative stress caused by the increased build-up of copper associated reactive oxygen 
species (ROS), than the neurons and glial cells associated with PrP null cultures (Brown 
et al. 1998). Therefore, neurodegeneration observed in TSE’s may not only be caused 
by the formation of protein aggregates and altered brain tissue morphology but may also 
be exacerbated by the loss of normal functions of PrP
c once converted to PrP
Sc. 
 
1.3.2 The pathological prion (PrP
Sc) 
 
Preliminary misperceptions occurred in determining whether the causative agent 
in TSE’s was a microbe or virus due to its infectious and variable properties. The lack 
of nucleic acids present in the causative agent was suggested after the infectious unit 
was  determined  to  be  resistant  to  UV  and  ionizing  radiation  which  would  usually 
destroy nucleic acids (Alper et al. 1967). Soon after, Griffith, 1967, determined that a 
protein with the ability to replicate in its host was the likely cause of prion diseases 
(Griffith  1967).  Furthermore,  Nobel  Prize  winner  Stanley  Prusiner  confirmed  the 
protein nature of the causative agent when he was the first person to isolate the prion 
protein (Aguzzi et al. 2009, Prusiner et al. 1981, Prusiner 1998). Subsequently, Prusiner 
described in 1981, that the infectious agent is a modification of a host encoded protein 
and  designated  this  as  the  “proteinaceous  infectious  unit”  or  prion  (Lumley  2008, 
Prusiner et al. 1981, Prusiner 1998). The main structural alteration that occurs between 
PrP
c and PrP
Sc is the misfolding of the monomeric PrP
c bulk α-helix structure to the 
multimeric β-sheet rich protein isoform PrP
Sc (Figure 4) (Aguzzi et al. 2008, Caughey   15 
and  Baron  2006).  Difficulties  in  determining  the  proportion  of  α-helix  and  β-sheet 
content of PrP
Sc arose due to the insolubility of the infectious unit. However estimates 
showed that PrP
c comprises of roughly 42% α-helix and 3% β-sheet compared to 30% 
α-helix and 43% β-sheet in PrP
Sc. The insoluble fragment post PK digestion, denoted 
PrP
27-30,  contains  21%  α-helix  and  54%  β-sheet  (Table  2)  (Pan  et  al.  1993).  This 
confirmed that the insolubility of the undigested, infectious prion sub-unit was most 
likely due to its highly β-sheet nature.  
 
 
Figure 4 – The PrP structural differences 
A representation of the differences in structure of PrP
c (left) and PrP
Sc (right), highlighting the 
differences in α-helix (green) and β-sheet (blue) content.  
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Isoform  α-helix content (%)  β-sheet content (%) 
PrP
c 
PrP
sc 
PrP
27-30 
42 
30 
21 
3 
43 
54 
 
Table 2 – Composition of prion secondary structures 
Comparison of the composition of the different prion protein isoform secondary structures 
 
 
1.3.2.1 Conversion of PrP
c to PrP
Sc 
 
The processes or mechanisms involved in the transformation of PrP
c to PrP
Sc 
have been extensively researched but are still not fully understood. The majority of 
research has suggested that there are two proposed mechanisms, involving a “protein 
only” reaction with or without a part folded protein intermediate named “Protein X” or a 
number of intermediates that are involved in the conversion of PrP
c to PrP
Sc, classed as 
the template assisted models and finally the presence of non-protein intermediates has 
also been considered.  
 
The  “protein  only”  hypothesis,  also  known  as  the  nucleation-polymerisation 
model states that the conversion of PrP
c to PrP
Sc is an autocatalytic reaction that occurs 
in the presence of already misfolded PrP
Sc which binds to form a nucleated structure 
which then polymerises (Figure 5 and Figure 6) (Laurent 1996, Soto et al. 2001). This 
process involves the self-replication of PrP
Sc once bound to PrP
c to form a hetero-dimer. 
PrP
c is then converted to form a PrP
Sc monomer which joins to the original PrP
Sc to 
form a PrP
Sc – PrP
Sc dimer. Additional PrP
c leads to further conversion to PrP
Sc which 
attaches to the dimer to form a PrP
Sc oligomer. In time more PrP
c undergoes conversion 
and  ultimately  a  PrP
Sc  protofibril  is  formed  (Figure  5).  During  this  conversion 
monomers of PrP
Sc can break off and themselves initiate the conversion of more PrP
c   17 
monomers (Aguzzi et al. 2008). Subsequently the stocks of PrP
c are replenished by 
cellular synthesis, occurring in the endoplasmic reticulum, due to the reduction in PrP
c 
levels, further fuelling the self-replication of PrP
Sc (Figure 6) (Stohr et al. 2008).  
 
PrP
0/0 knockout  mice are one of the supporting  experiments  for the “protein 
only” hypothesis, in which they show no signs of infection when inoculated with PrP
Sc, 
confirming the need of the cellular prion protein, not just the PrP
Sc isoform, for the 
replication of the infectious agent (Büeler et al. 1993, Weissmann et al. 2002). More 
recently,  PMCA  (protein  misfolding  cyclic  amplification)  and  cell  free  assay 
experiments are further proof of the “protein only hypothesis”, discussed in depth later. 
Briefly, PMCA involves the artificial amplification of PrP
Sc in the presence of PrP
c 
(Deleault et al. 2007, Saborio et al. 2001, Soto et al. 2005). Furthermore, experiments 
using yeast prion models, the [PSI
+] prion form of the protein Sup35 and [URE3] prion 
form of the protein Ure2 show similar properties to misfolded  β-sheet proteins that 
demonstrate an increased formation in the presence of the normal protein and form 
protease  resistant  protein  aggregates,  thus  again  supporting  the  “protein  only 
hypothesis” (Soto et al. 2004). 
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Figure 5 – Proposed mechanisms of PrP conversion  
Schematic diagram of the two predominant proposed mechanisms of prion conversion. (A) The 
“protein only” or nucleation-polymerisation model where the conversion or PrP
c is initiated by 
the seeding of PrP
Sc. (B) The template-assisted model where the conversion of PrP
c to PrP
Sc is 
instigated by the formation of a PrP intermediate (PrP
*) which binds to a chaperone (“protein 
x”) that initiates the conversion. (adapted from Soto and Sabor  o 2001)     19 
 
Figure 6 – Proposed locations of PrP conversion and toxicity 
Taken from Caughey and Baron (2006) showing the PrP
c processing and proposed locations of 
the transformation of PrP
c (white) to the infectious PrP
res (red) preceding amyloid formation. 
Potential mechanisms of toxicity caused by the presence of PrP
res or PrP
cyto within the cell are 
highlighted by the red PrP
res molecules and question marks. 
 
 
The  template  assisted  model  which  involves  the  occurrence  of  a  protein 
intermediate involved in the conversion of PrP
c to PrP
Sc is a dominant area of prion 
research, due to the potential of a therapeutic target to inhibit the PrP
c conversion. The 
“protein X” was described by Prusiner as “a factor defined by molecular genetic studies 
that binds to PrP
c and facilitates PrP
Sc formation” (Figure 5) (Prusiner 1998). The most 
recent evidence for a protein intermediate is again from using PMCA. Firstly, the use of 
homogenised normal brain containing PrP
c and an un-purified PrP
Sc seed could mean 
that  a  number  of  other  factors  within  these  samples  are  contributing  to  the  prion 
conversion  (Caughey  2003).  Secondly,  using  PMCA  researchers  have  managed  to 
produce de novo infectious prions from purified PrP
c and poly(A) RNA without using a 
PrP
Sc seed (Benetti et al. 2009, Deleault et al. 2007). Additionally, the purified PrP
c   20 
used  in  these  experiments  still  contains  some  natural  lipids  which  could  also  be 
involved in PrP conversion. As such, the production of de novo prions could suggest 
that polyanions or lipids could be intermediate factors involved in prion conversion. 
However, it has been observed that once these de novo formed infectious prions are 
introduced  into  wild-type  hamsters  they  produced  disease  with  a  new  phenotype, 
whether this is a factor of the technique or the production of a new prion strain is 
unknown (Barria et al. 2009). It has recently been demonstrated using serial PMCA 
(sPMCA) to amplify different prions strains with or without different cofactors, that the 
cofactors  determine  the  different  strain  properties  (Deleault  et  al.  2012).  Therefore, 
cofactors affect the infectious nature of different strains and must be involved in either 
PrP
Sc conversion or disease progression. A study into the capability of PrP
Sc to transmit 
across  the  “species  barrier”  further  postulates  the  proof  of  the  protein  intermediate 
theory. Mice that expressed both human and mouse PrP
c were not infected by human 
PrP
Sc. Conversely, mice that only expressed the human PrP
c were infected with human 
PrP
Sc suggesting the presence of a species dependant cofactor in the mouse PrP
c  that 
was inhibiting the human PrP
Sc transmission and is therefore required for mouse PrP
Sc 
conversion (Prusiner 1998). Work by Simoneau et al, 2007 also studied the possibility 
of a protein intermediate between the production of PrP
Sc and PrP
c which is involved in 
the structural conversion, but may also represent the infectious unit in TSE diseases. 
They  discovered  the  presence  of  β-PrP  oligomers  that  may  represent  the  so  called 
“Protein X” and these oligomers also showed major neurotoxicity, thus suggesting these 
β-PrP oligomers could be potential therapeutic targets in the future (Simoneau et al. 
2007). The one thing that is known is that there is an interaction between PrP
c and PrP
Sc 
for there to be propagation of further PrP
Sc and ultimately disease, whether there is an 
intermediate or not is still an interesting, on-going area of research. 
 
1.3.2.2 Prion strains and the “species barrier”   
 
  The existence of a number of different natural prion strains and the production 
of laboratory adapted strains complicates prion research. Variations in the properties of 
the various prion strains can be misleading in comparing different studies, especially 
regarding infectivity, decontamination and the time to disease onset. Different strains 
can be distinguished by their varying susceptibility to decontamination  and banding   21 
pattern on Western blot analysis due to their different glycosylation patterns. Clinically, 
strain variability can also be observed by the location of PrP
Sc deposition within the 
CNS (Bruce et al. 1989), degree of spongiosis (Fraser et al. 1968, Pattison et al. 1961), 
incubation period in different mammals (Dickinson et al. 1968) and the ability to infect 
different species (Figure 7) (Béringue et al. 2008b).  
 
 
 
Figure 7 – Analysis of strain variation 
The variation in phenotypes of two different prion strains inoculated in the same susceptible 
animal shown via different biochemical techniques. 1) The variations in incubation period and 
attack rate. 2) The difference in the banding pattern observed on Western blot analysis, showing 
variations  in  Di,  Mono  and  Un-glycosylated  glycoforms.  3)  Variations  in  regional  PrP
Sc 
deposition  in  immunochemically  labelled  histoblot  brain  sections.  4)  The  legion  profiles 
demonstrating  the  differences  in  the  distribution  and  intensity  of  vacuolation/spongiosis  in 
standardised brain regions (adapted from Béringue et al. 2008b). 
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The phenomenon known as  the “species  barrier” describes  the ability  of the 
infectious agent to transmit disease from one species to another. Prion strain variation is 
observed when one prion strain is introduced into a host containing a different PrP
c 
molecule, for example the introduction of BSE prions into humans which led to the 
generation of infectious prions that caused variant Creutzfeldt Jacob disease (vCJD). 
The cross-species transmission of prions can lead to disease with prolonged incubation 
periods  and  lower  attack  rate  over  the  early  passages,  thought  to  be  caused  by  the 
“species barrier”, and ultimately result in different disease phenotypes (Collinge et al. 
2007).  However,  these  differences  in  phenotype  can  be  reversed  after  several  sub-
passages within the new host, highlighting the adaptability of prions to different hosts 
(Béringue et al. 2008b).  
 
It is thought that the structural conformation, genotype, glycosylation pattern 
and compatibility of donor PrP
Sc with host PrP
c are the primary aspects that affect prion 
strain  phenotypic discrimination and transmission  (Bruce 1993, Carlson et  al.  1989, 
Collinge et al. 1996, Telling et al. 1996). For example PrP
Sc from classical CJD does not 
infect wild-type mice whereas it does infect humanised transgenic mice that contain 
human PrP
c. However, vCJD that has already been passaged through a bovine host 
infects wild-type mice more efficiently than the classical CJD prions (Hill et al. 1997). 
The  emergence  of  experimentally  produced  strains  highlights  the  adaptable 
conformation  of  PrP  in  developing  new  phenotypes.  The  transmission  of  a  pool  of 
scrapie  infected  sheep  brains  (SSBP/1)  into  goats  produced  two  different  clinical 
phenotypes  that  were  conserved  after  several  passages  and  were  denoted  as  either 
“drowsy” or “scratching” relating to the goats consequent behaviour pattern (Pattison 
and  Millson  1961).  This  suggests  that  within  the  SSBP/1  there  are  at  least  two 
conformations of PrP
Sc that led to the production of the two phenotypes observed upon 
transmission to goats. This has also been witnessed in similar experiments in hamsters, 
where the transmission of the transmissible mink encephalopathy (TME – Stetsonville 
isolate)  to  hamsters  produced,  again,  two  phenotypes  denoted  “drowsy”  (DY)  and 
“hyper” (HY) (Bessen et al. 1992b). Both strains displayed differences in incubation 
period and PrP
Sc deposition. Moreover, DY remained infectious in mink following four 
passages  in  hamsters,  suggesting  it  was  the  more  dominant  isolate  within  the  mink 
population  (Bessen et al. 1992a).    23 
 
Small changes in the PrP gene can also lead to variations in prion strain when 
transmitted to a different host. Lines of inbred mice that expressed either the a or b 
alleles  (Prn-p
a  or  Prn-p
b),  originally  known  as  the  Sinc
S7  and  Sinc
P7  alleles  (Sinc 
standing for scrapie incubation gene), which encode two PrP proteins that have different 
amino  acids  at  position  108  and  189,  yield  varied  strains  once  inoculated  with  an 
infectious  experimental  strain  (Bruce  1993,  Dickinson  et  al.  1968).  For  example,  a 
strain originally cloned in Prn-p
a mice, denoted 22C, produces a different strain denoted 
22H when passaged in Prn-p
b mice. Similarly the 22A strain originally cloned in Prn-p
b 
mice produces 22F when passaged in Prn-p
a mice, with all strains showing slightly 
different phenotypes (Béringue et al. 2008b). The study of eight different prion isolates 
which  can  be  propagated  in  Syrian  hamsters  demonstrated  that  it  is  possible  for 
similarities in certain phenotypes, including denaturation and incubation time, to occur. 
This suggests that some of these prion isolates are similar or possess the same PrP
Sc 
confirmation, although it should be noted that differences in PrP deposition and clinical 
signs have been observed between these strains (Peretz et al. 2001, Safar et al. 1998). 
Therefore, the number of different prion conformations and real differences between 
some strain phenotypes is questionable. As mentioned earlier, the use of sPMCA with 
or without various cofactors demonstrates that prion strain conformation is altered by 
the  cofactors  present  in  different  species  (Deleault  et  al.  2012).  The  prions  strains 
exhibited  different  biochemical  characteristics  without  the  presence  of  a  cofactor 
however when a single cofactor was introduced all of the prion strains demonstrated the 
same  properties  suggesting  it  is  the  cofactors  that  are  present  that  determine  strain 
characteristics  (Deleault  et  al.  2012).  The  different  experimentally  produced  prion 
strains are summarised in Table 3.  
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Name  Origin  Host 
ME7  Sheep scrapie
a  Mouse (Prn-p
a) 
87A  Sheep scrapie
a  Mouse (Prn-p
a) 
221C  Sheep scrapie
a  Mouse (Prn-p
a) 
87V  Sheep scrapie
a SSBP/1
b  Mouse (Prn-p
b)  
79A  SSBP/1
b  Mouse (Prn-p
a) 
79V  SSBP/1
b  Mouse (Prn-p
b) 
139A
c  SSBP/1
b  Mouse (Prn-p
a) 
22C  SSBP/1
b  Mouse (Prn-p
a) 
22H  Uncloned 22C  Mouse (Prn-p
b) 
22L  SSBP/1
b  Mouse (Prn-p
a) 
22A  SSBP/1
b  Mouse (Prn-p
b) 
22F  Cloned 22A  Mouse (Prn-p
a) 
301C
d  BSE  Mouse (Prn-p
a) 
301V  BSE  Mouse (Prn-p
b) 
139H  Cloned 139A  Syrian Hamster 
263K
e  SSBP/1
b  Syrian Hamster 
ME7-H  Cloned ME7  Syrian Hamster 
HY  TME  Syrian Hamster 
DY  TME  Syrian Hamster 
 
 
Table 3 – Summary of experimental prion strains 
The experimental strains produced in rodents, highlighting their origin and host that the strain is 
cloned in. 
a Scrapie field isolate, 
b SSBP/1 sheep scrapie brain pool 1, 
c Also known as Rocky 
Mountain Laboratory (RML) or chandler, 
d It is possible that 301C succumbs to 301V in Prn-p
b 
mice, 
e Sc237 is also a subclone of 263K. (Béringue et al. 2008b) 
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More worryingly from a human perspective is the discovery of two variations of 
the BSE strain in cattle. These two atypical BSE strains have been named the H-type 
(due to higher PrP
Sc band when analysed on Western blot) originally found in eight 
French BSE cases, (Biacabe et al. 2004) and L-type BSE (due to lower PrP
Sc bands 
when analysed on Western blot) originally observed in two Italian BSE cases (Casalone 
et  al.  2004).  Although  no  transmission  of  these  BSE  strains  to  humans  has  been 
confirmed, unlike classical BSE, transmission of L-type BSE has been demonstrated in 
two different humanised transgenic mice lines; firstly tg40 mice (overexpressing human 
PrP  M/M  at  codon  129  of  the  Prnp  gene)  (Kong  et  al.  2008)  and  in  tg650  mice 
(Béringue et al. 2008a). These findings suggest that there is an interaction between the 
atypical bovine and human prions which highlights the possibility of transmission of 
atypical BSE to humans causing a new vCJD-like disease with a potentially different 
phenotype. Moreover, the ability of the infectious agent associated with chronic wasting 
disease (CWD) in cervids to transmit to humans is unclear. As the epidemic of CWD in 
North America and two Canadian provinces is still on-going this could pose a potential 
risk to humans in regards to the ingestion of contaminated meat as was observed with 
the BSE outbreak (reviewed in Sigurdson 2008). 
 
1.3.2.3 PrP
Sc infectivity 
 
  The formation of PrP
Sc rich proteinaceous aggregates and amyloid plaques are 
associated  with  TSE  pathology  and  thought  to  be  involved  in  the  fundamental 
neurodegeneration, however the mechanisms are still unknown. Aggregates of PrP
Sc are 
primarily  found  in  tissues  of  the  central  nervous  system.  However,  studies  have 
identified PrP
Sc in the spleen, (Bruce et al. 2001, Doi et al. 1988) lymph nodes (Doi et 
al. 1988) and tonsil (Bruce et al. 2001). A number of questions have risen regarding 
whether it is the smaller subfibrillar oligomer deposits, the intermediate amyloid fibrils 
or the larger amyloid plaques that are the dominant infectious units associated with 
TSE’s.  Amyloid  plaques  are  ordered  structures  formed  from  the  non-covalent 
polymerisation of single protein monomers aligned in the cross-β configuration. These 
evolve through a number of states including dimers, trimers leading up to protofibrils 
and ultimately insoluble plaques (Malchiodi-Albedi et al. 2011, Shewmaker et al. 2011).   26 
Although the outcome of the aggregating proteins in prion diseases is the development 
of  amyloid  plaques,  it  is  not  thought  that  the  plaques  are  the  cause  of 
neurodegeneration.  However,  neurotoxicity  associated  with  mature  amyloid  fibrils 
produced  from  recombinant  PrP  has  been  demonstrated  (Legname  et  al.  2004, 
Novitskaya et al. 2007). Due to the loss of disease manifestation in PrP
0/0 mice it is 
suggested  that  the  prion  protein  is  involved  in  the  infectivity  of  prion  diseases. 
However, the presence of disease with no detectable PrP
res can question whether the PK 
resistant prion is the sole infectious agent (Gambetti et al. 2008, Thackray et al. 2007). 
It is hypothesised that smaller aggregates or small sequences of the prion protein are the 
neurotoxic  species  that,  once  converted  from  PrP
c,  aggregate  in  abundance  around 
neurons inhibiting there function causing the neurodegeneration observed (Bucciantini 
et al. 2002, Malchiodi-Albedi et al. 2011).   
 
  Work  by  Silveira  et  al,  2005  concluded  that  the  most  infectious  protein 
aggregates per mass of PrP were around 17-20 nm in size and around a mass of 300-600 
kDa,  which  are  on  the  smaller  size  of  protein  aggregates,  thus  contradicting  the 
hypothesis  that  the  larger  aggregates  demonstrated  increased  infectivity.  They  also 
determined that if these protein aggregates were made up mainly of PrP of an average 
size of 21.5 kDa each, then that would be an oligomer of around 14-28 PrP molecules 
which is the same as the smaller infectious units that have been observed previously 
(Silveira et al. 2005). This potentially suggests that novel decontamination techniques 
need to be able to denature or break up the PrP
Sc aggregates to single monomers rather 
than breaking up the larger aggregates into intermediate more infections oligomers of 14 
– 28 molecules, subsequently resulting in residual infectivity and potentially an increase 
in the transmission of PrP
Sc.  
 
  Although it is still unknown if PrP
Sc is the sole infectious agent in prion disease 
it is really the only available marker that correlates with disease infectivity. PrP
Sc, when 
compared to PrP
c, has altered biochemical as well as structural properties, including a 
partial  resistance  to  Proteinase  K,  strong  adhesion  to  many  surfaces  predominantly 
stainless steel and plastics, insolubility in most detergents and resistance to numerous 
chemical and physical decontamination methods including formaldehyde treatment and 
autoclaving  at  121
oC  (Jackson  et  al.  2005).  It  is  these  biochemical  properties  that   27 
contribute to the observed difficulty in the inactivation and decontamination of PrP
Sc. 
This  difficulty  is  the  main  contributing  factor  regarding  the  prevalence  of  acquired 
diseases caused by this infectious agent or infectious oligomers as suggested previously. 
In relation to decontamination protocols it is important that the PrP
Sc oligomers are 
broken down to either single molecules or that the proteins are denatured entirely to 
remove the most infectious units (Gale 2007). Proteinase K used for diagnostic tools, 
cleaves  the  infectious  PrP
Sc  at  around  the  90
th  residue,  leaving  the  C-terminal  end, 
denoted  PrP
27-30  (corresponding  to  the  kDa  mass  of  the  infectious  subunit  post  PK 
digestion) which is the region of the PrP
Sc that is deemed the main disease associated 
sub-unit (Figure 2) (Caughey et al. 1991, Stohr et al. 2008). 
 
1.4 Iatrogenic transmission 
 
The  iatrogenic  transmission  of  vCJD  is  the  primary  concern  of  this  study 
although  a  low  prevalence  is  documented.  Nevertheless,  the  long  incubation  period 
associated with CJD and the currently unclear effect of genetic background on disease 
progression and prognosis could imply there are an unknown number of carriers within 
the population, representing potential transmission sources. The incubation period of 
vCJD is to a certain degree unknown, due to variations in genetic susceptibility, but is 
currently estimated to be around 12  years; however, if compared to Kuru, with the 
potential of up to 50 years in a minority of cases, then the incubation period could be 
relatively longer than initially thought (Collinge et al. 2006). Furthermore, the initial 
interim data from the analysis of PrP
Sc prevalence in appendix specimens suggests that 
there  could  be  potentially  18,000  carriers  of  the  infectious  prion  within  the  UK 
population (Hilton et al. 2004, HPA 9 September 2011). However, more recent results 
from  a  second  appendix  study  suggests  there  could  be  as  many  as  double  (1/2000 
compared to 1/4000) the number of carriers in the UK as was initially proposed (Data 
from  the  Advisory  Committee  on  Dangerous  Pathogens  (ACDP)).  Therefore,  the 
number of estimated carriers and the potential for long incubation periods suggests there 
is still an increased risk of iCJD transmission.   
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The first documented case of iatrogenic CJD involved a corneal transplant from 
an undiagnosed CJD patient in 1974 (Duffy et al. 1974). The most common iatrogenic 
transmission  routes  since  this  study  are  cadaveric  dura  mater  grafts  (136  cases 
worldwide) and the inoculation of prion contaminated human growth hormone (162 
cases) extracted from the pituitary gland of CJD infected patients (Furtner et al. 2008, 
Will 2003). Other reported modes of transmission include infected blood transfusions, 
(Hewitt et al. 2006, Llewelyn et al. 2004, Wroe et al. 2006) infected tissue transplants 
(Aguzzi  et  al.  2008,  Lemmer et  al.  2008)  and  an increased risk  from  contaminated 
instruments during surgery on the spinal cord (Bosque et al. 2002). Infectious prions 
have also been found in urine (Andrievskaia et al. 2008, Gonzalez-Romero et al. 2008, 
Van Dorsselaer et al. 2011) and faeces (Maluquer de Motes et al. 2008) of infected 
animals. Levels of prion are around 10 fold less in urine than infected blood samples, 
although this could still pose a risk of disease transmission in both animals and humans.  
 
At  present  there  is  still  concern  over  the  risk  of  transmission  of  PrP
Sc  from 
inadequately decontaminated surgical instruments after potential use in asymptomatic 
CJD patients (Lipscomb et al. 2006e, Murdoch et al. 2006). The resistance of PrP
Sc to 
sterilisation was highlighted by the study of surgical electrodes that became infected 
from an unknown CJD patient. These were decontaminated following standard hospital 
sterile service department (SSD) protocols and used in two further patients, who both 
developed  CJD.  These  electrodes  were  experimentally  reprocessed  following  SSD 
standards and implanted in the brain of a test chimpanzee, which also subsequently 
developed  CJD  (Gibbs  et  al.  1994).  This  work  demonstrated  that  despite  numerous 
decontamination cycles PrP
Sc still remained intact and infectious. Iatrogenic vCJD is 
rare but as more modes of transmission have been reported it has become a greater 
health issue. Especially as recent reports of the transmission of PrP
Sc from blood and 
blood products, suggesting that any surgery where an instrument comes in contact with 
human tissue potentially infected with PrP
Sc could transmit the disease (Hewitt et al. 
2006, Wroe et al. 2006). Furthermore, the transmission of PrP
Sc from surgical stainless 
steel  has  been  clearly  demonstrated  in  both  animal  infectivity  bioassays  and  more 
recently in cell culture assays (Edgeworth et al. 2009, Fichet et al. 2007b, Flechsig et al. 
2001, Yan et al. 2004).  
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Protease-resistant prions bind to many surfaces, including stainless steel, and 
display a marked resistance to conventional methods of decontamination used in SSDs 
(Lemmer et al. 2004). Conventional methods will breakdown and remove most of the 
blood,  protein  and  biofilm  contamination,  but  are  less  effective  at  the  removal  of 
proteinaceous and potentially prion based contamination (Murdoch et al. 2006). Poor 
decontamination  methods  and  standard  controls  used  in  hospital  sterile  service 
departments  have  been  demonstrated  to  be  potential  risk  factors  influencing  iCJD 
transmission (Howlin et al. 2010, Lipscomb et al. 2006d, Lipscomb et al. 2006e, Ungurs 
et  al.  2010).  Moreover,  some  decontamination  chemistries,  when  combined  with 
autoclaving  at  121
oC  for  30  minutes,  were  demonstrated  to  be  less  effective  than 
autoclaving alone, suggesting a chemistry-dependent protective effect on the infectious 
agent  (Jackson  et  al.  2005).  Standard  tissue  fixation  methods  based  on  formalin  or 
aldehydes were found to preserve PrP
Sc infectivity on surfaces due to its proteinaceous 
nature (Stephenson 2007). Furthermore, it is hypothesised that formaldehyde treatment 
cross links the proteins, thus holding together the PrP monomers, potentially forming 
oligomers  containing  14-28  PrP  molecules  which  have  previously  demonstrated 
increased infectivity when compared to other disease associated aggregate sizes (Gale 
2007, Silveira et al. 2005). Treatment with 1-2 M NaOH or 2% NaOCl for 24 hours has 
been demonstrated to inactivate PrP
Sc. However, from a practical standpoint in terms of 
SSD management, using such concentrated alkaline solutions has a detrimental effect 
on instrument integrity and is particularly incompatible with box joints, carbide jaws, 
gold-coated  handles  and  is  completely  incompatible  with  electronic  equipment  and 
endoscopes (Brown et al. 2005, Fichet et al. 2007b, Lemmer et al. 2004, McDonnell et 
al. 2003).  
 
1.5 Prion decontamination 
 
Although heavily researched there is no current cure for this fatal disease and the 
minimum infectious dose required for CJD transmission is unknown (McDonnell and 
Burke  2003).  Therefore,  it  is  crucial  that  a  precautionary  principle  is  adhered  to 
regarding  the  risk  that  instruments  may  not  be  decontaminated  to  a  high  enough 
standard  to  prevent  infection  (Secker  et  al.  2012a).  Furthermore,  prion  protein   30 
aggregates  have  been  visualised  by  direct  instrument  staining  to  accumulate  in  the 
imperfections  within  stainless  steel  surfaces  providing  greater  concerns  regarding 
contamination and potential infectivity in older, damaged equipment (Herve et al. 2010, 
Jackson et al. 2005). The easiest way to reduce the risk of iCJD is to improve hospital 
policy’s  and  to  make  sure  that  all  instruments  used  on  suspected  CJD  patients  are 
quarantined and destroyed or to implement single use instruments in high risk surgeries 
(McDonnell and Burke 2003). However it is neither practical nor cost effective for all 
instruments to be single use, especially due to the intricate nature of many instruments 
used in neurosurgery. As such it is important to address current SSD decontamination 
policies. Certain steps have already been taken by the English Department of Health 
(DH) and the Spongiform Encephalopathy Advisory Committee (SEAC) to decrease 
iatrogenic transmission. These include the destroying and/or quarantining of all surgical 
equipment  that  has  been  in  contact  with  known  or  suspected  CJD  patients  and  the 
upgrading of SSD’s across the UK, in regards to decontamination protocols and the 
introduction of novel, specialised prion sterilisation techniques (Stephenson 2007).  
 
Currently  many  instruments  are  processed  at  centralised  SSDs  and 
decontaminated  through  washer-disinfector  cycles.  There  are  a  number  of  areas  of 
concern  during  the  decontamination  process  of  surgical  instruments.  Recent 
publications  have  highlighted  a  significant  reduction  in  the  efficacy  of  the 
decontamination process if a soiling is allowed to dry onto a surface  (Howlin et al. 
2010, Lipscomb et al. 2007b, Ungurs et al. 2010). Studies have demonstrated that a 
drying time of 15 minutes or longer significantly increases both residual protein and 
prion-associated amyloid biofouling following decontamination, relative to a surface 
which  was  cleaned  immediately  (Secker  et  al.  2011).  Furthermore,  to  address  long 
processing times often  associated  with  the use of  a  centralised SSD system, it  was 
demonstrated that storing instruments in a moist environment post contamination for up 
to 24 hours greatly reduced both protein and prion-associated amyloid bio-burden when 
compared to storage in atmospheric conditions (Secker et al. 2011). This highlighted 
how  simple,  cost  effective  changes  in  current  hospital  practice  could  improve 
decontamination and therefore reduce the risk of iCJD transmission.  
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Washer-disinfector cycles involve 3 main steps; a pre clean or pre-soak, usually 
in an enzymatic cleaner or pre-soak gel, followed by a water rinse and main wash in 
either an alkaline or enzymatic cleaner and a final disinfection step in deionised water at 
90
oC.  After  the  washer-disinfector  phase,  instruments  are  sterilised  through  an 
autoclave  cycle  before  visual  checks  to  confirm  the  instrument  is  clean  for  use. 
Instruments are processed within their surgical sets in large trays with no brushing or 
mechanical removal step and therefore there is no guarantee that all of the instruments 
surfaces  will  be  cleaned  evenly  or  efficiently  during  this  process.  The  cleaning 
chemistries  used  within  these  cycles  have  been  tested  within  both  small  laboratory 
washer-disinfectors and simulated cycles within the lab. Both of these studies relied on 
different  detection  methods  for  remaining  contamination  but  agreed  that  the  lowest 
levels of protein and prion-associated amyloid contamination was observed when an 
alkaline cleaner was used in the main wash (Howlin et al. 2010, Ungurs et al. 2010). 
Both studies also confirmed that prevention measures (either a pre-soak gel or pre-clean 
step) to ensure that surface soiling was not permitted to dry increased the efficacy of 
further  decontamination  steps  and  greatly  reduced  residual  contamination  thus 
correlating with the results of the wet vs. dry study (Secker et al. 2011).  
 
Murdoch  et  al,  2006  concluded  that  SSD  washer  disinfectors  showed  better 
decontamination results compared to hand washing of the surgical instruments, however 
the inadequate SSD decontamination highlighted in this study was likely caused by the 
poor  cleaning  chemistries  or  poor  knowledge  of  optimal  conditions  for  protein 
decontamination or poor maintenance of the washer/disinfectors. Another practice that 
has potential adverse effects on instrument contamination that has been documented is 
the handling of instruments, post decontamination, by SSD staff who do not, in standard 
practises, wear gloves. Whilst not an issue with regards to microbial contamination of 
the instrument surfaces by normal skin flora due to the fact that instruments go through 
a sterilisation process after handling, it has been described that touching the instruments 
with bare hands increases the proteinaceous bio-burden which, during the subsequent 
sterilisation process, will get hardened onto the instrument and potentially decrease the 
efficacy of further decontamination procedures during repeat use (Howlin et al. 2009). 
These proteinaceous deposits could in time harbour infectious prions increasing iCJD 
risk.    32 
 
A  number  of  enzymatic  cleaning  chemistries  have  also  been  tested  for  the 
removal  of  prion  infected  brain  homogenate  from  stainless  steel  surfaces.  Data 
demonstrated  that  there  were  significant  discrepancies  between  the  contamination 
remaining following the different enzymatic cleaners, suggesting that better knowledge 
of each commercially available cleaner is key to improving decontamination (Herve et 
al. 2010). Importantly however, this study only tested residual contamination and not 
the infectivity of the remaining biofouling which is key due to the uncertainty over the 
nature of the infection  agent.  Two different  infectivity  assays  have previously been 
utilised  to  assess  the  levels  of  infectivity  remaining  after  decontamination  in 
commercially available cleaning chemistries. Studies using the 263K hamster infectivity 
assay have determined that although enzymatic cleaners have the capacity to remove 
significant concentrations of soiling, they did not reduce the levels of infectivity. This is 
in contrast to an alkaline cleaner which was demonstrated to greatly reduce residual 
soiling in addition to infectivity (Fichet et al. 2007b, Yan et al. 2004). Importantly, 
contradictory results have been obtained using another infectivity assay using the same 
alkaline chemistry. In this study, the standard steel-binding assay (SSBA) using N2a-
PK1 cells and RML infected brain homogenate demonstrated that the contamination 
remaining after the same alkaline cleaner treatment used by Fichet et al. 2007 had a 
significantly higher level of residual infectivity compared to other products and 2 M 
NaOH treatment (Edgeworth et al. 2011b). Thus, both of these assays relying on two 
different detection methods and two different prion strains showed contradicting results 
highlighting the importance of experimental design in the interpretation of infectivity 
data and decontamination efficacy.  
 
There are a number of scientific groups researching novel prion decontamination 
techniques  which  could  either  be  incorporated  into  current  protocols  or  could  be 
employed as specialised techniques for prion decontamination. Work by Fichet et al, 
2007 experimented with liquid and gaseous hydrogen peroxide treatments. Fichet et al, 
2007 discovered that using gaseous hydrogen peroxidise treatment on 263K hamster 
scrapie prion and mouse 6PB1-adapted BSE strain inoculated on stainless steel wire 
models in hamsters completely attenuated disease transmission, reducing infectivity by 
>5.5 log lethal doses compared to no gaseous hydrogen peroxide treatment. Vaporised   33 
hydrogen peroxide decontamination demonstrated a reduced 263K infectivity of 4.5 log 
lethal  doses  without  damaging  electronic  components  (Fichet  et  al.  2004).  Other 
examples include studies by Jackson et al, 2005 and Weissmann et al, 2002, which 
tested seven different proteolytic enzymes for the decontamination and degradation of 
PrP
Sc. The most promising results from these studies indicate that a combination of PK 
and  Pronase  (a  combination  of  proteases  taken  from  the  extracellular  fluid  of 
Streptomyces  griseu)  in  conjunction  with  SDS removed PrP
Sc  to  below the limit  of 
Western  blot  detection  and  significantly  reduced  infectivity  in  Tg20  PrP
c 
overexpressing  mice  (1/18  mice  developed  disease)  with  a  complete  attenuation  of 
disease transmission in the CD-1 mouse model (Jackson et al. 2005). Jackson et al, 2005 
also showed that autoclaving at 134
oC with a weak alkali, such as NaOH reduces the 
infectivity  of  263K  hamster-adapted  scrapie  prion  on  wires  with  only  1  out  of  10 
hamsters showing signs of disease post intracranial implantation. Fichet  et  al,  2004 
showed autoclaving at 134
oC in only water demonstrated an infectivity reduction of 5.6 
log lethal doses of 263K and without water an infectivity reduction of 4.4 log lethal 
doses. Other novel decontamination methods include photocatalytic degradation using 
photo-fenton  reagents  which  breaks  down  the  prion  by  photo  induced  oxidative 
intermediates,  which  has  demonstrated  reduced  prion  contamination  below 
immunoblotting detection range (Paspaltsis et al. 2009). The use of proteases has also 
been  tested  for  prion  decontamination.  The  protease  MC3,  a  genetically  modified 
protease engineered from Bacillus lentus subtilisin, has been shown by Western blot to 
reduce contamination levels of BSE strain 301V at alkaline pH (Dickinson et al. 2009). 
A  further  study  has  claimed  that  a  secreted  protease  from  Aeropyrum  pernix  (a 
hyperthermophilic marine archeon) has the ability to digest PrP
Sc from mouse, bovine 
and  human  prion  strains  and  may  show  promise  as  a  novel  decontamination  agent 
(Alper et al. 1967).  
   
In  addition  to  the  improvement  or  introduction  of  novel  decontamination 
protocols,  advances  have  also  been  made  in  modifications  to  instrument  surface 
chemistry. Alternative anti-burden coatings consisting of diamond-like carbon (DLC) 
that can be incorporated onto surgical instruments have demonstrated a reduction in the  
initial  attachment  of  protein  and  prion  and,  as  a  consequence,  an  improvement  in 
subsequent decontamination efficacy (Secker et al. 2012b). The diamond-like carbon 
(DLC) coating study investigated several DLC coated stainless steel tokens doped with   34 
various  chemical  elements  and  their  effect  on  contamination  and  decontamination 
efficacy of prion biofouling. DLC coatings alone have a number of useful properties 
within a surgical environment including improved biocompatibility, low friction, hard 
wearing, high chemical inertness, low corrosion and increased smoothness (Roy et al. 
2007). Of particular benefit is that DLC has an amorphous structure which allows the 
doping  of  a  number  of  different  elements  at  different  concentrations,  enabling 
modification to the surface energies and hydrophobicity of the DLC surface. The doping 
of  DLC  with  elements  has  been  shown  theoretically  to  produce  the  right  surface 
conditions for reducing protein adhesion (Borisenko et al. 2008). The integration of 
silicon and nitrogen to DLC surfaces has also shown a reduction in the attachment of 
bacterial biofilms, especially with nitrogen doping, compared to un-doped DLC (Liu et 
al. 2008). Furthermore the incorporation of silicon in DLC improves the friction wear 
and  shows  lower  corrosion  compared  to  DLC  alone  (Kim  et  al.  2008).  This  study 
demonstrated that doped DLC coated tokens reduced ME7-scrapie prion attachment and 
improved  decontamination;  however  different  doped  tokens  showed  varying  results 
depending on the cleaning chemistry used (Secker et al. 2012b). This highlights the 
potential of a new generation of surgical instruments that could reduce the risk of iCJD 
without the need of changing current decontamination protocols.   
 
1.6 Prion detection technologies 
 
To  properly  utilise  the  research  and  development  of  new  decontamination 
protocols there needs to be a standard comparable method of detection for accurate 
comparison. Current prion detection technologies are split into two categories: those 
that detect PrP
Sc or prion-associated amyloid, or those assays which evaluate infectivity, 
primarily studied using animal infectivity bioassays (Fichet et al. 2007b, Lawson 2008). 
However, more recently technologies have moved towards the use of cell-based assays. 
The original methods used for prion detection on surgical instruments assessed total 
protein presence, including the ninhydrin chromogenic and biuret assays, in conjunction 
with visual assessment of surgical instrument contamination which have been reported 
to be grossly insensitive at detecting the protein contamination accurately (Lipscomb et 
al. 2006b). There is currently no set standard for prion detection and there is room for   35 
improvement of current techniques and the production of novel methods. The following 
section highlights the key techniques used in the field.  
 
1.6.1 Detection of prion proteins 
 
A number of techniques, both standard and novel have been produced to detect 
the presence of the prion protein or other markers of prion disease including amyloid 
plaques. These include Western Blot, Enzyme-linked immunosorbent assay (ELISA), 
Immunohistochemistry  (IHC),  Conformation-dependant  immunoassay  (CDI),  Fourier 
transform infrared spectroscopy (FT-IR) (Reviewed in Sakudo et al. 2007) and mass 
spectrometry (MS) to name a few  (Silva et al. 2011). However, this section is going to 
concentrate on Western Blot detection of PrP
Sc, as it is the most widely used method for 
prion detection and the SYPRO Ruby/Thioflavin T (SR/ThT) dual stain as it is the most 
relevant technique to this study.   
 
1.6.1.1 Western blot 
 
Western blot detection of PrP
Sc has been the most widely used method for prion 
detection.  This  involves  the  forceful  removal  of  contamination  from  a  surface  or 
instrument  being  assessed,  or  from  the  detection  of  PrP
Sc  within  infected  brain 
homogenates, cell lysates and formalin fixed or fresh tissue (Nicholson et al. 2007). 
Samples are firstly digested with proteinase K (PK) to breakdown the PK sensitive PrP
c 
and leave the PK resistant region of PrP
Sc (PrP
res or PrP
27-30) for immuno-detection. 
Briefly,  the  digested  proteins  are  separated  on  a  SDS/polyacrylamide  gel,  blotted 
overnight and immunochemically stained using one of many commercially available 
prion specific antibodies. The PK digestion is required because currently there are no 
commercially  available  antibodies  which  distinguish  between  PrP
c  and  PrP
Sc.  Some 
groups have claimed to have produced PrP
Sc specific antibodies, for example 15B3 from 
Prionics,  but  further studies  have highlighted problems  in  their design  (Korth  et  al. 
1997). 15B3 and three other motif-grafted monoclonal antibodies were shown to react 
to both infectious and non-infectious residues of the prion protein, suggesting a lack of   36 
specificity to  the  resistant  core of PrP
Sc alone  (Biasini et  al.  2008). Different  prion 
strains  demonstrate  different  intensities  of  the  three  glycoforms  of  PrP
Sc  (di-
glycosylated,  mono-glycosylated  and  un-glycosylated)  which  can  be  mapped  using 
Western blot (Grassi et al. 2008). As a result, Western blotting can also be used to 
characterise different prions strains by utilising a range of antibodies which bind to 
different regions of the prion protein. Although Western blotting is widely utilised it has 
a  limited  sensitivity  of  detection  of  around  100ng  of  PK  digested  prion  using 
chemiluminescence detection (Herve et al. 2009, Lipscomb et al. 2007a). Furthermore, 
the  need  to  forcefully  remove  prion  contamination  from  a  test  surface  before  PK 
digestion  can  give  inaccurate  results  due  to  the  inherent  variability  in  the  removal 
process  and  the  methods  used.  Western  blot  detection  is  also  an  in  vitro  detection 
method. Whilst this is useful for the study of prion removal, results have been shown to 
correlate poorly with in vivo animal infectivity bioassays (Fichet et al. 2007b, Howlin et 
al. 2010).           
 
1.6.1.2 SR/ThT dual stain 
 
A  novel  technique  involving  the  use  of  Episcopic  differential  interference 
contrast microscopy (EDIC) coupled with epi-fluorescence (EF) to detect both stained 
protein  and  prion-associated  amyloid  contamination  on  instruments  or  experimental 
metal token surfaces has been studied at the University of Southampton (Keevil 2003, 
Lipscomb et al. 2006c). Differential interference microscopy (DIC) is used to produce 
rapid, pseudo 3-dimensional images of specimens without the need of taking optical 
slices. Briefly, plane-polarised light is produced by passing the light beams through a 
polarizer  situated  beneath  the  stage  condenser.  This  light  then  travels  through  a 
Nomarski-prism which splits that light beam into two perpendicularly vibrating rays. 
These rays travel in parallel until they come into contact with the specimen at which 
point  the  wave  path  of  the  rays  of  light  are  altered  by  the  surface  properties  and 
refractive index of the sample. The beams of light pass through the objective lens where 
the beams are focused and passed through a second prism which unites the two separate 
beams. These beams then travel through another polarizer to create interference that 
brings the beams into the same focal plane and axis which can then be viewed through 
the eyepiece as the highly contrasted 3-dimensional image. DIC relies on transmitted   37 
light that requires transparent samples and oil immersion that poses difficulties when 
analysing  contamination  on  solid,  opaque  surfaces.  EDIC  microscopy  relies  on  the 
rearrangement of the DIC concept where one DIC polarizer is positioned in one of the 
filter bloc cubes above the stage and an adjustable analyser is fitted between the DIC 
block and the eyepiece (Keevil 2003). The adjustable analyser can be removed and the 
DIC filter block replaced for the use of the microscope for EF analysis that can be 
coupled with the EDIC images (Keevil 2003). Furthermore, the EDIC microscopes are 
fitted with long distance working lenses that negate the need for coverslips and oil 
immersion (Keevil 2003). The use of episcopic light and the long distance lenses allows 
the  EDIC  analysis  of  opaque,  curved  solid  samples  such  as  surgical  instruments, 
surgical  surfaces  and  leaves.  Furthermore,  the  EF  analysis  of  protein,  amyloid  or 
microbes can be coupled with the EDIC analysis of the surface for the correlation of 
surface topography with contamination (Herve et al. 2009, Herve et al. 2010, Lipscomb 
et al. 2006c, Lipscomb et al. 2006d, Secker et al. 2011, Secker et al. 2012b, Warner et 
al. 2008).      
 
Using EDIC/EF, the use of SYPRO ruby (SR – A protein blot stain usually used 
for  staining  total  protein  on  Western  blot  membranes)  as  a  rapid  method  for  the 
detection of protein contamination on stainless steel instrument surfaces was reported 
(Lipscomb  et  al.  2006c).  Subsequently  Lipscomb  et  al  2007  went  on  to  develop  a 
staining protocol to detect prion-associated amyloid contamination on surgical surfaces. 
This method involves the use of either of two thiazole derivatives, Thioflavin T (ThT) 
and Thioflavin S (ThS) (Lipscomb et al. 2007a). Thiazole derivatives and Congo red are 
known stains that readily bind to amyloid fibrils (Kroes-Nijboer et al. 2009, Maezawa et 
al. 2008). One significant benefit of ThT in fluorescent microscopy is that it possesses a 
large  Stoke’s  shift  when  bound  to  amyloid,  compared  to  ThS,  which  improves  its 
contrast against background autofluorescence (Colby et al. 2007). Amyloid fibrils are 
formed from the polymerisation of β-sheets that run in both parallel and anti-parallel 
directions forming rows and subsequently neat channels that have been proposed as the 
binding sites for ThT which is thought to bind in parallel to these channels (Wilesmith 
et al. 1992). Due to the size of ThT and the channels, it is only possible for the ThT 
molecules to fit in one direction and it is this conformation of the ThT within these 
channels that yields the highest levels of fluorescent emission (Wilesmith et al. 1992). 
Interestingly, ThT has also been demonstrated to form micelles at higher concentrations   38 
in aqueous solutions (Bradley and Brown 2012). It has been observed using atomic 
force microscopy (AFM) that these ThT micelles bind in the channels of the amyloid 
fibrils and therefore show increased fluorescent properties (Bradley and Brown 2012). 
Therefore, Thioflavin T is used in this protocol as it will bind to prion rich amyloid 
thus, detecting the presence of prion contamination; however, ThT is not specific to 
prion-associated amyloid but it will also bind to amyloid aggregates formed in AD and 
other neurodegenerative diseases. Lipscomb et al, 2007a concluded that ThT staining 
visualised using EDIC/EF was at least 2 logs more sensitive than Western blot for the 
detection of prion contamination. Recently these two stains were brought together to 
produce a SR/ThT dual stain which was able to detect protein and prion-associated 
amyloid  contamination  down  to  less  than  1ng  in  situ  on  surgical  instruments 
maintaining the increased sensitivity previously reported by Lipscomb et al. 2007a over 
the Western blot technique (Herve et al. 2009).  
 
1.6.2 PrP
Sc amplification methods 
 
One of the biggest breakthroughs in the research of prion detection methods has 
been the development of methods to artificially amplify small, undetectable levels of 
PrP
Sc to levels that can be detected via standard techniques such as Western Blot or ThT 
fluorescence. However these techniques, although very useful do have their limitations 
which are discussed within the next sections.  
 
1.6.2.1 Protein misfolding cyclic amplification (PMCA)  
 
To  address  the  problem  of  low  sensitivity  in  current  detection  methods  an 
innovative technique has been developed that amplifies the low levels of PrP
Sc in dilute 
samples prior to detection using Western blot. Protein misfolding cyclic amplification 
(PMCA) relies on a similar logical process as the polymerase chain reaction (PCR), 
where the template-assisted model of prion propagation is utilised to amplify levels of 
PrP
Sc (Grassi et al. 2008, Saborio et al. 2001). Samples potentially containing PrP
Sc are 
incubated  with  large  quantities  of  PrP
c  from  the  same  species.  This  initiates  the   39 
formation of PrP
Sc - PrP
C protein aggregates which are then broken down to smaller 
PrP
Sc  aggregates/single  proteins  by  sonication  thereby  seeding  further  conversion 
reactions  (Saborio  et  al.  2001,  Soto  et  al.  2005).  These  steps  are  repeated  until  a 
detectable level of PrP
Sc is reached via the detection of PrP
res utilising WB analysis. The 
theory of these reactions suggests there should only be PrP
Sc amplification if there is 
infectious prion present in the sample in the first place.  
 
PMCA has been demonstrated to amplify various prions strains including 263K, 
BSE, sCJD, vCJD, RML (Rocky Mountain laboratory derived mouse scrapie) and goat 
scrapie (Saborio et al. 2001, Soto et al. 2005). Following this, Soto’s group studied the 
infectivity  of  various  amplified  prion  strains  following  20  cycles  of  PMCA.  It  was 
concluded that the artificially amplified prions displayed the same infectious properties 
as their parental PrP
Sc samples, suggesting that PMCA does not alter the biochemical 
properties or conformation of PrP
Sc (Castilla et al. 2008). PMCA has also been used to 
amplify PrP
Sc after dry heating and autoclave inactivation to determine if these methods 
removed  and/or  denatured  the  prion.  This  work  was  confirmed  by  analysis  of  the 
samples utilising infectivity bioassays which correlated with the WB PrP
Sc detection 
after PMCA (Murayama et al. 2006). 
 
 Adaptations to the original PMCA protocol have been made to improve the 
sensitivity  and  speed  of  the  reactions.  Serial  PMCA  (sPMCA)  involves  the  same 
underlying protocol as standard PMCA with the exception that after every 10 rounds the 
reaction  mixture  is  diluted  with  normal  hamster  brain  homogenate  to  restock  the 
depleted PrP
c levels to instigate more PrP
Sc conversion and therefore improve sensitivity 
of this assay (Weber et al. 2007). The sPMCA assay produced infectious prions with the 
same characteristics as the original prion seed and no loss of PrP
Sc infectivity in animal 
infectivity models (Weber et al. 2007). Another adaption of PMCA, denoted PMCAb, 
involves the incorporation of small beads of differing materials into the assay. This has 
two beneficial effects. Firstly, PrP
Sc will favourably bind to some of the bead surfaces, 
thus,  concentrating  the  PrP
Sc  molecules  within  a  sample.  Secondly,  during  the 
sonication  stages  the  nano-beads  will  further  aid  the  breakup  of  PrP
c  and  PrP
Sc 
aggregates  producing  a  favourable  environment  for  further  propagation  (Gonzalez-
Montalban  et  al.  2011).  Different  beads  instigate  varying  rates  of  amplification  of   40 
different prion strains, therefore it is crucial to understand which beads are required for 
the optimal amplification of the prion strain that is being assessed (Gonzalez-Montalban 
et al. 2011).   
 
Although PMCA is a useful tool it does present some limitations. It is difficult to 
obtain large amounts of PrP
c from specific species samples (Grassi et al. 2008). Whilst 
recombinant  PrP  can be used, it is  not  fully  understood whether this  may  alter the 
structure of PrP
Sc in unknown ways or introduce false amplification within the assay.  
The  other  limitation  is  that  the  infectivity  of  amplified  PrP
Sc  appears  to  drop  with 
increasing PMCA cycles up to and over three. This could suggest that PMCA is not just 
amplifying PrP
Sc but it is also altering its properties or conformation (Murayama et al. 
2006). Critically however, a study by Deleault et al, 2007 managed to use PMCA to 
form de novo infectious prion in a prion free environment with no PrP
Sc seed. They used 
the PMCA reaction with only PrP
c and co-purified lipid molecules and managed to form 
infectious  PrP
Sc  within  16  rounds  of  PMCA.  This  potentially  highlights  a  severe 
drawback  in  the  PMCA  technique  demonstrating  that  PMCA  can  produce  artificial 
infectious molecules after excessive amplification rounds under the right conditions, 
therefore questioning the reliability of PMCA based assays (Deleault et al. 2007). 
 
1.6.2.2 Real-time quaking induced conversion assay (RT-QUIC) 
 
The  Real-time  quaking  induced  conversion  assay  (RT-QUIC)  is  an 
amalgamation of two different assays; the quaking induced conversion assay (QUIC) 
(Atarashi  et al. 2008) and the amyloid seeding assay (ASA)  (Atarashi et al. 2011a, 
Colby et al. 2007, Wilham et al. 2010) to produce an assay that amplifies prions with a 
highly sensitive method of detection. The QUIC method involves the amplification of 
PrP
Sc by incubation with recombinant PrP
c in order to solve the issue of poor availability 
of large quantities of natural PrP
c. The amplification is induced by the periodic shaking 
or quaking of the sample to break-up formed aggregates and therefore induce further 
PrP
Sc conversion (Atarashi et al. 2008). Instead of Western blot detection, the ASA 
technique is used to increase detection sensitivity. This method involves the detection of 
amyloid  production  as  a  pathological  marker  of  prion  propagation  using  ThT   41 
fluorescence detected via spectroscopy (Colby et al. 2007). The RT-QUIC assay has 
demonstrated  improved  sensitivity  and  has  no  observed  issues  when  compared  to 
PMCA  regarding  the  observation  of  the  spontaneous  production  of  de  novo  prions. 
However, one concern that has  arisen pertains  to the question of how  much  of the 
amplification  of  PrP
Sc  using  a  recombinant  PrP
c  source  and  subsequent  amyloid 
detection relates to prion infectivity (Wilham et al. 2010). Nevertheless, RT-QUIC has 
demonstrated a sensitivity matching animal bioassay models with an additional benefit 
of the ability of RT-QUIC to obtain results in several days compared to the hundreds of 
days required for standard animal bioassays. In addition, RT-QUIC has demonstrated 
100% specificity and 80% sensitivity of PrP
Sc detection in cerebral spinal fluid (CSF) 
samples from sCJD patients (Atarashi et al. 2011b, McGuire et al. 2012). The RT-QUIC 
assay has also established the detection of prion amplification from 263K, nasal lavage 
from HY TME samples, CSF from 263K infected hamsters, scrapie and CWD samples 
(Wilham et al. 2010). Furthermore, RT-QUIC has been adapted to involve an immuno-
precipitation  step  utilising  the  prion-specific  monoclonal  antibody  15B3,  for  the 
sensitive detection of vCJD prions in blood plasma (Orrú et al. 2011).       
 
 
1.6.3 Detection of PrP
Sc in blood 
 
Since the heightened concern over the risk of vCJD transmission from infected 
blood  transfusions,  there  has  been  an  increase  of  research  into  methods  capable  of 
detecting PrP
Sc in blood. The use of substrates to capture PrP
Sc within blood samples 
prior  to  detection  seems  to  be  the  crucial  step  for  these  assays.  The  immuno-
precipitation of prions within the blood samples uses antibody labelled beads to capture 
PrP
Sc, which can then be detected using an improved ELISA sandwich method allowing 
for the sensitive detection of PrP
Sc in vCJD spiked whole blood without the use of PK 
digestion (Tattum et al. 2010). This is of particular relevance as the detection of disease 
with PrP
Sc sensitive to PK digestion has been noted (D'Castro et al. 2010, Kuczius et al. 
1999, Pastrana et al. 2006, Thackray et al. 2007). The use of a magnetic bead system, 
called Magnabind beads or magnetite nanoparticles, has been utilised to capture and 
remove PrP
Sc from biological samples that can then be detected using PMCA and WB   42 
detection (Miller et al. 2011). However, whilst this technique has the potential for the 
detection of prions in vCJD bloods, it has not yet been validated.  
 
There are two promising techniques for the detection of vCJD infected blood 
regarding increased sensitivity and specificity above other techniques. Enhanced RT-
QUIC, that has involved the specific detection of vCJD in plasma (but not whole blood) 
has demonstrated a detection limit of 10
-14 fold dilutions of vCJD in plasma (Orrú et al. 
2011). The second technique is the use of a solid state matrix, containing stainless steel 
particles used to capture the PrP
Sc from vCJD infected blood, allowing the sensitive 
detection of PrP
Sc using super signal ELISA (Edgeworth et al. 2011a). This technique 
has  demonstrated  the  ability  to  detect  both  vCJD  and  sCJD  infected  whole  blood 
samples  from  a  cohort  of  190  masked  bloods  with  100%  specificity  showing  its 
potential  as  a  blood  screening  technique  (Edgeworth  et  al.  2011a).  However  this 
technique is ~10,000 fold less sensitive than the enhanced RT-QUIC assay (Edgeworth 
et  al.  2011a,  Orrú  et  al.  2011).  Whilst  these  techniques  are  valuable  tools  for  the 
detection of the potential for blood transmission of vCJD, they cannot demonstrate the 
infectivity of the prions within the blood samples and therefore the real risk of vCJD 
transmission.  
 
1.6.4 Detection of PrP
Sc infectivity 
 
1.6.4.1 Infectivity Bioassays 
 
The methods described previously are the foremost methods used for detecting 
the presence of PrP
Sc within a sample or on a surgical instrument, but they do not detect 
the infectivity of the remaining contamination. The only current methods used to detect 
prion infectivity are animal infectivity bioassay models (Fichet et al. 2007b, Grassi et al. 
2008, Lawson 2008, Lemmer et al. 2008). Bioassays involve the controlled infection of 
small rodents, usually mice or hamster. The samples are introduced to the animal by an 
injection of an infected sample or brain homogenate via the intracranial route, or by   43 
inserting pre-infected wires, as instrument models into the prefrontal sub-cortical region 
of the rodent’s brain (Figure 8) (Fichet et al. 2007b, Grassi et al. 2008). The animals are 
then left, typically for 365 days or until they succumb to disease. At this point, common 
detection  methods,  such  as  Western  blot  and  immunohistochemistry,  are  used  to 
determine the presence of PrP
Sc and TSE disease symptoms. Fichet et al, 2007b used 
infectivity bioassays to study the effects of heat and chemical decontamination on prion 
infectivity and also the difference between 263K and 6PB1 prion homogenates tested in 
vivo. Their conclusions showed that there were no discrepancies in the resistance of 
263K and 6PB1 to various decontamination methods. This has been contradicted by the 
work of others including Giles et al, 2008 where they have shown differences in the 
resistance of the same prion strains to different decontamination methods, highlighting 
the importance of understanding the efficacy of different decontamination protocols on 
different prion strains.  
 
A significant limitation of the animal bioassay model is that it relies on Western 
blot detection which has previously reported low sensitivity. Additionally, the use of 
wires implanted into the brain could pose problems because the prion contamination 
could  be  partially  removed  during  implantation.  Moreover,  implantation  wires  have 
been proven to be easier to decontaminate relative to bigger, flat stainless steel surfaces 
and so  represent  a poor model to  replicate the  complexities of surgical instruments  
(Lipscomb  et  al.  2006a).  Furthermore,  the  problem  with  current  animal  infectivity 
bioassays  is  there  suitability  to  only  analyse  the  infectivity  of  animal  prion  strains, 
which previously seemed like a good model for vCJD. However, recent studies have 
demonstrated  variations  in  the  resistance  of  different  prion  strains  to  different 
decontamination  strategies  (Giles  et  al.  2008,  Peretz    et  al.  2006).  This  questions 
whether  animal  prion  strains  are  valid  models  for  vCJD  decontamination  and 
inactivation and opens the scope for novel infectivity assays that have the ability to 
assess the infectivity and decontamination of vCJD. 
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Figure 8 – Schematic of animal infectivity bioassays 
A schematic diagram of model PrP
Sc animal infectivity assays for the determination of PrP
Sc 
infectivity and decontamination. The infectivity of infected brain homogenate (IBH) is either 
tested by serial dilution in normal brain homogenate (NBH) or from IBH inoculated wires. 
(adapted from Lawson 2008) 
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1.6.4.2 Cell culture assays 
 
There  are  currently  a  large  variety  of  prion  detection  methods,  but  all  have 
limitations. Some lack sensitivity, whilst others are not specific enough. Moreover, no 
method is currently capable of assessing both infectivity and prion presence in situ. 
  
New  cell-based  assays  have  the  potential  to  detect  the  infectivity  after 
decontamination  of  both  animal  and  human  prions  without  the  need  to  remove 
contamination from instruments prior to analysis (Reviewed in Solassol et al. 2003, 
Vilette 2008). Another advantage of utilising cell culture systems for the detection of 
prion infectivity is that different cell lines are susceptible to infection from different 
prion  strains.  A  sensitive  detection  method  can  then  be  utilised  to  detect  the  prion 
propagation  or  accumulation  within  the  cell  as  a  marker  of  infectivity.  Table  4 
highlights  a  number  of  neuronal  cell  lines  and  the  prion  strains  that  have  been 
transmitted to these cells. However, a single cell line has not yet been demonstrated to 
be capable of being infected by more than a few prion strains and so far only one cell 
line has demonstrated the ability to detect infectivity from CJD samples. Therefore the 
method of detection has to be transferable between different cell lines to improve the 
dynamic range of prion strains that can be analysed. 
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                                                                                                                            Prion strains or isolates 
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N1E-115  Mouse  Neuroblastoma                                 
C-1300  Mouse  Neuroblastoma                                 
N2a  Mouse  Neuroblastoma                                 
N2a #58  Mouse  Subclone of N2a                                 
N2a-PK1  Mouse  Subclone of N2a                                 
N2a-R33  Mouse  Subclone of N2a                                 
SHSY-5Y  Human  Neuroblastoma                                 
PC12  Rat  Phenochromocytoma                                 
GTI-1  Mouse  Hypothalamic neuronal cells subclone 1                                 
GTI-7  Mouse  Hypothalamic neuronal cells subclone 2                                 
SN56  Mouse  Hybrid septal neuron/neuroblastoma                                 
CAD-2A2D5  Mouse  CNS catecholaminergic cell line                                  
HpL3-7  Mouse  Hippocampal cells                                 
CGN
ov  Mouse  Cerebellar granule neurons                                  
NSC  Mouse  Neural stem cells                                  
 
Table 4 – Cell lines and reported prion strain susceptibility    
Neuronal cell lines from various hosts susceptible to infection from different prion strains. (adapted from Nuvolone et al. 2009).  
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The most commonly used cell lines for prion research are neuroblastoma cells. 
Neuroblastoma cells are a cancer cell line that show one of the highest rates of tumour 
regression (Schwartz et al. 2013). Neuroblastoma cells characteristically demonstrate a 
small, round, tear shaped morphology. In addition, mature cells tend to grow neurite 
processes and a portion of cells group to form a large number of tumour spheroids 
within confluent cells (Figure 9) (Schwartz and Boles 2013). 
 
Figure 9 – Micrograph of N2a #58 cells  
A  micrograph  of  N2a  cells  captured  using  inverted  phase  contrast  microscopy.  A)  The 
beginning of neurite process formation. B) Early accumulation of cells associated with spheroid 
growth. 
 
Mouse  neuroblastoma  or  “N2a”  cells  have  been  utilised  for  prion  research, 
particularly infectivity based studies because of their ease of culture and their ability to 
be transfected easily, thus adapting their susceptibility to infection of different prion 
strains. The prion transmission within these cell lines has been studied from the late 
1980’s. Butler et al, 1988  studied neuroblastoma cell lines relative to other cell lines for 
their ability to propagate scrapie prions (Butler et al. 1988). This work demonstrated 
that  other  cell  lines,  for  example  mouse  L  cell  lines  and  N1E  115  (a  murine 
neuroblastoma cell line) lost detectable prion infectivity after several passages. Also 
A 
B  
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PC12, a rat cell line showed “species-barrier” compatibility problems after infection 
with murine prions (Butler et al. 1988).  
 
Different clones of N2a cells have demonstrated susceptibility to infection from 
various prion strains (Table 4). An assay using a clone of scrapie N2a cells, denoted 
scN2a, which overexpresses the wild type mouse cellular prion protein, managed to be 
infected by three different mouse adapted prion scrapie strains; 139a, Chandler and 22L.  
However these cells were not infected by similar murine scrapie strains; 87V and 22A 
(Nishida et al. 2000). Klohn et al, 2003 first published work on a new cell assay they 
called the standard scrapie cell assay (SSCA). Using this assay they demonstrated the 
Rocky  mountain  laboratory  (RML)  prion  infection  of  two  sub-clones  of  N2a  cells, 
denoted N2aPK1 and N2a PD88, and concluded that the SSCA is about as sensitive as 
the mouse bioassay, 10 times faster, less expensive and suitable for production within 
an automated system (Klohn et al. 2003). This assay also demonstrated the transmission 
of prion infectivity from a 10
-8 dilution of  RML infected brain homogenate (Klohn et 
al. 2003). The SSCA has been further utilised to assess four different N2a sub-clones; 
PK1, R33, CAD5 and LD9 and the transmissibility of four different prion strains; RML, 
22L, 301C and ME7 was compared in these four cell lines (Mahal et al. 2007). The 
infectivity of the four prion strains varied in each of the N2a sub-clones with different 
prions  strains  showing  infectivity  in  different  sub-clones.  Mouse  22L  showed  the 
greatest infectivity in all of the cell lines whereas 301C only showed infectivity in the 
CAD5 cell line (Mahal et al. 2007). 
 
 More recently the SSCA was adapted to form the scrapie cell endpoint assay 
(SCEPA) which involved the analysis of cells exposed to serial dilutions of prion strains 
to analyse the sensitivity of this assay (Edgeworth et al. 2009, Klohn et al. 2003, Mahal 
et  al.  2007). The SCEPA  was  then further  adapted to  evaluate prion contamination 
absorbed onto model stainless steel wires (Edgeworth et al. 2009). This assay managed 
to detect prion down to a 10
-10 dilution of RML prion infection on inoculated wires 
(Edgeworth et al. 2009). However this assay involved a large number of cell passage 
steps, post infection, which could pose a problem when adapting this assay for the use 
of different, less hardy cell lines. In addition, the infected cells are analysed by each 
well of a 96 well plate being filtered off, PK digested and the detected via antibody  
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labelling. Therefore, it is unknown whether PK digestion is digesting the cells captured 
on the filter membrane and whether the results are a true representation of the natural 
propagation. Furthermore, the same group demonstrated the propagation of infectious 
prions from wires that had only been inoculated with uninfected normal mouse brain 
homogenate  using  the  SCEPA  assay  (Edgeworth  et  al.  2010).  The  spontaneously 
formed  prions  observed  in  this  assay  are  likely  a  consequence  of  either  de  novo 
formation, as in the PMCA assay, or a consequence of minute, undetectable infectious 
prions in normal, uninfected brain homogenate; furthermore it could also be a limitation 
or the production of an artefact with in this assay. However, the SCEPA assay utilised 
to  detect  infectivity  of  prions  absorbed  on  stainless  steel  wires,  also  known  as  the 
stainless steel-binding assay (SSBA), was later utilised to assess the efficacy of various 
cleaning chemistries in relation to remaining infectivity post treatment (Edgeworth et al. 
2011b).  
 
N2a cell lines have also been used in a number of other aspects of prion research 
ranging from the search for anti-prion agents to detecting the mechanisms behind PrP
Sc 
infectivity. A common factor in these studies seems to be the addition or subtraction of 
certain molecular factors to understand the effects these have on prion infectivity or to 
try and further our understanding of the infectious agent.  Further studies of the PK 
digestion of PrP
Sc confirmed the resistance of PrP
Sc to PK digestion and demonstrated 
remaining  infectivity  (Neary  et  al.  1991).  Zhang  et  al,  2003  studied  the  effects  of 
cathepsin activity on the conversion of PrP
c to PrP
Sc and determined there may be a 
second  autocatalytic  route  in  the  production  of  PrP
Sc  (Zhang  et  al.  2003).  Various 
reports  have  used  N2a  cell  infectivity  to  look  at  the  use  of  anti-prion  agents  in 
preventing prion transmission and propagation. Agents that have been proven to stop 
prion  infection  using  these  cell  assays  include  β-cyclodextrins  and  methyl  β-
cyclodextrins, (Prior et al. 2007) various monoclonal antibodies including; 7H6, 7A12 
(Pankiewicz et al. 2006) and 6H4 (Enari et al. 2001) and finally phosphatidylinositol-
specific  phospholipase  C  for  the  digestion  of  the  GPI  anchors  associated  with  PrP
c 
(PIPLC)  (Enari  et  al.  2001).  N2a  cells  have  recently  been  used  to  visualise  the 
immunolocalisation of PrP
Sc using novel light and electron microscopy techniques to 
understand more of the prion cellular pathways and the routes of transmission of PrP
Sc 
involved in prion infection (Veith et al. 2009). All of these techniques highlight N2a 
cells as good models for prion infectivity, albeit only utilising animal derived prion  
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strains. Subsequently cell lines need to be determined and selected for each prion strain; 
currently  none  are  versatile  for  a  range  of  prion  strains  or,  most  importantly,  CJD 
infected material. 
 
PrP
c is predominantly found on cells of the CNS, especially neuronal cells and 
are the main cell type associated with the neurodegenerative symptoms associated with 
PrP
Sc infection in TSE’s. Neural stem cells (NSC) are multi-potent primary cells that 
self-proliferate into various progenitor cells which have the ability to differentiate to 
three important cell types of the CNS; neurons, astrocytes and oligodendrocytes. It is 
possible to culture NSC’s and induce differentiation of these cells by the removal of the 
mitotic  factor  at  which  point  different  supplements  can  be  introduced  to  control 
differentiation to favour one of the three cell types. In the case demonstrated in Figure 
10,  B27  supplement  was  used  to  initiate  differentiation  of  a  neuronal  rich  culture, 
instead of oligodendrocytes and astrocytes. This highlights the potential to produce a 
neuron  rich  culture  with  the  possibility  of  utilising  them  for  a  cell  based  prion 
infectivity assays without the need to genetically manipulate the cells and therefore the 
development of an assay that utilises natural PrP
c.   
 
 
Figure 10 – Example micrographs of NSC’s 
Example micrographs of neural stem cells both undifferentiated (left) and differentiated (right) 
captured using phase contrast microscopy.  
 
The use of NSC’s for prion infectivity studies is a relatively new concept and 
very little information has been reported on this subject. Kellermann et al, 2002 have  
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studied an F9 teratocarcinoma cell line, denoted 1C11, which has similar differentiation 
properties to NSC’s. The 1C11 line has been infected with three prion strains; Chandler, 
22L and Fukuoka-1. However this cell line is not capable of evaluating CJD prions 
(Kellermann et al. 2002). RML prion infection into mouse neurospheres, which contain 
stem cells of the CNS has also been demonstrated, but again this is a mouse based 
model and is unlikely to be susceptible to CJD infection (Giri et al. 2006). Sylvain 
Lehmann’s group from Montpellier have produced a NSC based model for the detection 
of prion infectivity. For this study they used mouse foetal NSC’s in which they studied 
the use of various growth factors at the point of differentiation to aid prion transmission 
post differentiation. This confirmed that growth factors play an important role in the 
sustainability of prion infection within NSC cultures and also demonstrated that fetal 
calf serum (FCS) induced the highest propagation of prion infectivity within this culture 
system  (Milhavet  et  al.  2006).  This  assay  demonstrated  the  ability  to  infect  mouse 
NSC’s with 22L mouse adapted scrapie prion (Milhavet et al. 2006). However, whether 
mouse NSC’s have the ability to propagate CJD prions is unknown. It is possible that a 
mouse NSC or human NSC cell line has the ability to propagate infection from human 
CJD samples, which would give rise to a cell-based assay to detect prion infectivity 
before and after decontamination of suspected CJD contaminated surgical instruments.  
 
1.7 Aims and objectives  
 
  The current risk of iCJD appears to be in decline; however, with the increased 
number of PrP
Sc carriers discovered during the recent appendices study, the potentially 
long incubation periods of CJD and the unknown effects of genetic predisposition on 
disease outcome, the risk of iCJD could be very much larger than anticipated. Cell-
based  bioassays  for  the  detection  of  prion  infectivity  offer  the  potential  for  a  new 
generation of infectivity assays that can be easily adapted to detect multiple disease 
markers  alongside  being  flexible  for  the  detection  of  different  prion  strains. 
Furthermore, they have fewer limitations, when compared to the currently used animal-
bioassays, which have been previously highlighted within this report. Current cell-based 
assays utilise ex situ analysis of PrP
res accumulation by immuno labelling post digestion  
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of PrP
c with PK. However it has been documented that up to 80% of disease associated 
material  is  also  digested  by  PK,  thus,  questioning  the  viability  of  these  assays  as 
standalone techniques in relation to relevant risk of disease. Therefore, this project has 
three main aims: 
 
  To produce a sensitive, in situ, amyloid-based detection method for the analysis 
of prion infectivity in neuroblastoma cells. 
 
  To adapt this sensitive cell-based assay for the detection of prion infectivity in 
relation to prion decontamination efficacy, alongside comparison with animal-
bioassay data.  
 
  To  study  the  use  of  neural  stem  cells  (NSC)  for  the  detection  of  prion 
infectivity with a cell line that does not require genetic manipulation to enhance 
propagation susceptibility.  
 
  To also study adaptations in NSC culture conditions to improve assay 
reliability  and  to  produce  optimal  conditions  for  enhanced  prion 
propagation.    
 
Murine neuroblastoma subclone, N2a #58, that express ~4-fold higher levels of 
PrP
c compared to wild-type neuroblastoma cells were utilised to propagate 22L-infected 
brain  homogenate  and  to  develop  a  sensitive  prion  infectivity  detection  protocol. 
Chapter 3 of this report summarises the optimisation of a ThT-based, amyloid specific 
staining  protocol  for  the  analysis  of  22L  infectivity  in  the  N2a  #58  cells  over  a 
fortnight-based time course assay and directly compares the sensitivity of this staining 
protocol to Western blot detection of PrP
res within the cell lysates.  
 
Animal-bioassays rely on the natural turnover of PrP
c within the experimental 
host to aid the propagation of PrP
Sc to reach detectable levels and to instigate disease 
pathology.  Consequently,  published  cell-based  bioassays  utilise  cell  passages  to 
increase cell turnover and subsequently increase the PrP
c that the infectious material 
comes  into  contact  with,  thus  increasing  the  sensitivity  of  these  assays.  Therefore,  
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Chapter 4 of this report describes the adaptation of the N2a/22L SB/ThT time-course 
assay  described  in  Chapter  3  to  include  cell  passage  steps  to  further  improve  the 
sensitivity and reliability, regarding levels of cell death, of this assay. Furthermore, the 
sensitivity of WB analysis of PrP
res content in the infected cell lysates will be directly 
compared to the ThT-based amyloid detection. 
 
To  test  the  infectivity  of  surface-bound  prion  biofouling  pre  and  post-
decontamination animal bioassays utilise small lengths of surgical grade stainless steel 
wire  that  is  inoculated  in  the  prion  strain  in  question,  decontaminated  and  then 
incorporated  into  the  rodent  brain.  Cell  based-bioassays  also  incorporate  prion 
inoculated wires as a means to analyse prion decontamination technologies in regards to 
residual prion infectivity. Therefore, Chapter 5 of this report aims to adapt the N2a/22L 
SB/ThT assay, optimised in the previous two chapters, for the analysis of wire bound 
infectivity. Furthermore, this assay for the detection of wire bound infectivity will be 
utilised  for  the  analysis  of  commercially  available  cleaning  chemistries  and  the 
infectivity data will be compared to previously published animal-bioassays investigating 
the same cleaning chemistries.  
 
 The N2a #58 cells, utilised in the first three results chapters of this report, are 
genetically modified to  express  increased levels of PrP
c to  artificially  improve their 
susceptibility to prion infection. Furthermore, they are limited to prion infection from 
only four murine prion strains. Different cell lines can offer varying properties that 
could aid the production of novel assays that can propagate different prion strains but 
also present a closer representation of wild-type disease propagation. Therefore, Chapter 
6 of this report aims to utilise murine neural stem cells (NSC’s) for the propagation of 
murine 22L scrapie as a neuronal rich culture naturally contains high levels of PrP
c 
without genetic manipulation. Furthermore, the number of prions strains infectable in 
NSC’s  is  currently  unknown.  However,  natural  cell  loss  at  the  point  of  induced 
differentiation  hindered  the  SB/ThT  staining  utilised  within  the  infectivity  assay. 
Therefore,  adaptations  in  the  culture  protocol  regarding  atmospheric  conditions  and 
improved trophic support at the point of differentiation will be addressed to improve 
quality of the NSC culture for future prion infectivity assays.   
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Chapter 2 
General Methods 
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2.1 Cells and Brain homogenates  
 
2.1.1 Neuroblastoma cells 
 
Neuroblastoma cell sub-clone (N2a #58), previously transfected with wild-type 
mouse PRNP α-cDNA to increase the levels of PrP
c production within the cells and 
therefore increase the  cells  susceptibility to  PrP
Sc infection, was  kindly  supplied by 
Sylvain Lehmann’s group (Institut de Génétique Humaine, Montpellier, France) (Mange 
et al. 2002, Nishida et al. 2000). N2a #58 cells were received in 1ml DMEM media in 
cryo frozen aliquots ready for seeding.  
   
2.1.2 Neural Stem cells (NSC) 
 
Neural  stem  cells  (NSC)  were  dissociated,  isolated  and  again  supplied  by 
Sylvain  Lehmann’s  group  (Institut  de  Génétique  Humaine,  Montpellier,  France). 
Briefly, multipotent progenitor cells were isolated from the cortices of pregnant female 
CD1  mice  E13.5  embryos  and  collected  in  hanks  buffered  salt  solution  (HBSS; 
excluding magnesium and calcium) and frozen in NSC proliferation media in liquid 
nitrogen cryo-vials for long term storage (Milhavet et al. 2006). 
 
2.1.3 Brain homogenates 
   
Murine-scrapie  22L-infected  brain  homogenate,  supplied  by  Ayodeji  Asuni 
(Neuroscience department, University of Southampton), was prepared from the brains 
of  C57BL  mice  infected  via  bilateral  intra-hippocampal  injections  of  22L-infected 
homogenate (sourced from the TSE resource centre, The Roslin Institute, University of 
Edinburgh),  animals  were  culled  between  19-21  weeks  and  infected  brains  were 
dissected and homogenised to 10% (w/v) in phosphate buffered saline (PBS) (Šišková 
et al. 2013).   
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Murine-scrapie ME7-infected brain homogenate (supplied by the TSE resource 
centre, The Roslin Institute, University of Edinburgh) was prepared from C57BL mice 
infected  via  bilateral  intra-hippocampal  injections  of  ME7  infected  homogenate, 
animals were then culled at 171 days post infection and infected brains were dissected 
and homogenised to 10% (w/v) in PBS.  
 
Hamster  263K-infected  brain  homogenate  (supplied  from  the  TSE  resource 
centre, The Roslin Institute, University of Edinburgh) was prepared from LVG golden 
Syrian hamsters infected via bilateral  intra-hippocampal injections  of  263K infected 
brain homogenate, animals were culled at 73 days post infection and infected brains 
were dissected and homogenised to 10% (w/v) in PBS.  
 
Murine  normal  brain  homogenate  (NBH  –  supplied  by  The  Roslin  Institute, 
University of Edinburgh) was prepared from brains dissected from adult C57BL mice 
homogenised to 10% (w/v) in PBS. Brain homogenates were stored at -80
oC for long 
term and -20
oC for short term storage prior to use.   
 
2.2 General cell culture 
 
2.2.1. Neuroblastoma cell culture 
 
N2a  cells  were  cultured  in  sterile,  pre-warmed  Dulbecco’s  Modified  Eagle 
Medium (DMEM – Gibco, Invitrogen) supplemented with 10% (v/v) fetal bovine serum 
(FBS – Gibco, Invitrogen or Biosera), 1% (v/v) 100x Penicillin/Streptomycin (pen/strep 
– Gibco, Invitrogen) and 1% (v/v) 100x GlutiMAX (Gibco, Invitrogen). Media was 
prepared  in  500  ml  batches,  sterile  filtered  in  a  0.22  µm  filter  unit  (Nalgene)  and 
refrigerated until required.     
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N2a cell stock aliquots (1 ml) were removed from the -196
oC liquid nitrogen 
stores and allowed to defrost slowly at room temperature. Each aliquot was seeded into 
14 ml of media in 75 mm tissue culture flasks (Nunc) for stock production or in 9 ml of 
media in 90 mm tissue culture dishes (Greiner bio-one) for experimental preparation. 
N2a cultures were incubated in a humidified environment at 37
oC and 5% (v/v) CO2 (in 
a Galaxy
® 170S incubator, New Brunswick) and media was replaced 24 h post seeding, 
then every 2-3 days after depending on the confluency of the cultures. Once 90 – 100% 
confluency  (~8.8  x  10
6  cells)  was  reached  the  cells  were  passaged  into  either  1ml 
aliquots  (DMEM  diluted  with  10%  (v/v)  Dimethyl  sulphoxide  (DMSO))  for  frozen 
stocks or split at a ratio of 1:50 into small, 35 mm dishes for infection studies. N2a cells 
were passaged by dislodging the cells from the surface of the tissue culture dishes using 
a sterile cell scraper, re-suspended in fresh media and split between the required dishes.  
 
2.2.2 Neural Stem cell culture  
 
Prior to NSC culture all tissue culture dishes were coated with 15 µg/ml Poly-L-
Ornithine (PLO - Sigma) overnight and 1 µg/ml bovine fibronectin (Sigma) for at least 
4 hours. NSC aliquots (1 ml) were defrosted  rapidly  at  room temperature and then 
seeded into 10 ml of N2 max media, for NSC proliferation, in a pre-coated 90 mm 
tissue  culture  dish.  N2  max  media  comprised  of  DMEM/F12  medium  (Gibco, 
Invitrogen),  1%  (v/v)  100x  GlutiMAX  (Gibco,  Invitrogen),  1%  (v/v)  100x 
penicillin/streptomycin  (Gibco),  25  µg/ml  Insulin  (Sigma),  20  nM  Progesterone 
(Sigma), 100 nM Putrescine (Sigma), 30 nM Sodium Selenite (Sigma) and 100µg/ml 
Human apo-transferin (Sigma). Media was prepared in 500 ml batches, sterile filtered in 
a 0.22 µm filter unit (Nalgene) and refrigerated until required. The NSC’s were cultured 
at 37
oC and 5% (v/v) CO2 for normoxia experiments and 37
oC, 5% (v/v) CO2 and 8% 
(unless  stated  otherwise)  (v/v)  O2  (in  a  specialised  Galaxy
®  170R  incubator  with 
sensitive oxygen control) for the hypoxia experiments. Media was replaced 24 hours 
after seeding and then every 48 hours thereafter, cultures were supplemented with 10% 
(v/v) basic fibroblast growth factor (bFGF - R&D systems) every 24 hours to inhibit 
spontaneous differentiation. Once 80% confluency was reached, either differentiation 
was induced or NSC’s were sub-cultured by covering the cells in Hanks buffered salt 
solution (HBSS, Gibco) supplemented with  NaHCO3 (Sigma), 4-(2-hydroxyethyl)-1- 
  60 
peperazineethanesulfonic  acid,  (HEPES,  Sigma)  and  1%  (v/v)  100x  pen/strep.  This 
modified  HBSS  solution  alters  the  pH  causing  the  cells  to  detach  from  the  coated 
surface, the cells are then gently dislodged, re-suspended in fresh N2 max media and 
split between the required dishes.  
 
Differentiation  was  induced  by  the  removal  of  the  bFGF  (mitotic  factor) 
supplement  and  replacement  of  the  N2max  media  with  Neurobasal  media  to  aid 
neuronal  growth. Neurobasal  (NB) media  (Gibco)  was  supplemented with 1% (v/v) 
100x Penicillin/Streptomycin (pen/strep – Gibco), 1% (v/v) 100x GlutiMAX (Gibco) 
and 2% (v/v) B27 supplement (Invitrogen). Media was prepared in 500 ml batches, 
sterile filtered in a 0.22 µm filter unit (Nalgene) and refrigerated until required. The 
differentiated NSC’s were cultured as described previously with media changes every 
24-48 hours.        
 
2.3 Neuroblastoma prion infections 
 
2.3.1 Preparation of infectious material 
 
Infectious material was prepared from previously 22L-infected N2a cell lysates 
or  from  22L-infected  brain  homogenate.  Infected  cell  lysates  were  tested  for  the 
presence of PrP
Sc by Western blot prior to preparation for cell infection studies. Firstly, 
lysates were centrifuged at 10,000 g for 5 min and the supernatant was discarded. The 
pellet was re-suspended in 20 µl lysis buffer (0.5% (w/v) sodium deoxycholate, 150 
mM NaCl, 0.5% (v/v) Triton X-100 and 50 mM Tris-HCl) for 15 min on ice, followed 
by centrifugation at 10,000 g for 5 min. The supernatant was transferred to a fresh 
Eppendorf, made up to 1 ml with DMEM medium and the pellet was discarded. The 
22L-infected solution was filtered through a 0.22 µm filter and further diluted to the 
required dilutions, taking into account the volume of media in the 35 mm cell culture 
dishes.   
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Prior  to  cell  infection  the  22L-infected  homogenate  was  partially  purified  to 
prevent brain material sticking to the cells and hindering microscopic detection using a 
previously described method (Milhavet et al. 2006). Briefly, homogenate was lysed in 
small volumes of lysis buffer (0.5% (w/v) sodium deoxycholate, 150 mM NaCl, 0.5% 
(v/v)  Triton  X-100  and  50  mM  Tris-HCl)  for  20  min  on  ice,  followed  by  10  min 
centrifugation at 10,000 g. The supernatant was then re-suspended in DMEM media and 
sterile filtered through a 0.22 µm filter and further diluted to the required concentration, 
taking into account the volume of media in the 35mm cell culture dishes.   
 
2.3.2 Neuroblastoma time-course infection 
 
To  determine  the  sensitivity  of  prion  detection  methods  (Western  blot,  ThT 
staining and SB/ThT staining) and the susceptibility of N2a #58 cells to prion infection 
N2a cells were infected with varying dilutions of either 22L-infected lysate or 22L-
infected  brain  homogenate.  N2a  cells  were  infected  just  after  passage  with  final 
dilutions of 22L in DMEM media ranging between 10
-2 and 10
-9 of the original 22L 
infected solution. Cells were infected in 14x 35 mm dishes for each experiment and 2 
dishes of un-infected cells were kept for the 14 days as controls and analysed in the 
same way. After 24 hours post infection the DMEM media was replaced to remove any 
excess un-established infectious material. Subsequently the DMEM media was replaced 
every 48 hours and the cells were incubated at 37
oC humid conditions and 5% CO2 for 
the  whole  duration  of  the  study.  Two  dishes  were  analysed  for  prion  infection  by 
fluorescent staining or lysed to detect PrP
Sc content by Western blot analysis every two 
days throughout the 14 day time course.  
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2.3.3 Neuroblastoma passage infections 
 
To improve the sensitivity and viability of the N2a cell infections, PrP
Sc was 
propagated within the cells for longer by analysing the increase in 22L infection of the 
N2a cells over several passages as opposed to 14 days.  
 
Firstly, the optimal time point post infection for passaging the infected cells was 
determined  by  infecting  the  N2a  cell  cultures  with  a  final  10
-4  dilution  of  22L 
homogenate at the point of passage. The media was then replaced after the first 24 hours 
and every 48 hours thereafter. Infected cells and control (un-infected) cells were then 
analysed  for  prion  infection  by  Sudan  black/Thioflavin  T  (SB/ThT  –  section  2.4.2) 
staining and lysed for detection of PrP
Sc content by Western blot after 8, 10 and 12 days 
post infection. The final dish of both infected and un-infected cells (~1.2 x 10
6 cells) 
were split at a ratio of 1:20 and left to propagate for a further 8, 10 or 12 days at which 
point the levels of prion infection were again analysed as above (Figure 11). The cells 
were  passaged  and  analysed  as  described  previously  until  an  endpoint  was  reached 
when the loss of cell viability was observed.  
 
Secondly, the N2a cells were subjected to a titre of 22L brain homogenate with 
final dilutions ranging from 10
-2 – 10
-10 to determine if propagating the prion infection 
over several passages in the N2a cells increases the sensitivity of this assay. The N2a 
cells were infected at the point of passage and the media was replaced after 24 hours 
and every 48 hours thereafter. Then the level of prion propagation in both the infected 
and  uninfected  cell  cultures  was  detected  by  SB/ThT  staining  (section  2.4.2)  and 
Western blot (section 2.4.6) analysis of the cell lysates after 10 days post infection. At 
this point both the infected and uninfected cells (~ 1.2 x 10
6 cells) were split at a ratio of 
1:20 and the levels of prion propagation were again analysed after 10 days. The cells 
were passaged and analysed by the described method (Figure 11) until an endpoint was 
reached when the loss of cell viability was observed.    
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Figure 11 – Schematic diagram defining the passage study experiments  
Three 35 mm dishes were infected with serial dilutions of 22L-infected homogenate (red) and 
three were left uninfected (controls, black). After 8, 10 or 12 days one dish from each parameter 
was stained with Sudan black/Thioflavin T (SB/ThT) and the other dish was lysed for Western 
blot detection (WB). The third dish was passaged into a further 3 dishes and cultured for the 
same number of days to produce the passage 2 samples. These steps were repeated until an end 
point passage was obtained and cell viability was lost (passage x).   
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2.3.4 Neuroblastoma wire infectivity assays 
 
  To  adapt  the  N2a  22L  infectivity  assay,  described  previously  to  assess 
decontamination  efficacy  at  reducing  prion  infectivity,  the  introduction  of  22L-
inoculated wires to transmit PrP
Sc infection pre and post decontamination to the cells 
was studied. Firstly, the number of inoculated wires required to induce optimal prion 
infection  per  35  mm  dish  of  cells  was  analysed.  All  wires  were  prepared, 
decontaminated and deemed clean prior to each assay using the following method.  
 
Surgical grade 316 stainless steel wires (0.16 mm diameter, Ormiston wire - 
UK) were cut to 5 mm lengths, soaked in acetone to remove any organic material, and 
then autoclaved in distilled water for 20 min at 121
oC. The wires were removed from 
the  autoclave  and  dried  on  filter-paper  covered  Petri  dishes  overnight  at  room 
temperature.  To  determine  the  number  of  wires  required  per  well  for  optimal 
propagation 5, 10, and 20 wire batches were inoculated in 10
-4 and 10
-6 dilutions of 10% 
(w/v) 22L-infected brain homogenate in DMEM media, for infected samples or 10% 
(w/v)  NBH  in  DMEM  media  for  uninfected  controls.  Wires  were  inoculated  in  the 
diluted brain homogenates for 2 hours at room temperature and then removed and dried 
in separate filter-paper covered Petri dishes for 2 hours at 37
oC. Inoculated wires were 
placed in separate 35 mm cell culture dishes and covered with 2 ml of fresh pre-warmed 
DMEM media and N2a cells split at a ratio of 1:50 from cells grown to confluency 
(~8.8 x 10
6 cells) in 90 mm culture dishes (prepared as described earlier). Cells were 
grown over the wires to confluency (around 7 day’s culture) with media changes every 
48 - 72 hours. Once a confluent culture was established, the cell covered inoculated 
wires were removed and placed in 2 ml of fresh pre-warmed DMEM media in new 35 
mm  dishes.  The  cells  remaining  in  the  original  dishes  were  analysed  by  SB/ThT 
(section 2.4.2) staining to determine initial 22L propagation from the wires. In the new 
dishes the cells were grown from the wires to confluency (around 7 day’s culture) with 
media changes every 48 – 72 hours (Figure 12). At the time of confluency the wires 
were removed and discarded, the cells were then passaged into fresh 35 mm dishes and 
treated like the passage infection studies (described in section 2.3.3); with passages and 
SB/ThT analysis every 7 days until cell viability was lost (Figure 11).     
  65 
 
 
Figure 12 – Schematic of N2a wire infectivity assay 
A schematic diagram to demonstrate the steps involved in the N2a wire infectivity assay. A) 
NBH or 22L Inoculated wires and N2a #58 cells introduced to 35 mm tissue culture dishes and 
cultured to confluency. B) Wires coated in N2a cells transferred to fresh 35mm tissue culture 
dishes and again cultured to confluency. The cells remaining in the dishes from step A were 
analysed with SB/ThT staining. C) The wires were removed and discarded and the remaining 
cells were passaged and grown to confluency. D) The confluent cells were treated as an N2a 
Passage study shown in Figure 11 cells were split and SB/ThT analysis every 7 days until cell 
viability was lost.   
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Once the number of wires required for optimal 22L propagation within the N2a 
cells was confirmed, the sensitivity of the wire infectivity assay was determined. The 
number of wires required for optimal propagation was determined to be 20 wires per 35 
mm dish. Therefore, 20, 5 mm wires per dish were inoculated with titre dilutions of 
22L, for infected samples, or NBH for un-infected controls, ranging from 10
-4 to 10
-10 
dilutions of original brain homogenate. The wires were then introduced to the N2a cells 
and 22L propagation was analysed as described in the previous section (2.3.4, Figure 
12).  
 
2.3.5 Neuroblastoma wire decontamination infectivity assays 
 
The sensitive 22L N2a wire infectivity assay with SB/ThT detection, described 
in the previous section was utilised for the analysis of decontamination efficacy. Firstly 
efficacy of 3 cleaning chemistries for the removal of protein, lipid and prion-associated 
amyloid from the wire surfaces was determined. Wires (5 mm length) were prepared as 
described  earlier  and  inoculated  in  10%  22L  or  10%  263K-brain  homogenate  (for 
comparison of two prion strains originating from different hosts) for 2 hours at room 
temperature. Wires were dried for 2 hours on filter covered Petri dishes at 37
oC. Once 
dried, the wires were treated using one of three commercially available cleaners; Enzol 
(20 ml/l, Room temperature, 10 min, Johnson and Johnson); Klenzyme (8 ml/l, 43
oC, 5 
min, Steris
©) and HAMO 100 (8 ml/l, 43
oC, 7 min, Steris
©). Furthermore, the working 
pH for each cleaning chemistry was determined. All wires were processed in separate 
soda glass vials, per condition, throughout the cleaning and staining process. Cleaning 
was carried out in an Electrothermal STEM RS900 reaction station with gentle agitation 
from a stirring rod throughout. Control, untreated wires were left at room temperature 
for analysis in parallel with decontaminated wires. Once wires were subjected to the 
decontamination  protocols  they  were  rinsed  in  deionised  water  and  dried  at  room 
temperature for 1 hour before analysis of remaining contamination. Both control and 
decontaminated wires were stained, in separate soda glass vials, with either SYPRO 
Ruby/Thioflavin T (SR/ThT – section 2.4.3) staining for the detection of protein and 
prion-associated amyloid or Nile red/Thioflavin T (NR/ThT – section 2.4.4) staining for 
the detection of lipid and prion-associated amyloid. Fluorescent signal was visualised  
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using EF microscopy and analysed using Image J software (Version 1.44p, National 
institute for health, USA) both described later in section 2.4.5.  
 
To determine infectivity of residual contamination post decontamination within 
one of the three cleaners presented previously, wires decontaminated as described were 
analysed  using  the  22L  wire  N2a  infectivity  assay  and  SB/ThT  detection  described 
earlier. Briefly, 20 wires per sample inoculated in 10% 22L-infected brain homogenate 
were decontaminated in one of the three cleaners described earlier or left un-cleaned as 
positive controls. The wires were then analysed using the wire infectivity N2a assay 
described  in  the  previous  section  (section  2.3.4)  for  remaining  infectivity  post 
decontamination (Figure 12).  
 
2.4 Prion detection 
 
2.4.1 Sudan black (SB) for reduced autofluorescence 
 
  The autofluorescent quenching properties of Sudan black staining with relevance 
to the autofluorescence associated with the wavelengths required for the detection of 
ThT (excitation 405 – 445 nm and emission ≥475 nm) fluorescence was analysed. It 
was  hypothesised  that  the  autofluorescence  was  caused  by  lipids  within  the  tissue. 
Therefore the autofluorescence was compared to the lipid content of ME7 infected brain 
homogenate  using  Nile  red  staining  (9-diethylamino-5H-benzo[α]phenoxazine-5-one, 
NR, Sigma). Nile red is a lipid soluble fluorescent dye that when prepared within a 
solvent based solution it emits a deep red colour once bound to lipids. Sudan black 
(SB), a histological stain that stains lipids black and does not fluoresce itself was tested 
for its ability to quench lipid based autofluorescence. Spots of 1 µl of 1 mg/ml ME7 
infected brain homogenate (diluted in PBS and 1% (v/v) tween 20) were pipetted onto a 
316 surgical stainless steel token and left to dry at 37
oC for 1 hour. One spot was 
stained with NR (25 mM diluted in DMSO, Sigma Aldrich), one spot was left unstained 
to show the autofluorescence and the third spot was stained with SB (0.3% (w/v) SB  
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made up in 70% ethanol) and analysed for remaining autofluorescence using the ThT 
microscope filter block.    
 
2.4.2 Prion amyloid staining within cells 
 
Prion-associated amyloid levels were detected in the cell culture samples using 
the amyloid specific fluorescent fluorophore Thioflavin T (ThT). The cell cultures were 
stained every two days during the time-course experiments or at every passage point for 
the passage infection studies with either ThT alone or SB/ThT to try and produce an 
optimal staining protocol for the detection of prion-associated amyloid as a pathological 
marker of prion infection. The staining protocol was adapted for amyloid staining in 
cells  from  previously  described  ThT  staining  protocols  used  on  tissue  sections  and 
surface contamination (Herve et al. 2009, Herve et al. 2010, Lipscomb et al. 2007a). 
 
All staining was completed at room temperature and in a dark environment to 
prevent loss of fluorescence signal from photo-bleaching. Culture medium was removed 
and the cells were washed thoroughly in phosphate buffered saline (PBS, Gibco) to 
remove excess media, then fixed for 6 min in 4% (v/v) paraformaldehyde in PBS (PFA, 
VWR).  Cells  were  permeablised  in  0.1%  (v/v)  Triton  X-100  in  PBS  for  10  min, 
followed by three PBS washes. The cells being stained with ThT alone were left in 
dH2O while other cells were stained with 0.3% (w/v) SB made up in 70 % ethanol for 
10 min. After SB staining cells were washed in PBS and all cells were stained with 
0.02% (time-course and passage day optimisation) or 0.004% (passage and wire studies) 
(w/v) ThT made up in 0.01 M hydrochloric acid for 15 min. After ThT staining the cells 
were washed in 0.1% (v/v) acetic acid for 2 min to remove any non-specifically bound 
ThT, followed by washes in PBS and dH2O. Cells were left in the final wash of dH2O 
until microscopic analysis. 
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2.4.3 SR/ThT dual staining  
 
The  dual  staining  procedure  for  prion-associated  amyloid  and  total  protein 
contamination,  as  well  as  detection  and  analysis  methods,  have  been  described 
previously  (Herve  et  al.  2009).  Briefly,  prion  amyloid  contamination  was  identified 
using Thioflavin T (ThT; 0.2% (w/v) in 0.01 M HCl; Sigma Aldrich), and total protein 
was visualised using SYPRO Ruby protein blot stain (SR; Invitrogen UK, Renfrew, 
UK). Fluorescent signal was visualised by EF microscopy (Keevil 2003) and analysed 
using Image J software.  
 
2.4.4 NR/ThT dual staining  
   
  NR/ThT staining involved an adaptation of the SR/ThT staining described in the 
previous section. The main differences to the SR/ThT protocol were that the SR was 
replaced with NR (25 mM diluted in DMSO, Sigma Aldrich) to analyse total lipid as 
opposed to total protein. In addition, the NR staining preceded the ThT staining as the 
DMSO  would  quench  the  ThT  signal.  The  remaining  protocol  was  left  unchanged 
regarding the ThT staining and steps described previously (Herve et al. 2009). 
 
2.4.5 Epifluorescence (EF) microscopy and image analysis 
  
Stained cells were analysed using epifluorescence (EF – Best scientific) with 
long distance working lenses (Nikon) to analyse the fluorescent signal directly on the 
sample without the need for cover slips or oil immersion. This allows for the rapid 
analysis of staining without the hindrance of using coverslips in a large well of cells. 
This also allows the potential for in situ analysis of inoculated wires within the cultures 
in future work. Cells were analysed by capturing images using the 100x magnification 
objective from 10 random areas spanning the whole visual area of each sample, using 
the ThT filter block (excitation 405 – 445 nm, emission barrier 475 nm, Nikon). Images  
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were captured using a CCD colour camera (Roper Industries, UK) with identical camera 
detection  settings  for  each  individual  experiment,  optimised  to  detect  low  levels  of 
background in the control samples and subsequently positive fluorescence in infected 
samples. Images were analysed using Image  J software to count pixel intensities of 
positive ThT signal observed in all of the images. The threshold of the image analysis 
was  set  to  pick  up  pixel  intensities  of  ThT  staining  above  the  background  levels 
observed in the controls for each experiment.      
 
  EF microscopy with long distance working lenses (Nikon) was also utilised for 
the analysis of the SR/ThT and NR/ThT staining of the inoculated wires pre and post 
decontamination.  Scans  of  the  contaminated  areas  were  acquired  at  x10  objective 
magnification showing the SYPRO Ruby or NR signal (excitation: 470 nm; emission: 
618  nm)  and  ThT  signal  (excitation:  450  nm;  emission:  480  nm)  signal.  Captured 
images were analysed using Image J software and positive signal was standardised to 
the  surface  areas  of  the  wires  and  reported  in  pg/mm
2  as  described  previously 
(Lipscomb  et  al.  2006c).  Briefly,  1  µl  spots  of  22L-infected  brain  homogenate 
(normalised to 1 mg/ml as determined using the Dc protein assay kit (Bio-rad) with BSA 
standards, therefore a 1 µl spot would correspond to 1 µg of protein) were dried onto 
316 grade stainless steel tokens for 4 hours at 37
oC. The homogenate spots were then 
stained with SR and scans were taken of the whole spots as previously described. Image 
analysis was carried out to determine the number of pixels per 1 µg of protein which 
was  then  used  as  a  standard  to  convert  the  number  of  pixels  remaining  post 
decontamination to pg/mm
2.      
 
2.4.6 Western blot analysis 
 
Western blot (WB) analysis  was  carried out  alongside the ThT and SB/ThT 
staining as a comparison of the sensitivity of these novel assays against a current and 
routinely used methodology for prion detection. Cells were washed thoroughly in PBS 
to remove excess cell media, re-suspended in cold PBS, centrifuged at 13,000 rpm and 
the pellet was treated in lysis buffer for 15 min. Once lysed the samples were stored at -
20
oC until the end of each experiment once all of the samples were collected. Protein  
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content was determined using the Dc (Detergent compatible Bradford assay)  protein 
assay  kit  (BioRad),  the  protein  volume  in  each  sample  was  standardised  for  each 
Western  blot.  The  samples  were  digested  in  proteinase  K  (PK,  Sigma)  to  a  final 
concentration of 10 ng/µg of total protein for 30 min at 37
oC which was followed by the 
addition of Pefabloc (Sigma-Aldrich) to halt the digestion. After digestion samples were 
boiled for 5 min in loading buffer (2% (w/v) SDS, 10% (v/v) glycerol, 2% (v/v) β-
mercaptoethanol, 0.01% (v/v) bromophenol blue, in 50 mM Tris–HCl, pH 6.8). Samples 
were loaded into a pre-cast, 12% (v/v) polyacrylamide gel (BioRad) and run in SDS, 
Tris – glycine buffer (BioRad) at 90 V for 1.5-2 hours. Once separated the proteins were 
transferred in Tris-glycine-methanol buffer and captured on a nitrocellulose membrane 
(BioRad)  overnight  at  30  V.  Following  transfer  the  unspecific  binding  sites  were 
blocked by submerging the membrane in 5% (w/v) skimmed milk powder (Marvel) in 
PBS-T (PBS containing 0.1% (v/v) Tween 20, Sigma) for 1 hour at room temperature. 
After 3 washes in PBS-T, PrP detection was carried out using the anti-prion mouse 
monoclonal  antibodies  SAF  60  (Commissariat  à  l'Énergie  198  Atomique,  Saclay, 
France; 1/5000 – 1/10,000 in PBS-T) or 6H4 (Prionics, 1/5000 in PBS-T) for 1 hour at 
room temperature. Following another 3 washes in PBS-T, the membrane was incubated 
in  horseradish  peroxidase-conjugated  anti-mouse  IgG  secondary  antibody  (GE 
Healthcare,  UK;  1/10000  in  PBS-T)  for  1  hour  at  room  temperature.  The 
immunoreactive bands were visualised using the enhanced chemiluminescence substrate 
(Amersham, ECL plus, GE Healthcare, UK) and developed on X-ray film (Amersham, 
GE Healthcare, UK or Fuji Film, UK).    
 
2.5 Improving NSC culture conditions 
 
Improvements  in  culture  conditions  for  the  neural  stem  cells  (NSC)  were 
required to improve the viability of the cells and therefore improve the quality of the 
NSC prion infectivity assays without the hindrance of compromised cells during prion 
detection.  Firstly  the  confluency  of  the  undifferentiated  neural  stem  cells  prior  to 
differentiation was varied to see if the density of the cells affected the level of cell 
death. Then the cells were incubated in varying levels of oxygen (hypoxic environment) 
to  closer  mimic  the  physiological  environment  of  the  cells  cerebral  cortex  origin.  
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Following  this,  the  effect  of  introducing  different  supplements  at  the  point  of 
differentiation were tested in both normoxia and hypoxia environments.  
 
2.5.1. Hypoxia 
 
Neural stem cells were grown, according to the protocol described in section 
2.2.2, in varying levels of oxygen to mimic the physiological environment that the cells 
were dissociated from. The cells were incubated in the Galaxy 170R incubator (New 
Brunswick) with sensitive oxygen control capabilities. The level of cell proliferation 
was observed in increasing oxygen levels starting at 1% O2 until an environment was 
found that the level of cell proliferation and viability was optimal. At this point further 
experiments were carried out to compare cells grown in the lower O2 atmosphere with 
cells grown at normoxia (~20% O2), including the addition of supplements at the point 
of differentiation and the ratio of live and dead cells.   
 
2.5.2. Improved supplements post differentiation 
 
When  differentiation  of  the  NSC’s  is  induced  the  media  is  changed  to 
Neurobasal  media  and  the  growth  supplements  (bFGF)  are  removed.  So  another 
hypothesis for cell death could be the lack of nourishment and growth factors for the 
cells at the point of differentiation. To study this affect NSC’s were differentiated in the 
presence of further doses of bFGF or with the addition of FBS or no supplement at all in 
both normoxia and hypoxia environments. At the point of differentiation dishes of cells 
were subjected to either daily doses of 0.1% (v/v) bFGF, to continue the supplements 
from the proliferation stage or 0.1% (v/v) daily doses of FBS. Some cells were given no 
supplements post-differentiation and were treated as the controls for this study. The 
supplements were administered to the cells for two days post-differentiation to reduce 
the  initial  cells  shock  of  nutrient  removal  when  differentiated.  After  two  days  the 
Neurobasal media was replaced and the cells were cultured for a further 7 days until 
analysis of the cell type and viability was performed.   
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2.6 NSC microscopy analysis 
 
The changes in NSC growth were analysed using phase contrast microscopy and 
fluorescent microscopy utilised to determine the number of neuronal and glial cells post 
differentiation  as  well  as  the  ratio  of  live  and  dead  cells  to  compare  cell  viability 
between conditions. 
 
2.6.1 Phase contrast microscopy  
 
Phase contrast microscopy was used to acquire live images of the cells before 
and  during  the  differentiation  process  to  document  the  changes  in  cell  morphology 
between the different culture conditions. Phase contrast microscopy was introduced by 
Frits  Zernike  in  1934  as  a  technique  that  improves  the  contrast  of  transparent 
specimens, such as living cells, by detecting minute changes in the refractive index 
between cell components and the surrounding media, without the need to pre-stain the 
sample (Zernike 1942). Briefly, phase contrast microscopy involves the incorporation of 
a phase condenser annulus situated near the condenser, and a phase ring plate usually 
situated within specialised objective lenses to a standard bright field microscope. Light 
passes through the phase condenser annulus and is split into two light beams which 
either pass straight through the specimen and are classed as un-deviated or diffracted by 
the changes in phase by structures within the specimen. The light travels through the 
phase plate within the objective lens which segregates the un-deviated light from the 
diffracted light with shifted phase which forms the highly contrasted image observed in 
the eyepiece. Images (x20 and x40 objective magnification) were captured every other 
day  from the time of differentiation and used to document the variations in culture 
quality and confluency of the cells post-differentiation between the different conditions. 
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2.6.2 NSC Cell type analysis 
 
2.6.2.1 Nestin  
 
Nestin  is  an  intermediate  filament  protein  that  is  expressed  on  proliferating 
neuronal cells and is widely used as a marker for undifferentiated neural stem cells. The 
level of nestin expression was determined before and after differentiation to show the 
confluency of undifferentiated NSC cultured in hypoxia and normoxia and to show the 
efficiency of differentiation by showing the number of remaining undifferentiated cells 
seven days after initial induced differentiation in the various pre mentioned conditions. 
 
Culture medium was removed from the cells followed by three washes in PBS. 
The  cells  were  fixed  in  4%  (v/v)  paraformaldehyde  (PFA)  for  10  min  before  three 
further washes in PBS. Unspecific binding was blocked with 5% (v/v) FBS in PBS for 1 
hour followed by three washes in PBS. The anti-nestin primary antibody (Millipore, 
1:100 dilutions (v/v) in PBS) was incubated on the cells for 1 hour and then removed 
with three further washes in PBS. Visualisation was carried out using an Alexa Fluor® 
488  conjugated  goat  anti-mouse  IgG  secondary  antibody  (Invitrogen,  1:500  dilution 
(v/v) in PBS) for 1 hour then removed with three washes in PBS. The nuclei were 
counter stained with SYTO 59 nucleic acid stain (Invitrogen, 1:1000 dilutions (v/v) in 
PBS)  and  then  visualised  immediately.  Random  field  of  view  (50x  magnification) 
images were captured using EF microscopy with the excitation 470-495 nm, emission 
510-550 nm filter for the Alexa Fluor® 488 dye and excitation 510-550 nm, emission 
590 nm for the SYTO 59 (Best scientific, UK). Images were analysed using Image J 
image analysis software by counting pixels of nestin staining compared to the number 
of cells (SYTO 59 staining) and cell counts of nestin positive cells was performed to 
determine the ratio of nestin positive and negative cells between samples.        
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2.6.2.2 GFAP staining  
 
Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein 
that is largely expressed on astrocytic cells of the central nervous system. The number 
of astrocytes was determined by staining the differentiated neural stem cells with an 
anti-GFAP  antibody  to  study  the  effect  on  the  different  supplements  and  growth 
conditions on the number of astrocytes.  
 
Culture medium was removed from the cells followed by three washes in PBS 
and the cells were fixed in 4% (v/v) paraformaldehyde for 10 min before three further 
washes in PBS. Unspecific binding was blocked with 5% (v/v) FBS in PBS for 1 hour 
followed by three washes in PBS. The anti-GFAP primary antibody (Millipore, 1:200 
dilutions (v/v) in PBS) was incubated on the cells for 1 hour and then removed with 
three further washes in PBS. Visualisation was carried out using an Alexa Fluor® 488 
conjugated goat anti-mouse IgG secondary antibody (Invitrogen, 1:500 dilution (v/v) in 
PBS) for 1 hour and washed off with three washes in PBS. The nuclei were counter 
stained with SYTO 59 nucleic acid stain (Invitrogen, 1:1000 dilutions (v/v) in PBS) and 
then visualised immediately. Random field of view (50x magnification) images were 
captured with the epi-fluorescence microscope using excitation 470-495 nm, emission 
510-550 nm filter for the Alexa Fluor® 488 dye and excitation 510-550 nm, emission 
590 nm for the SYTO 59 (Best scientific, UK). Images were analysed using Image J 
image analysis software by counting pixels of GFAP staining compared to the number 
of cells (SYTO 59 staining) and cell counts of GFAP positive cells was performed to 
determine the ratio of GFAP positive and negative cells between samples.  
 
2.6.2.3 β-III-Tubulin staining  
 
Class  3  β-Tubulin  is  a  globular  protein  expressed  exclusively  on  the 
microtubules of neuronal cells and is widely used as a marker for neurons. Therefore, 
the level of neurons post-differentiation was visualised using an anti-β-Tubulin antibody 
on cells grown in the different conditions with altered supplements.   
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Culture medium was removed from the cells followed by three washes in PBS 
and then the cells were fixed in 4% (v/v) paraformaldehyde for 10 min before three 
further washes in PBS. Unspecific binding was blocked with 5% (v/v) Goat serum in 
PBS-tween (PBS and 1% (v/v) tween 20) for 1 hour followed by three washes in PBS. 
The  anti-β-Tubulin  primary  antibody  (E7,  The  Developmental  Studies  Hybridoma 
Bank, University of Iowa, 1:50 dilutions (v/v) in PBS) was incubated with the cells 
overnight at 2-4
oC and then removed with three further washes in PBS. Visualisation 
was carried out using an Alexa Fluor® 488 conjugated goat anti-mouse IgG secondary 
antibody (Invitrogen, 1:500 dilution (v/v) in PBS) for 1 hour and removed with three 
washes  in  PBS.  The  nuclei  were  counter  stained  with  SYTO  59  nucleic  acid  stain 
(Invitrogen, 1:1000 dilutions (v/v) in PBS) and then visualised immediately. Random 
field  of  view  (50x  magnification)  images  were  captured  with  the  epi-fluorescence 
microscope using excitation 470-495 nm, emission 510-550 nm filter for the Alexa 
Fluor® 488 dye and excitation 510-550 nm, emission 590 nm for the SYTO 59 (Best 
scientific,  UK).  Images  were  analysed  using  Image  J  image  analysis  software  by 
counting  pixels  of  β-Tubulin  staining  compared  to  the  number  of  cells  (SYTO  59 
staining) and cell counts of β-Tubulin positive cells was performed to determine the 
ratio of β-Tubulin positive and negative cells between samples.  
 
2.6.3 Cell viability analysis 
 
The  differentiated  cells  from  the  different  environments  and  varying 
supplements were analysed to determine the ratio of cell viability to define the best 
environment  for  improved  cell  growth.  SYTO  9  was  used  to  stain  all  cells  and 
propidium iodide (PI) to stain any cells with a compromised membrane.  
 
The medium was removed from the cells and the cells were washed in three PBS 
washes. The cells were then fixed in 4% PFA for 10 min, washed in PBS and stained 
with a mixture of 40 µM PI and 7 µM SYTO 9 (Invitrogen, UK) diluted in PBS, for 30 
min at room temperature. The stains were washed off with PBS and then immediately  
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visualised with EF microscopy using the excitation 470-495 nm, emission 510-550 nm 
filter for the SYTO 9 and excitation 510-550 nm, emission 590 nm for the PI. Images 
(10x magnification) of both stains were taken together within the same field of view to 
allow overlaying of live and dead cell signal within the same image. The ratio of live: 
dead  cells  were  determined  using  Image  J  software  and  used  to  compare  the  cell 
viability in the different culture conditions.  
 
2.7 Statistical analysis      
 
Statistical analysis in the neuroblastoma prion infection experiments was used to 
compare the mean pixel counts of ThT positive staining between the uninfected controls 
and the days or passage post infection. A one way ANOVA was used for comparisons 
between the means in each data set and then a Tukey HSD post hoc test was used for 
data with equal variance or a welch test followed by a Games-Howell post hoc test for 
data with unequal variance was used to determine the statistical difference between the 
controls and the infected cells at the different times points, p values of  ≤0.05 were 
classified  as  significant.  In  the  NSC  experiments  statistical  analysis  was  used  to 
compare  the  differences  in  the  percentage  of  each  cell  type  and  the  cell  viability 
between the various different culture conditions. As before a one way ANOVA was 
used for comparisons between the means in each data set and then a Tukey HSD post 
hoc test was used for data with equal variance or a welch test followed by a Games-
Howell  post  hoc  test  for  data  with  unequal  variance  to  determine  the  statistical 
difference  between  the  various  culture  conditions,  again  p  values  of  ≤0.05  were 
classified as significant.     
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Chapter 3  
 
N2a time-course prion infectivity 
assays and SB/ThT detection  
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3.1 Introduction and aims 
 
The development of cell-based assays to detect prion infectivity has been an 
important area of prion research as they have the potential to become a standard method 
to  analyse  prion  infectivity  from  many  biological  samples  pre  and  post 
decontamination. A sensitive cell-based assay could be used as an alternative to current 
animal infectivity bioassays as they would be cheaper to run, produce a quicker result 
and possess fewer ethical considerations than animal assays. Moreover, different cell 
lines have the potential to detect infectivity of a wider range of prion strains. 
   
Cell-based infectivity assays have been researched by a number of groups within 
the  prion  field  with  variations  in  both  cell  lines  and  prion  detection  methods  used 
(Reviewed in Solassol et al. 2003, Vilette 2008). The three main aspects to take into 
account when developing a cell based assay for prion infectivity is the cell line used and 
its susceptibility to propagate different prion strains and the detection method utilised to 
detect prion propagation and subsequently infectivity. It is important to understand the 
cell lines used as different cell lines are only susceptible to infection from certain prion 
strains due to the effect of the “species barrier” and strain conformation (Nuvolone et al. 
2009). Detection methods utilised to quantify the prion propagation within the cells 
currently  rely  on  biochemical  techniques,  such  as  Western  blot  or  ELISA  to  detect 
accumulation of PrP
res (Edgeworth et al. 2009, Klohn et al. 2003, Nishida et al. 2000). 
These methods focus on the ex situ detection of PrP
res post PK digestion; however, more 
recently  evidence  has  arose  demonstrating  that  not  all  disease-associated  PrP
Sc  is 
resistant to PK digestion and that a considerable amount of disease related material is 
potentially lost during these methods (D'Castro et al. 2010, Kuczius and Groschup 1999, 
Thackray et al. 2007). Furthermore, it has been demonstrated that the PK sensitive PrP
Sc 
still has the ability to induce PrP
c conversion (Pastrana et al. 2006). This suggests that 
these assays could potentially produce false negatives if the infectivity is associated 
with sPrP
Sc. As such, the question can be asked as to whether these assays alone are 
capable of providing a realistic picture of prion propagation.    
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This  chapter  will  focus  on  the  development  of  a  sensitive  method  for  the 
detection of prion infectivity to be utilised within cell-based assays. N2a #58 cells were 
the chosen cell line as they have previously demonstrated susceptibility to infection 
from several murine prion strains. In addition, they are easy to culture and so represent 
an  excellent  model  to  develop  and  optimise  an  infectivity  detection  method.  ThT 
detection of amyloid associated with prion disease has been utilised in a number of 
detection methods including RT-QUIC, ASA and the SR/ThT dual stain (Atarashi et al. 
2011a, Colby et al. 2007, Herve et al. 2009). Therefore a sensitive ThT-based detection 
method with in situ microscopic analysis was developed to detect prion infectivity in 
N2a cells over 14 days propagation. This assay was then compared to Western Blot 
detection of PrP
Sc to directly compare sensitivity of the two methods within the same 
quantity of cells.  
 
3.2 Material and methods 
 
Details of the materials and methods for this section can all be found within 
Chapter 2 of this report. Briefly, N2a #58 cells (2.1.1) were cultured as described in 
section  2.2.1  and  then  subjected  to  22L  (2.1.3  and  2.3.1)  infection  following  the 
neuroblastoma time course described in section 2.3.2. Detection of prion infectivity was 
obtained by utilising both ThT staining alone and a combination of SB (2.4.1) and ThT 
as described in section 2.4.2. ThT signal was analysed by epi-fluorescent microscopy 
and  quantified  using  Image  J  software  described  in  section  2.4.5.  Furthermore,  cell 
lysates were analysed for PrP
res content using the Western blot protocol described in 
section 2.4.6. All statistical analysis was carried out as highlighted in section 2.7.  
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3.3 Results 
 
3.3.1 Colour conversion 
 
Raw images of the blue fluorescent ThT signal were captured; due to printing 
and  visualisation  purposes  all  images  have  been  converted  to  green  to  improve  the 
visual  image  quality  post  printing  within  this  report  (Figure  13).  All  image 
quantification and statistical analysis was carried out on the data produced from the 
original, raw images prior to any image manipulation.  
 
 
Figure 13 – Micrographs of colour conversion 
Example micrographs demonstrating the colour conversion from the raw ThT image (blue) to 
the visually improved image (green). Scale bars = 10 µm.  
 
3.3.2 Sudan Black 
 
The addition of Sudan black in the ThT staining protocol was used to lower the 
background autofluorescence which is emitted in the same spectral range as ThT. The 
autofluorescence was hypothesised to be lipid based and to confirm this 1 µg spots of 
ME7 murine scrapie-infected brain homogenate were dried onto stainless steel tokens.  
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The autofluorescence was then visualised under the ThT filter of the EF microscope. 
The  spot  was  then  stained  with  Nile  red  to  determine  the  lipid  content,  thus 
demonstrating  that  the  lipid  positive  staining  correlated  with  the  autofluorescence. 
Sudan black was chosen as a quenching agent as it is a histological dye that binds to and 
stains  lipids  a  deep  brown/black  without  itself  fluorescing,  therefore  quenching  the 
autofluorescence. This was demonstrated by staining one of the ME7 spots with SB and 
comparing this to the autofluorescence observed prior to staining (Figure 14).  
 
 
Figure 14 – Example micrographs demonstrating autofluorescence issues  
Example micrographs of ME7 infected homogenate spots on stainless steel tokens stained with 
Nile red (NR) and Sudan black (SB) compared to the autofluorescence (AF) associated with the 
excitation and emission spectra of the ThT filter block. Scale bars = 100 µm.  
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3.3.3 Prion time course infections  
 
The 14 day time course infections were used to produce and optimise the best 
staining method to detect the amyloid plaque build-up in the 22L-infected N2a cultures. 
Firstly, the ThT staining alone was compared to the ThT staining with the addition of 
SB to quench the autofluorescence, as demonstrated previously. Secondly the dynamic 
range of the 14 day time course assay was tested to determine the sensitivity of the ThT 
assay,  SB/ThT  assay  and  the  Western  Blot  detection  of  PrP
Sc.  The  infections  were 
started with a final 10
-4 dilution of 22L-infected brain homogenate because novel cell 
based  assays  require  a  detection  sensitivity  of  lower  than  a  final  10
-6  dilution  of 
infectious material to compete with the sensitivity of current used animal bioassays. As 
a  result,  these  assays  were  primarily  assessed  with  higher  doses  to  optimise  the 
detection protocols.  
 
3.3.3.1 ThT alone and SB/ThT staining to determine prion propagation  
 
N2a cells were infected with a final 10
-4 dilution of 22L infectious material and 
were stained using either the ThT alone or SB/ThT staining protocol every two days 
post  introduction  of  the  22L  material  to  determine  the  increase  of  prion-associated 
amyloid and therefore prion infection. Representative micrographs in Figure 15 taken 
on  days  4,  8  and  12  post  infection  demonstrate  an  increase  in  ThT-positive  signal 
compared to the uninfected controls over the time course using both the ThT alone and 
SB/ThT staining protocols. However, it can be observed from the micrographs that the 
bright spots of ThT-positive staining within the cells stained with the SB/ThT protocol 
tend to  be more distinct and clearer to  visualise especially when localised with  the 
remaining background and autofluorescence of the cell bodies (Figure 15). Background 
autofluorescence associated with the cells is also observed in the control samples from 
both sets of experiments.   
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Figure 15 – Example micrographs from the 10
-4 22L-infected N2a time-course 
Representative micrographs from the 10
-4 22L infected N2a cells stained with ThT alone (top) 
or SB/ThT (bottom) 4, 8 and 12 days post initial infection (D.P.I) and the uninfected controls 
(left to right respectively). Scale bars = 10 µm. 
 
 
Image analysis software was used to quantify the number of ThT-positive pixels 
above an intensity threshold which was set to disregard any pixels associated with the 
uninfected controls for each sample set. The quantification of the ThT staining alone 
showed an initial increase in ThT signal at 2 days post infection which decreased until a 
significant increase was observed at 12 days post infection where the peak of positive 
signal  was  demonstrated  (Figure  16,  Graph  A).  The  intensity  of  the  staining  signal 
within the samples with the lower propagation between days 4 and 8 was difficult to 
observe because of issues distinguishing between positive staining and autofluorescence 
with the ThT staining alone.  
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Figure 16 – Image analysis data from the 10
-4 22L N2a time-course infection 
The pixel counts of ThT-positive staining, taking into account the background autofluorescence 
of the uninfected controls over 12 days post 10
-4 22L infection in N2a cells. A), shows the pixel 
counts of the ThT staining alone and B), the pixel counts of SB/ThT-positive staining. The Y-
axis scale has been normalised to the 10
-4 22L infected N2a SB/ThT scale to compare dose 
response. Error bars shown are SEM (n = 20-40 images over 2-4 experiments), ** = p ≤ 0.01; 
*** = p ≤ 0.001 when compared to the uninfected controls. 
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The image analysis of the SB/ThT stained samples from the 10
-4 22L infected 
N2a cells showed the same trend as the ThT stained samples, with a slight increase in 
ThT signal at 2 days and then a decrease over the next 8 days with the peak expression 
shown at 12 days post infection (Figure 16, Graph B). However, the ThT signal was 
easier to observe and quantify after the SB staining and the variation between images 
was also lower than the ThT staining alone, demonstrated by the reduced error post SB. 
The addition of SB in the staining protocol demonstrated improved visualisation and 
contrast  of  the  lower  intensity  ThT-positive  staining  which  allowed  the  trend  and 
detection of the smaller plaques with reduced ThT staining to be quantified more easily 
than ThT staining alone.  
 
The  sensitivity  of  the  two  different  staining  methods  were  further  tested  by 
comparing which method was able to detect prion propagation in the N2a cells after an 
initial 10
-6 22L infection. The representative micrographs in Figure 17 demonstrate that 
the brightest spots of ThT-positive signal in ThT alone stained samples were extremely 
difficult to distinguish from the background autofluorescence. After 12 days several 
small indistinct areas of positive staining in some fields of view were observed but not 
enough  to  demonstrate  a  trend  in  propagation  compared  to  the  uninfected  controls. 
However, the SB/ThT staining detected amyloid plaque accumulation over the time 
course with a significant increase in ThT-positive signal observed between 6 and 12 
days post infection (Figure 17). No initial increase in ThT signal was observed on day 2 
post initial infection as was the case with the 10
-4 22L infected samples (Figure 16).  
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Figure 17 – Example micrographs from the 10
-6 22L-infected N2a time-course 
Representative micrographs from the 10
-6 22L infected N2a cells stained with ThT alone (top) 
and SB/ThT (bottom) 4, 8 and 12 days post initial infection and the uninfected controls (left to 
right respectively). Scale bars = 10 µm. 
 
 
The image analysis of the 10
-6 22L infected N2a cells confirmed that there was 
only a statistically significant increase in ThT signal when using ThT staining alone 
after 12 days post infection. Conversely, when using the SB/THT staining method, a 
clear increase in ThT-positive staining was observed when compared to the uninfected 
controls, with a statistically significant increase in ThT signal observed between 6 and 
12 days post infection (Figure 18). The quantified positive ThT signal observed in the 
SB/ThT stained samples was higher than that observed in the samples stained with ThT 
only. 
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Figure 18 – Image analysis data from the 10
-6 22L-infected N2a time-course 
The pixel counts of ThT-positive staining, taking into account the background autofluorescence 
of the uninfected controls over 14 days post 10
-6 22L infection in N2a cells. A), shows the pixel 
counts of the ThT staining alone and B), the pixel counts of SB/ThT-positive staining. The Y-
axis scale has been normalised to the 10
-4 22L infected N2a SB/ThT scale to compare dose 
response. Error bars shown are SEM (n = 20-30 images over 2-3 experiments), * = p ≤ 0.05; ** 
= p ≤ 0.01 and *** = p ≤ 0.001 when compared to the uninfected controls. 
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As the level of sensitivity for the ThT staining alone had been greatly reduced 
for the 10
-6 22L infected samples, only the SB/ThT staining was further analysed for the 
sensitivity of amyloid detection within the N2a cells by further reducing the initial 22L 
dose.  
 
 
 
 
Figure 19 – Example micrographs from the 10
-8 22L-infected N2a time-course 
Representative micrographs from the 10
-8 22L infected N2a cells stained with SB/ThT 4, 8 and 
12 days post initial infection and the uninfected controls. Scale bars = 10 µm. 
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Representative micrographs in Figure 19 demonstrate the accumulation of ThT-
positive  staining  after  8  -  12  days  post  initial  10
-8  22L  infection,  compared  to  the 
uninfected  controls  in  the  N2a  cells.  When  compared  to  the  previous  higher  titre 
infections, the amyloid plaque accumulation appeared to demonstrate smaller and fewer 
plaques in this lower 22L dose (Figure 19). The image analysis of the ThT-positive 
staining in the SB/ThT stained 10
-8 22L infected N2a cells confirmed that there was an 
increase in ThT positive signal after 6 days post infection, with a peak signal observed 
after 8 - 12 days which seems to plateau over these time points (Figure 20). The peak 
pixel counts in the 10
-8 22L infection were considerably lower than that of the higher 
dose infections.  
 
 
 
Figure 20 – Image analysis data from the 10
-8 22L-infected N2a time-course 
The  pixel  counts  of  SB/ThT-positive  staining,  taking  into  account  the  background 
autofluorescence in the uninfected controls over 14 days post 10
-8 22L infection in N2a cells. 
Error bars shown are SEM (n = 30 images from 3 separate experiments), * = p ≤ 0.05, ** = p ≤ 
0.01 and *** = p ≤ 0.001 when compared to the uninfected controls.  
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Finally, N2a cells were infected with a 10
-9 dilution of 22L infectious material 
and the prion propagation over 12 days was observed by the accumulation of amyloid 
specific SB/ThT staining. The representative micrographs in Figure 21 demonstrate no 
significant increase in ThT positive staining up until 8-12 days post infection. However 
after 12 days post infection, a number of smaller ThT positive amyloid plaques were 
observed accumulating around the cells (Figure 21). The plaques observed were visually 
smaller than the plaques observed in any of the previous higher dose experiments.  
 
 
 
Figure 21 – Example micrographs from the 10
-9 22L-infected N2a time-course 
Representative micrographs from the 10
-9 22L infected N2a cells stained with SB/ThT 4, 8 and 
12 days post initial infection and the uninfected controls. Scale bars = 10 µm.  
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The increase in ThT signal was confirmed by image analysis with a significant 
peak in ThT signal intensity shown after 8 - 12 days post initial infection (Figure 22). 
The levels of ThT signal within this lower dose infection where considerably reduced in 
comparison to the higher dose infections when propagated over 12 days.    
 
 
 
Figure 22 – Image analysis data from the 10
-9 22L-infected N2a time-course 
The  pixel  counts  of  SB/ThT-positive  staining,  taking  into  account  the  background 
autofluorescence in the uninfected controls over 14 days post 10
-9 22L infection in N2a cells. 
Error bars shown are SEM (n = 30 images from 3 separate experiments), * = p ≤ 0.05 and *** = 
p ≤ 0.001 when compared to the uninfected controls. 
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3.3.3.2 Western blot analysis 
 
Firstly, a current Western blot protocol used for the detection of PrP
Sc in ME7-
infected  brain  homogenate  (Herve  et  al.  2009),  was  adapted  and  optimised  for  the 
detection of PrP
Sc in 22L-infected samples. Initially, two commercially available prion 
specific antibodies (SAF 60 and 6H4) were tested using different dilutions of PK to 
determine the level of PK required digesting PrP
c and still detecting PrP
Sc or PrP
res in 
the 22L-infected brain homogenate.  
 
Initial evaluation of the protocol used for the detection of PrP
Sc/PrP
res in ME7 
infected brain homogenates in previous experiments was tested using SAF 60 (binding 
to region 142 – 160 of PrP) at a dilution of 1/5000 (v/v) (Figure 23).    
 
 
 
Figure 23 – Western blot optimisation with SAF 60 monoclonal antibody 1 
Western blot analysis of prion protein content in normal brain homogenate (NBH ) and 22L-
infected brain homogenate (22L) after digestion in varying dilutions of proteinase K (PK) (none 
(-), 100, 200 and 300 ng PK). The primary antibody used was SAF 60 at a dilution of 1/5000 
(v/v) and the equivalent of 30 µg of brain homogenate protein was loaded in each lane.  
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Figure 23 indicates that, even using a PK concentration of 300 ng, PrP
c was not 
fully degraded. In addition, despite only a 5 sec exposure to the X-ray film, the signal 
was too high, suggesting that either the primary or secondary antibody concentrations 
were not optimum. To correct this, the following blot was developed using SAF 60 at a 
1/10000 (v/v) dilution to see if an improvement in the quality of the previous blot could 
be attained (Figure 24).   
 
 
 
Figure 24 – Western blot optimisation with SAF 60 monoclonal antibody 2 
Western blot analysis of prion protein content in normal brain homogenate (NBH ) and 22L-
infected brain homogenate (22L) after digestion in varying dilutions of proteinase K (PK) (none 
(-), 100, 200 and 300 ng PK). The primary antibody used was SAF 60 at a dilution of 1/10000 
(v/v) and the equivalent of 30 µg of brain homogenate protein was loaded in each lane.  
 
 
The chemiluminescent signal observed while using the lower concentration of 
SAF 60 was improved compared to the higher concentration in Figure 24. However, 
there was still positive signal in the NBH suggesting either the levels of PK are not high 
enough to digest the PrP
c or that there is some unspecific binding associated with the 
binding region of this antibody associated with the 22L-infected brain homogenate.  
 
Finally, the primary antibody 6H4 (Prionics, binding to region 144 -152 of the 
prion protein) was used to replace SAF60 to determine if the bands remaining after PK 
kDa  
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digestion  were  caused  by  unspecific  binding  of  the  SAF  60  antibody.  The  blot 
demonstrated  a  clear  reduction  in  PrP
c  expression  in  the  NBH  controls  through 
increased concentrations of PK (Figure 25). Moreover, PrP
27-30, characterised by the 
three bands (Di, mono and un-glycosylated) associated with PrP
Sc digestion by PK, are 
clearly present in the lanes containing 22L infected homogenate (Figure 25). This blot 
confirmed that using 6H4 (1/5000 v/v) as the primary antibody and a PK concentration 
of 10 ng PK per µg of sample protein (300 ng PK digested 30 µg of cellular protein in 
the optimisation blots) was the chosen parameters for 22L PrP
Sc detection using this 
Western blot protocol.  
 
 
 
Figure 25 – Western blot optimisation with 6H4 monoclonal antibody   
Western blot analysis of prion protein content in normal brain homogenate (NBH ) and 22L-
infected brain homogenate (22L) after digestion in varying dilutions of proteinase K (PK) (none 
(-), 100, 200 and 300 ng PK). The primary antibody used was 6H4 at a dilution of 1/5000 (v/v) 
and the equivalent of 30 µg of brain homogenate protein was loaded in each lane. 
 
 
The sensitivity of the detection of PrP
Sc accumulation in 22L-infected N2a cell 
lysates from the time course experiments using the Western blot analysis was tested 
using the described, optimised protocol. Initial blots demonstrated no PrP
Sc-associated 
bands  after  PK  digestion  in  the  uninfected  control  cell  lysates.  However,  a  small 
accumulation of the di-glycosylated band of PrP
Sc over the 12 day time course with an 
kDa  
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initial 10
-2 22L infection was observed in the infected N2a cell lysates (Figure 26, A and 
B).  Clear  triplicate  bands  associated  with  PrP
Sc  in  the  22L  control  lanes  post  PK 
digestion were observed (Figure 26, A and B).  
 
A similar result was shown in the 10
-4 22L infected samples with a very small 
amount of the Di-glycosylated PrP
Sc isoform present in the infected samples with a 
slight increase in expression over 10 days post initial infection. The final blot is from 
the samples taken from the 10
-6 22L infected N2a time course and demonstrates no 
PrP
Sc positive bands across the 14 day time course; suggesting that the limit of the WB 
detection of PrP
Sc from 22L propagation in the N2a time course infections is below a 
10
-4 dilution of initial 22L infectious material when analysing the cell lysate material 
from 35 mm cell culture dishes.    
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Figure 26 – Western blot of N2a lysates from the 22L infection time-courses  
Western  blot  analysis  of  the  N2a  cell  lysates,  taken  from  the  time  course  infections,  after 
varying initial doses of 22L-infected brain homogenate. Blot A shows the uninfected controls 
from the 12-day series. Blot B shows the 10
-2 infected N2a lysate samples, the lane numbers 
represent days post infection with or without PK digestion and the “22L” lane represents the 
22L-positive control. Blots C and D show the samples from the 10
-4 22L-infected N2a time-
course  (C)  and  the  10
-6  22L-infected  N2a  time-course  (D),  lanes  represent  the  days  post 
infection and controls (c) with or without PK digestion. The equivalent of 20 µg of lysate 
protein was loaded in each lane. 
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3.4 Discussion 
 
The  iatrogenic  transmission  of  infectious  prions  has  been  demonstrated  in  a 
number  of  studies  confirming  the  ability  of  PrP
Sc  to  be  transmitted  from  infected 
instruments  (Duffy  et  al.  1974,  Gibbs  et  al.  1994,  Weissmann  et  al.  2002),  tissue 
transplants and blood transfusions (Aguzzi et al. 2008, Furtner et al. 2008, Lemmer et 
al. 2008, Will 2003, Zanusso et al. 2005). Furthermore, the presence of PrP
Sc has been 
observed in a number of other biological samples including urine and stools (Gonzalez-
Romero  et  al.  2008,  Maluquer  de  Motes  et  al.  2008).  The  increase  in  reported 
anatomical regions associated with PrP
Sc accumulation amplifies the risk of iatrogenic 
CJD; especially from transplants, transfusions and surgical procedures; thus heightening 
a concern for public health. The poor efficacy of current decontamination protocols 
regarding  prion  decontamination  used  in  SSD’s  also  increases  the  potential  risk  of 
iatrogenic CJD transmission.  
 
Although  new  decontamination  techniques  are  currently  being  researched 
(Fichet et al. 2004, Fichet et al. 2007a, Paspaltsis et al. 2009) most methods of prion 
detection used in these studies rely on Western blot and immunoassays. These methods 
have  previously been reported to  have limitations in  sensitivity, in  addition  to  only 
detecting the presence of residual PrP
Sc and not the remaining infectivity. Currently, 
infectivity of remaining prion contamination following decontamination is performed 
by animal infectivity bioassays (Fichet et al. 2007b, Lawson 2008) which also have 
limitations as previously reported. As well as being very time consuming, expensive 
and pose significant ethical issues; they are limited to detecting the infectivity of animal 
and animal adapted prion strains due to the “species barrier”. A recent study by Giles et 
al. 2008 has alerted the English Department of Health to the validity of animal and 
animal  adapted  prions  as  models  for  CJD  due  to  the  variations  in  different  strains 
resistance to inactivation (Giles et al. 2008).  
 
These  issues  in  current  detection  methods  have  opened  the  way  for  the 
production of sensitive cell-based bioassays to detect prion infectivity from potentially a  
  101 
number  of  different  prion  strains.  A  study  by  Edgeworth  et  al.  2009  produced  an 
N2aPK1-based assay that has the ability to detect prion infectivity from infected wires 
with  a  sensitivity  of  detecting  down  to  a  10
-10  dilution  of  RML  infected  brain 
homogenate using an immunoblot based assay (Edgeworth et al. 2009). However, as 
discussed previously, these assays rely of immuno detection of PrP
Sc within the cells. 
More recently it has been questioned that the majority of disease-associated PrP
Sc is 
actually sensitive to PK digestion; therefore, the assays that rely on PK digestion may 
not  be  detecting  all  disease-associated  material  (D'Castro  et  al.  2010,  Kuczius  and 
Groschup 1999, Thackray et al. 2007). Therefore, this chapter introduced the production 
of  a  sensitive  N2a  based  cell  assay  using  in  situ  prion  amyloid  staining  to  detect 
infectivity which can be adapted to different cell lines for the potential detection of CJD 
infectivity.  
 
N2a#58 cells were used in these studies as opposed to other N2a sub-clones 
because they have been transfected with wild type mouse Prnp-α cDNA, in order to 
amplify the production of PrP
c therefore increasing the susceptibility of prion infection 
within  these  cells  (Mange  et  al.  2002,  Nishida  et  al.  2000).  Their  susceptibility  to 
infection from several murine prion strains has also been demonstrated (Mange et al. 
2002, Nishida et al. 2000). DMEM media without HEPES buffer was used as it has 
been previously demonstrated in N2a cells and NSC’s that HEPES buffer inhibits prion 
propagation (Delmouly et al. 2011).  
 
Firstly, the sensitivity of two new ThT-based stains, for the detection of prion 
amyloid as a pathological marker of the propagation of prion infection in N2a cells over 
14 days post initial infection was analysed. The N2a cells were initially infected with 
either a final dilution of 10
-4 or 10
-6 22L and stained with ThT alone. A serial dilution 
titre of ThT concentration was first analysed to find a compromise between specific 
signal of ThT bound to prion-associated amyloid and the background autofluorescence 
observed in previous studies using ThT staining (Herve et al. 2009, Lipscomb et al. 
2007a). The optimal dilution of 0.02% (w/v) ThT in 0.01 M HCl was used to stain the 
infected N2a cells every two days post initial infection over a 14 day time course. In the 
10
-4 22L-infected N2a cell experiment, ThT staining alone showed an increase in prion 
amyloid signal from 8 days post initial infection up until a peak level of prion amyloid  
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observed after 12 days. However, when ThT alone was used for the detection of prion 
amyloid in the cells initially infected with a final 10
-6 dilution of 22L-infected brain 
homogenate  there was  very limited ThT signal observed until  10 and  12 days  post 
infection where very small amounts of ThT staining was observed. The image analysis 
was not able to detect a significant increase in ThT-positive signal and demonstrated no 
correlation in the ThT signal and the expected propagation of 22L prion within the cells.  
 
Initial  problems  using  ThT  staining  alone  were  associated  with  a  significant 
level of autofluorescence, which was confirmed to be caused by lipids in the cells and 
tissues observed in previous experiments relying on ThT staining. Sudan black is  a 
histochemical stain that binds to, and stains lipids black/deep red and does not itself 
fluoresce, therefore quenching autofluorescence caused by lipids. As a consequence, the 
addition of SB staining prior to ThT was evaluated. This SB/ThT staining used in the 
10
-4 22L infection experiment showed an initial ThT signal in the 2 days post initial 
infection sample, caused by the initial dose of prion infected material remaining after 
media change in the cells. This signal increased slowly from 6 – 8 days post infection 
and  then  greatly  increased  up  to  12  days  post  infection.  The  SB/ThT  staining  also 
improved the signal of ThT visible in the 10
-6 22L infected N2a cells experiment where 
an increase in prion amyloid staining up until 12 days post infection was observed. This 
confirmed that the addition of the SB before the ThT staining improved the sensitivity 
of this protocol.  
 
The  sensitivity  of  the  SB/ThT  assay  was  further  demonstrated  by  initially 
infecting the N2a cells with a final 10
-8 or 10
-9 dilution of 22L-infected homogenate and 
then  observing  the  propagation  over  14  days  as  before.  In  both  cases  a  significant 
propagation of amyloid was observed, however the levels of ThT-positive signal were 
lower than those in  the higher dose infections.  In all the time-course  infections  the 
levels of prion-associated amyloid peaked at 10 - 12 days post infection. Although all of 
the time-course experiments were run for 14 days, only data up until day 12 has been 
shown in this Chapter. Increased and inconsistent loss of viable cells was observed after 
12 days culture post initial infection as the levels of confluency in the 35 mm dishes 
reached around 100 % between 10 and 12 days. After 12 days the cells had become 
stressed and were lost during media change and staining which deemed the 14 day time  
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point as un-analysable as the data would be inconsistent between repeat experiments. 
This observation highlighted the need for cell passages to improve the long term culture 
of the infected cells.  
 
Western blot (WB) detection is widely used to analyse the levels of PrP
Sc in 
prion infected samples, thus WB was used to analyse the levels of PrP
Sc in lysates taken 
at every time point in the time-course infections so that the sensitivity of WB could be 
directly compared to the SB/ThT assay. Initial experiments aimed to optimise the WB 
protocol for the detection of PrP
Sc in 22L-infected brain homogenates used to infect the 
cells. A protocol used for the detection of PrP
Sc in ME7-infected brain homogenates 
was first tested using the monoclonal prion specific antibody SAF60; however, at both 
1/10000 and 1/5000 dilutions bands still showed up in the PK digested NBH controls. 
Therefore, another widely used prion specific monoclonal antibody 6H4 was tested at a 
dilution of 1/5000. This antibody produced clear three bands associated with PrP
Sc in 
the 22L-infected homogenate and low to no signal was observed in the PK digested 
NBH control. Consequently, the optimised protocol using the primary antibody 6H4 at a 
1/5000 concentration and a PK concentration of 10 ng PK/µg protein alongside the very 
sensitive Amersham ECL plus chemiluminescent detection were used to analyse the 
infected lysates. 
 
 The band relating to the di-glycosylated isoform of PrP
Sc was observed in the 
10
-2 infected N2a lysates showing prion accumulation within the cells over the time 
course propagation. A similar result was observed in the 10
-4 22L-infected N2a lysates 
with a slight increase in density of the di-glycosylated isoform of the infectious prion 
observed over 12 days of infection. This correlated with the bands shown in a 10
-4 22L-
infected NSC’s in a previous study (Figure 27) (Milhavet et al. 2006). The increased 
density of the three PrP
res bands demonstrated in the 10
-2 22L infection could be due to 
the higher levels of propagation observed in the NSC’s potentially from the increased 
endogenous PrP
c when compared to N2a cells (Milhavet et al. 2006). Furthermore, the 
increased  PrP
Sc  associated  bands  found  in  published  WB  analysis  of  cell  culture 
infectivity is caused by the increased protein loaded into each well (~100 – 200 µg) 
(Delmouly et al. 2011, Mange et al. 2002, Milhavet et al. 2006). Whereas, we are only 
analysing one 35 mm dish of cells per well (~20 µg of protein) so that the analysis is  
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directly comparable to the cell population that are analysed with the SB/ThT analysis. 
No PrP
Sc positive bands were observed in the 10
-6 22L infected N2a lysates, suggesting 
this is the level of WB sensitivity for these assays.  
 
 
 
Figure 27 – Example Western blot of 22L titre infection in NSC’s 
Western blot analysis of 22L titre infections in NSC’s taken from Milhavet et al. 2007, used to 
show the single di-glycosylated band shown in the 10
-4 22L infection (0.0001%) (Milhavet et al. 
2006).  
 
These preliminary results  confirm  that the SB/ThT assay has  a much higher 
sensitivity when directly compared to WB analysis and this sensitivity could be further 
improved in the passage infection assays described later. Amyloid specific ThT is not 
only specific to amyloids formed from aggregated prion protein but it also binds to 
amyloids  formed  in  other  amyloidosis,  including  Alzheimer’s  disease  (Herve  et  al. 
2009, Lipscomb et al. 2007a, Maezawa et al. 2008). However, ThT binding to amyloid 
is still a relevant pathological marker to detect prion infectivity in cell based assays. The 
sensitivity of this assay is almost equal to that of the Collinge group N2a PK1 scrapie 
cell  assay  but  the  SB/ThT  assay  has  the  added  benefit  of  being  able  to  detect  the 
accumulation  of  prion  infectivity  in  situ  without  having  to  elute  or  PK  digest  the 
infected cell material (Edgeworth et al. 2009). Consequently, this new assay procedure 
was utilised for subsequent experiments.  
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Chapter 4 
 
Neuroblastoma passage infections 
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4.1 Introduction and aims 
 
  The previous chapter introduced the development of a SB/ThT staining protocol 
for the detection of amyloid accumulation within N2a #58 cells as a marker of prion 
infectivity. Although the detection of an initial dose of a final 10
-9 dilution of 22L-
infected brain homogenate using SB/ThT staining far surpassed the sensitivity of WB 
analysis (10
-4 –
 10
-6 22L); there were some observed limitations within the initial format 
of this assay. Primarily, 12 - 14 days growth of the N2a cells without passaging caused 
significant cell stress within days 10 – 14 and ultimately the level of cell loss with 
media change and staining at the 14
th day led to unreliable and poor quality results. The 
variations  in  propagation  over  the  different  separate  experiments  led  to  larger  error 
within the quantitative results, especially when detecting lower prion doses. Whether 
this  is  caused  by  further  issues  with  background  fluorescence  or  variations  in 
propagation  over  these  short  time  courses  is  currently  unknown.  It  could  also  be 
postulated that slower cell proliferation at the point that the cells become fully confluent 
between days 8 – 10 and the poor attachment of newly split cells could lead to a lower 
turnover of PrP
c and therefore reduced prion conversion within the culture environment. 
 
  The majority of the most sensitive assays used to detect both prion presence and 
prion infectivity rely on several cycles or cell splits/passages to increase incubation 
time. Furthermore, the introductions of fresh substrates are used to aid the conversion or 
propagation of the infectious material. PMCA amplification relies on several rounds of 
sonication and incubation with or without the introduction of new seeds or prion capture 
beads to aid and increase amplification (Gonzalez-Montalban et al. 2011, Saborio et al. 
2001, Weber et al. 2007). RT-QUIC relies on multiple rounds of shaking to induce PrP
c 
conversion with or without the addition of an immuno-precipitation step (Atarashi et al. 
2008, Atarashi et al. 2011a, Orrú et al. 2011). Animal bioassays require >100 days in 
vivo propagation of the prion protein to induce disease and ultimately an end point of  
death (Fichet et al. 2007b, Lawson 2008). The majority of current cell based assays rely 
on several  cell passages post initial inoculation in  the diluted infectious  material  to 
improve the sensitivity and reliability of the assays (Edgeworth et al. 2009, Klohn et al. 
2003, You et al. 2010).           
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  Therefore, this chapter concentrates on incorporating several cell passages into 
the N2a #58 cell propagation discussed in Chapter 3. Firstly the, optimal day for cell 
passage was determined. This was followed by the analysis of the sensitivity of the 
SB/ThT staining in relation to the increased propagation time introduced with the cell 
passages. The SB/ThT detection sensitivity was again directly compared to WB analysis 
as described in the previous chapter.  
 
4.2 Materials and methods 
 
  Details of the materials and methods for this chapter can all be found within 
Chapter 2 of this report. Briefly, N2a #58 cells (2.1.1) were cultured as described in 
section  2.2.1  and  then  subjected  to  22L  (2.1.3  and  2.3.1)  infection  following  the 
neuroblastoma  passage  infections  described  in  section  2.3.3.  Detection  of  prion 
infectivity was obtained by utilising the SB/ThT staining as described in section 2.4.2. 
ThT signal was analysed by epi-fluorescent microscopy and quantified using image J 
software described in section 2.4.5. Furthermore, cell lysates were analysed for PrP
res 
content  using  the  Western  blot  protocol  described  in  section  2.4.6.  All  statistical 
analysis was carried out as highlighted in section 2.7. 
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4.3 Results 
 
4.3.1 Optimising passage day 
 
To improve the sensitivity of the neuroblastoma time-course assays described in 
Chapter  3  and  to  minimize  the  loss  of  cells  associated  with  increased  confluency 
observed in these assays, the amyloid accumulation associated with prion propagation 
was  analysed  over  several  passages  post  initial  infection  to  determine  if  increased 
propagation time could be used to increase the sensitivity of the assay or subsequently if 
infection susceptibility was compromised by the splitting of the cells.  
 
Firstly,  the  optimal  day  to  passage  the  cells  in  order  to  achieve  a  balance 
between cell confluency and optimal propagation was tested by comparing passages 
every 8, 10 and 12 day post initial 10
-4 22L inoculation. At each passage point the 
amyloid  accumulation  was  assessed  by  SB/ThT  staining  described  previously. 
Passaging  every  8  days  post  initial  infection  demonstrated  a  slow  accumulation  of 
amyloid  with  the  peak  levels  reached  after  4  passages  or  34  days  post  infection. 
Representative micrographs shown in Figure 28 demonstrate very small ThT-positive 
aggregates after the first and third passages and then the accumulation of larger plaques 
were observed at each subsequent passage thereafter (Figure 28). The image analysis 
data showed an initial increase in ThT-positive signal at the point of the first passage (8 
days), this signal then dropped after the next passage (16 days) and then significantly 
increased over the passages 4 – 6 (days 32-48) where a plateau of ThT-positive signal 
was observed (Figure 28).   
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Figure 28 – Example micrographs and SB/ThT image analysis from the 10
-4 22L-
infected N2a 8 day passage study 
Representative micrographs from the 10
-4 22L-infected N2a cells stained with SB/ThT after 
passages  every  8  days  post  initial  infection  (left  to  right  respectively)  and  the  uninfected 
controls (below). Scale bars = 10 µm. The image analysis data demonstrates the pixel counts of 
SB/ThT-positive staining taking into account the background autofluorescence in the uninfected 
controls. Error bars shown are SEM (n=10), * = p ≤ 0.05, ** = p ≤ 0.01 when compared to the 
uninfected controls.  
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Passaging  the  N2a  cells  every  10  days  post  initial  10
-4  22L  infection 
demonstrated a similar slow initial increase in ThT signal over the first 3 passages, as 
demonstrated in Figure 28 with the 8 day passages. However no initial drop in signal 
and amyloid accumulation was observed as was the case in the 8 day passage samples. 
The representative micrographs highlighted very little amyloid accumulation after the 
first passage (10 days) with a few infrequent, larger plaques after passages 2 and 3 (days 
20 - 30) and larger, more widely occurring plaques were revealed after passage 4 (40 
days)  (Figure  29).  This  was  further  highlighted  by  the  image  analysis  data  which 
demonstrated  a  significant  increase  in  ThT-positive  signal  over  the  first  and  third 
passages (days 10 – 30) even though an increase in plaque size was observed. A further 
and  larger  significant  increase  in  ThT-positive  signal  was  demonstrated  after  four 
passages (40 days) post initial infection (Figure 29).  
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Figure 29 – Example micrographs and SB/ThT image analysis from the 10
-4 22L-
infected N2a 10 day passage study  
Representative micrographs from the 10
-4 22L-infected N2a cells (top) stained with SB/ThT 
after passages every 10 days post initial infection (left to right respectively) and the uninfected 
controls (below). Scale bars = 10 µm. The image analysis data demonstrates pixel counts of 
SB/ThT-positive staining from the 10 day passage study samples taking into account the level 
of background autofluorescence found in the uninfected controls from each passage. Error bars 
shown are SEM (n=10), * = p ≤ 0.05, ** = p ≤ 0.01 when compared to the uninfected controls.  
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Passaging the N2a cells every 12 days post initial 10
-4 22L infection showed a 
more rapid amyloid accumulation than the 8 and 10 day passages. The representative 
micrographs highlighted very small ThT positive amyloid plaques formed over the first 
passage  (12  days,  Figure  30).  Visually  the  plaque  size  and  frequency  significantly 
increased over the next three passages (days 12 - 48), where the highest level of ThT-
positive signal and plaque size was observed at the point of the fourth passage (48 days) 
(Figure 30). However without extensive 3-dimensional analysis of the plaque size it is 
difficult to confirm the changes in plaque size apart from what is visually observed in 
the micrographs. The image analysis data confirmed a clear increase in ThT-positive 
signal over each of the passages following an almost linear trend. A significant increase 
in ThT signal was observed at passage 2, 3 and 4 when compared to the signal in the 
uninfected controls (Figure 30). However a loss of cells during media change between 
11 - 12 days was observed questioning the reliability of passaging the infected cells 
every 12 days.       
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Figure 30 – Example micrographs and SB/ThT image analysis from the 10
-4 22L-
infected N2a 12 day passage study 
Representative micrographs from the 10
-4 22L-infected N2a cells stained with SB/ThT after 
passages  every  12  days  post  initial  infection  (left  to  right  respectively)  and  the  uninfected 
controls (below). Scale bars = 10 µm. The image analysis data demonstrates the pixel counts of 
SB/ThT-positive staining taking into account the levels of background autofluorescence in the 
uninfected controls at each passage. Error bars shown are SEM (n=10), * = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001 when compared to the uninfected controls.  
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4.3.1.1 Western blot analysis (optimal passage day) 
 
The accumulation of PrP
Sc following several passages was analysed using the 
optimised  Western  blot  protocol  utilising  the  6H4  monoclonal  antibody  (Prionics) 
described previously in Chapter 3. The cell lysate samples from the 12 day passage 
study  were  analysed  to  determine  if  the  sensitivity  of  the  Western  blot  protocol  is 
improved  by  allowing  the  prion  aggregation  to  propagate  over  several  passages  as 
opposed to just 14 days post initial infection as discussed in the previous chapter. There 
were no infectious prions bands present in the control samples taken at each passage 
when compared to the 22L brain homogenate positive control (Figure 31). However, in 
the  10
-4  22L-infected  cell  lysates  there  was  a  6H4-positive  band  highlighting  the 
accumulation of the di-glycosylated isoform of PrP
Sc that increased in density over the 5 
passages (Figure 31).   
 
 
Figure 31 – Western blot analysis of the N2a lysates from the 10
-4 22L-infected N2a 
12 day passage study 
Western blot analysis of the PrP
Sc accumulation in the Neuroblastoma cells passaged every 12 
days after an initial 10
-4 22L infectious dose (bottom) and the uninfected controls samples taken 
at every passage (top). The lane numbers represent the passage number post infection with or 
without PK digestion and the “22L” lane represents the 22L positive control. The equivalent of 
15 µg of lysate protein was loaded in each lane. 
kDa  
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  Analysis of the density of the 6H4 immunoreactive bands representing the di-
glycosylated isoform of PrP
Sc were analysed using the density analysis macro built into 
the Image J software. The image analysis confirmed an increase in band density over 
the 5 passages every 12 days post initial infection. This suggests that the di-glycosylated 
glycoforms of PrP
Sc increased during the 5 passages every 12 days post initial infection 
with a 10
-4 dilution of 22L-infected brain homogenate (Figure 32). 
 
. 
Figure 32 – Image analysis of Western blot band density 
Image analysis of the pixel counts of the density of the 6H4 immunoreactive bands present after 
the WB analysis of the N2a lysate samples, taken at each passage point, every 12 days post 
initial 10
-4 22L infection. 
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4.3.2 Titre passage infection in N2a cells 
 
The optimal passage day post infection to allow a consistent propagation of the 
infectious prion in the neuroblastoma cells was every 12 days. However, more crucially, 
passaging every 12 days was unreliable from experiment to experiment and passage to 
passage as the cells at this point were fully confluent and contact inhibition caused loss 
of cells during media changes and staining and subsequently could jeopardise the clarity 
of  the  assay.  Thus,  to  compromise  between  cell  viability  and  consistency  of  prion 
propagation, 10 days passaging post infection was determined to be optimal for the 
subsequent  set  of experiments  used to  determine the sensitivity of the  N2a passage 
assays with SB/ThT detection. It was also observed that increased levels of background 
staining occurred in the confluent cells, which was also further hindered by the spheroid 
production associated with the cancerous nature of the N2a cells. Therefore a more 
dilute  concentration  of  ThT  [0.004%  (v/v)]  was  used  as  a  compromise  between 
background and positive staining.  
 
A titre infection of the N2a cells over several passages using dilutions of 22L-
infected brain homogenate ranging from 10
-4 to 10
-10 was analysed. Lowering the initial 
22L infectious dose showed a clear reduction in the level of ThT-positive signal. Also, 
as the dose was lowered, an increased number of passages were required to demonstrate 
a significant increase in ThT signal. However, a propagation of amyloid was observed 
over several passages after each of the initial 22L dilutions (Figure 33). Furthermore, 
the observed size of the plaques decreased whilst, conversely, the numbers of them 
increased as the infectious dose was lowered (Figure 34). All of the assays reached the 
highest levels of ThT positive signal after passage 8 (80 days) at which point the assays 
were terminated as a clear propagation was observed.     118 
 
 
Figure 33 – The image analysis of ThT signal from the 22L titre dose response study 
The image analysis of ThT-positive amyloid accumulation in the N2a cells over several passages every 10 days post initial 22L titre dilutions ranging from 10
-4 – 10
-
10 of 22L-infected brain homogenate. Error bars represent SEM (n = 30) *** = p ≤ 0.001 when compared to the uninfected controls.  
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Figure 34 – Example micrographs of 22L dose response propagated in N2a cells 
Micrographs of ThT staining taken from infected (A) and uninfected (B) N2a #58 cells at passage 8 (80 days) post initial 22L inoculation. The images represent a 
dose response from 10
-4 22L – 10
-10 22L (left to right respectively). The white rings highlight ThT-positive amyloid staining and demonstrate the changes in plaque 
size associated with the initial 22L dose concentration. Scale bars = 10 µm.  
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4.4 Discussion 
 
  In vivo animal-based bioassays demonstrate increased propagation of
 PrP
Sc over 
time. This is due to the fact that the natural cell turnover of PrP
c within the brain aids 
the prion conversion process from an infected inoculum or wire, amplifying PrP
sc and 
furthering  disease  progression.  Therefore,  current  cell  based  assays  used  to  analyse 
prion  infectivity utilise several  cell splits  post initial inoculation with  the infectious 
prion material to closer mimic the in vivo
 cell PrP
c turnover and therefore improve the 
sensitivity of the assays. The end point dilution TCIA (tissue culture infectivity assay) 
demonstrated  that  weekly  passages  post  inoculation  increased  the  sensitivity  of  the 
assay  from  detecting  10
-4  dilution  of  127S  (sheep  scrapie  strain)  infected  brain 
homogenate after 5 passages to detecting 10
-6.8 after 10 passages (You et al. 2010). The 
SCEPA assay utilises several passages every 3 days using different cell split ratios (1:3 
and 1:8) to improve the sensitivity of detection to detect infectivity after an initial 10
-10 
dilution of RML-infected brain homogenate (Edgeworth et al. 2009).     
 
Therefore, to improve the sensitivity, reliability and to prevent the loss of cells 
observed  in  the  SB/ThT  N2a  time-course  assays,  the  22L  prion  infections  were 
propagated  over  several  passages  of  the  N2a  cells.  The  number  of  incubation  days 
between passages was thought to be the crucial step to reach an optimal propagation 
within the cell assay and therefore aid the sensitivity of the SB/ThT detection protocol. 
Firstly,  the  optimal  day  for  passaging  the  infected  cells  was  determined.  Passaging 
every 12 days gave the highest propagation over the shortest time. However the cell 
confluency after the 12 days was not always consistent and variations in cell loss was 
observed during media change and staining, thus questioning the clarity of the assay 
passaging at this time point. Therefore, a day 10 passage was chosen as optimal in order 
to compromise between the level of prion propagation and cell loss. Ten day passaging, 
demonstrated  a  significant  increase  in  ThT  over  several  passages,  but  an  improved 
consistency in cell number adhered to the tissue culture plates at the point of analysis. 
After 10 days the N2a cells were ~90% confluent, thus a more reliable and consistent 
assay than over confluent and potentially stressed cells. The WB analysis of the PrP
Sc 
content in the cell lysates taken from the 12 day passage study demonstrated an increase  
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in  just  the  di-glycosylated  band  of  the  prion  protein  (as  observed  in  Chapter  3) 
correlating with the bands shown in the Milhavet NSC blot shown previously (Figure 
27). However the discrepancies in band intensities can be explained by the increased 
protein loads used in the Milhavet work (Milhavet et al. 2006). The increase in the 
accumulation of the di-glycosylated PrP
res was confirmed by analysing the density of 
the bands over the 5 passages post initial infection. 
 
Once the optimal passage day was confirmed the sensitivity of this assay was 
tested by inoculating the cells with a titre of final 22L dilutions ranging from 10
-4 to 10
-
10. An increase in ThT signal was observed after several passages in all of the cells apart 
from the uninfected controls. The SB/ThT staining highlighted an increase in amyloid 
accumulation  demonstrating  a  dose  dependent  response  after  7  –  8  passages.  The 
different dilutions of 22L homogenate reached a statistically significant (p = ≤0.001) 
increase in ThT signal compared to the uninfected controls at different passage points, 
with the lower initial 22L dose requiring more passages. This demonstrated that lower 
initial doses required more passages to reach a detectable level of infectivity; however 
even the most dilute (10
-10) still contained infectious material that was detectable once 
amplified. Also the size and distribution of the plaques varied depending on the initial 
22L dose. Larger and less diffuse amyloid plaques were observed in the higher dose 
infections, whereas the lower doses resulted in smaller plaques at the same passage 
point. However, when smaller plaques  were observed their  frequency seemed to  be 
increased when compared to the larger plaques. This could potentially suggest that the 
smaller plaques combine together over time to produce the larger plaques observed in 
the later passages with the higher doses. The passage infectivity studies determined that 
the  SB/ThT  detection  of  prion  infectivity  was  1  log  more  sensitive  after  several 
passages  when  compared  to  the  time  course  assays.  The  SB/ThT  detection  also 
demonstrated >5 log improved sensitivity when directly compared to WB detection of 
prion propagation in cell lysates from the 35 mm tissue culture dishes.    
 
These  results  confirm  that  the  SB/ThT  assay  for  the  detection  of  prion-
associated amyloid accumulation has a much improved sensitivity when compared to 
WB analysis of PrP
Sc accumulation in the cell lysates. The sensitivity of the SB/ThT 
assay matches that of the Collinge group scrapie cell assay but the SB/ThT assay has the  
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added ability of being able to detect the accumulation of prion infectivity in situ without 
having to membrane capture the cells for detection of PrP
res material (Edgeworth et al. 
2009). Furthermore, the SB/ThT assay does not require PK digestion of the cells prior 
to detection. Therefore this assay would work well alongside assays using PK digestion 
and immuno detection as the combined results would portray a more realistic picture of 
the  remaining  infectivity  within  biological  samples.  This  work  demonstrates  the 
potential of the SB/ThT assays after the propagation of infectivity over several passages 
post  initial  infection  to  be  a  novel,  sensitive  cell  based  infectivity  assay.  However, 
further adaptation of the assay is required for the detection of infectivity remaining on 
surfaces post decontamination.  
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Chapter 5 
 
Neuroblastoma wire infectivity 
assays and the determination of 
decontamination efficacy  
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5.1 Introduction and aims  
 
The previous chapter demonstrated the sensitivity of the SB/ThT assay for the 
determination of prion infectivity in N2a cells when infectious material was incubated 
in  the  cells  over  several  passages  every  10  days.  The  assay  demonstrated  a  dose 
response to different dilutions of 22L homogenate detecting infectivity in samples as 
dilute as a 10
-10 dilution of 22L-infected brain homogenate. However, these passage 
studies  were  detecting  infectivity  from  the  direct  introduction  of  infected  brain 
homogenate to the cells, which is not ideal to test decontamination protocols.  
 
Techniques that analyse the presence of general protein, PrP
Sc and amyloid, such 
as PMCA, RT-QUIC, ASA, SR/THT dual staining and Western blot, are all useful tools 
in prion research (Atarashi et al. 2011b, Colby et al. 2007, Herve et al. 2010, Saborio et 
al.  2001).  However,  it  is  not  always  guaranteed  that  the  presence  of  protein 
contamination  or  any  other  prion  related  markers  post  decontamination  actually 
correlate with residual infectivity. Therefore, the questions remains as to whether these 
techniques can really assess decontamination protocols in relation to residual infectivity 
post treatment.  
 
Animal bioassays assess decontamination protocols by utilising small lengths of 
surgical stainless steel (SS) wires to act as model surfaces (Fichet et al. 2004, Fichet et 
al. 2007b, Flechsig et al. 2001, Lawson 2008, Yan et al. 2004, Zobeley et al. 1999). The 
wires are inoculated with the prion strain under investigation and then decontaminated 
using various protocols. Then wires are inserted into the brain of the rodent and disease 
progression is assessed via behavioural studies, disease incubation time or lack thereof 
and the analysis of disease markers in the brain post death, depending on the efficacy of 
decontamination. More recently the standard steel-binding assay (SSBA), an adaptation 
of the SCEPA cell assay introduced earlier, utilises small 5 mm lengths of surgical 
grade SS wires to assess decontamination protocols in a cell-based infectivity assay 
through the analysis of PrP
Sc accumulation in N2a-PK1 cells (Edgeworth et al. 2009, 
Edgeworth et al. 2011b).    
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  This chapter concentrates on the adaptation of the N2a #58 passage-based 22L 
infectivity  assay  with  SB/ThT  detection  discussed  in  the  previous  chapter,  for  the 
analysis of infectivity remaining post decontamination. This will entail the optimisation 
and incorporation of inoculated surgical SS wires to introduce infectivity to the cells as 
is used in the SSBA assay. The infectivity will then be compared to the protein, lipid 
and amyloid contamination present on SS wires pre and post decontamination. This will 
confirm if residual contamination is related to infectivity. The infectivity results of the 
SB/ThT  analysis  of  the  22L-infected  N2a  cells  post  decontamination  will  then  be 
compared to animal infectivity assays assessing the same decontamination chemistries.    
 
5.2 Materials and methods 
 
Details of the materials and methods for this chapter can all be found within 
Chapter 2 of this report. Briefly, N2a #58 cells (2.1.1) were cultured as described in 
section 2.2.1 and then subjected to 22L (2.1.3 and 2.3.1) infection following the wire 
infectivity assay protocol described in section 2.3.4 for the optimisation of the number 
of  wires  required  per  dish  and  to  determine  the  sensitivity  of  the  wire  assays.  The 
decontamination efficacy of three commercially available cleaning chemistries; Hamo 
100, Klenzyme and Enzol were then analysed in relation to infectivity in N2a cells 
(2.3.5) and remaining protein, lipid and prion-associated amyloid post decontamination 
using SR/ThT and NR/ThT staining (2.4.3 and 2.4.4). Detection of prion infectivity post 
decontamination (2.3.5) in the N2a cells was obtained by utilising the SB/ThT staining 
protocol as described in section 2.4.2. Fluorescent signal from all of the experiments 
was analysed by epi-fluorescence microscopy and quantified using Image J software 
described  in  section  2.4.5.  All  statistical  analysis  was  carried  out  as  highlighted  in 
section 2.7. 
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5.3 Results  
 
5.3.1 Wire number optimisation  
 
  Rodent based prion infectivity assays require the implantation of, 5 mm lengths 
of  0.15  mm  diameter  surgical  grade  SS  wires  inoculated  in  prion-infected  brain 
homogenate  to  the  brain  of  each  test  animal  to  assess  the  infectivity  pre  and  post 
decontamination (Flechsig et al. 2001). Similarly, the SSBA uses 20, 5 mm lengths of 
RML-inoculated  surgical  SS  wires  per  35  mm  well  of  a  6-well  plate  to  induce 
infectivity within the N2a-PK1 cells (Edgeworth et al. 2009, Edgeworth et al. 2011b). 
Therefore, the number of 22L inoculated wires required to induce a consistent, SB/ThT 
detectable infection in the N2a #58 cells was tested. N2a cells were introduced to wells 
containing 5, 10 or 20, 10
-4 22L-inoculated wires or 10 or 20, 10
-6 22L-inoculated wires. 
Cells were grown to confluency at which point the cell coated wires were transferred to 
new dishes and the cells were cultured to confluency from the wires. Once confluent, 
the cells were split and treated as a passage study with SB/ThT analysis every 7 days (as 
it took 7 days to reach confluency from the wires so this was kept standard throughout 
the assays).  
 
  The image analysis of SB/ThT staining clearly demonstrated that the number of 
wires  required  per  35  mm  dish  is  crucial  to  obtain  reliable  and  consistent  prion 
propagation in the N2a cells. The cells that had been in contact with 20, 10
-4 and 20, 10
-
6 22L-inoculated wires demonstrated a clear dose dependant prion-associated amyloid 
accumulation over the 7 passages post wire removal (Figure 35). The cells that had been 
in  contact  with  10,  10
-4  22L-inoculated  wires  demonstrated  an  increase  in  amyloid 
accumulation, however, the significance  was  lost  over the last  two passages  due to 
increased variance between samples (Figure 35). The cells that had been in contact with 
5, 10
-4 22L-inoculated wires showed an initial increase in amyloid accumulation that 
levelled over the 7 passages (Figure 35). The cells that had been in contact with 10, 10
-6 
22L-inoculated wires demonstrated a minimal increase in amyloid accumulation with 
high  variance  between  the  samples  and  only  passage  4  demonstrated  a  significant 
increase when compared to the un-infected controls (Figure 35).     128 
 
 
Figure 35 – Determination of the number of wires required for optimal prion propagation per 35 mm dish 
Image analysis of SB/ThT-positive staining above the background observed within the controls, to determine the number of wires required, per 35 mm dish, to 
induce an optimal amyloid accumulation within the N2a cells. Error bars represent SEM (n=10–20). * = p ≤ 0.05, ** = p ≤ 0.01 and *** = p ≤ 0.001 when compared 
to the uninfected controls.  
  129 
5.3.2 Wire titre infections  
 
  The previous work demonstrated that the number of inoculated wires in contact 
with the N2a cells in the 35 mm dishes is crucial to induce sufficient prion infection. It 
was confirmed that 20 wires per 35mm dish of cells was the optimal number of wires 
required, as observed in previous studies. Therefore, the next step was to determine the 
sensitivity of the wire infectivity assay in the N2a cells with SB/ThT analysis. Batches 
of 20, 5 mm surgical stainless steel wires were inoculated in dilutions of 22L-infected 
brain homogenate ranging from 10
-4 – 10
-10. The cells were then subjected to the wires 
following the wire infectivity assay protocol described previously, with passaging and 
SB/ThT analysis every 7 days post wire removal. Furthermore, the cells remaining in 
the first 35 mm dishes after the cell covered wires were removed were analysed for 
amyloid accumulation using the SB/ThT staining to determine the levels of infectivity 
initially transferred from the wires.  
 
  Firstly, the image analysis of the SB/ThT-positive signal demonstrated that there 
was already prion-associated amyloid accumulation in the N2a cells that had been in 
contact with the inoculated wires prior to wire removal for the first step of the wire 
infectivity protocol. There was a dose response trend of amyloid accumulation with the 
cells  in  contact  with  wires  inoculated  with  10
-4  dilution  of  22L-infected  brain 
homogenate demonstrating the highest levels of amyloid and the cells in contact with 
10
-10 22L-inoculated wires showing the least (Figure 36). A significant increase of ThT 
positive amyloid accumulation was observed in cells that had been in contact with wires 
inoculated with 10
-4, 10
-6 and 10
-8 dilutions of 22L-infected brain homogenate (Figure 
36). Cells that had been in contact with wires inoculated with 10
-9 and 10
-10 dilutions of 
22L-infected brain homogenate showed a small but statistically insignificant increase in 
ThT signal when compared to the un-infected controls (Figure 36). 
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Figure 36 – Analysis of amyloid content in the remaining cells after wire removal 
Image  analysis  of  SB/ThT-positive  staining  to  determine  the  amyloid  content  within  the 
remaining N2a cells after wire removal at the first passage point. Error bars represent SEM 
(n=10). * = p ≤ 0.05 and ** = p ≤ 0.01 when compared to the uninfected controls. 
 
  Secondly, the sensitivity of the SB/ThT detection of amyloid accumulation in 
N2a #58 cells post contact with 22L-inoculated wires was tested. A dose dependent 
increase in SB/ThT signal was observed in the N2a cells after 8 cell passages post 
removal  of  the  wires  which  were  inoculated  with  varying  dilutions  of  22L-infected 
brain homogenate. This was confirmed with the image analysis which demonstrated 
significant increases in SB/ThT-positive signal in all of the infected N2a samples when 
compared  to  the  uninfected  control  cells  (Figure  37).  A  correlation  was  observed 
between the different 22L dilutions and the number of passages taken to demonstrate an 
increase in ThT-positive signal with a significance of p ≤ 0.001 when compared to the 
uninfected controls (Figure 37). The cells that had been in contact with the 10
-4 22L-
inoculated wires demonstrated a more rapid increase in amyloid accumulation when 
compared to the lower dose infections, especially in the 10
-10  22L-infected cells where a 
significant (p ≤ 0.001) increase in ThT signal was only observed at passage 7 – 8 post 
wire removal (Figure 37).   
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Figure 37 – Amyloid content in the N2a cells demonstrating a titre dilution of 22L infectivity from inoculated wires 
Image analysis of SB/ThT-positive staining above the background observed within the controls, from the N2a cells infected from stainless steel wires inoculated 
with a titre dilution of 22L-infected brain homogenate ranging from 10
-4 – 10
-10. Error bars represent SEM (n = 20). ** = p ≤ 0.01 and *** = p ≤ 0.001 when 
compared to the uninfected controls.  
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5.3.3 SR/ThT and NR/ThT analysis of decontamination efficacy  
 
  Prior to testing residual infectivity post-decontamination of the 22L-inoculated 
SS wires using the optimised N2a #58 wire infectivity assay; residual protein, lipid and 
prion-associated amyloid contamination on the wires post decontamination treatment 
was analysed. As the N2a #58 infectivity assay is only optimised to detect infectivity 
from 22L-infected samples, the residual contamination from 22L-inoculated wires was 
also compared to 263K-inoculated wires to compare the resistance of contamination 
removal of prion strains from two different species. Both 22L and 263K-infected brain 
homogenates were normalised to 1 mg/ml prior to wire inoculation. Direct SR/ThT and 
NR/ThT staining was utilised to highlight protein (SR), lipid (NR) and prion-associated 
amyloid (ThT) biofouling present on the wires.  
 
  Firstly, the contamination pre and post decontamination treatment on the 263K-
inoculated wires was analysed. Representative micrographs of scans of the whole wires 
show that the control wires (no decontamination) clearly contained the highest levels of 
protein, lipid and prion-associated amyloid contamination when compared to the three 
cleaning chemistries (Figure 38 and Figure 39). The wires decontaminated with Hamo 
100  demonstrated  the  highest  levels  of  protein  and  prion-associated  amyloid 
contamination post treatment, when compared to the other two cleaners (Figure 38). The 
micrographs show that Hamo 100 was poorly effective at removing the larger protein 
deposits (Figure 38). The wires decontaminated with Klenzyme and Enzol demonstrated 
very  similar  levels  of  protein  and  prion-associated  amyloid  contamination  post 
treatment  (Figure  38).  The  wires  decontaminated  with  Hamo  100  and  Klenzyme 
demonstrated similar volumes of lipid deposits remaining post treatment (Figure 39). In 
contrast, treatment with Enzol demonstrated fewer larger lipid deposits but what looked 
like areas of smaller lipid deposits compared to the other two cleaning chemistries was 
observed (Figure 39).  
 
The  image  analysis  of  the  SR,  NR  and  ThT  signal  quantitated  the  263K 
contamination  on the surgical  stainless  steel  wires  pre and post decontamination. A 
significant decrease in protein, lipid and prion-associated amyloid contamination on the  
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263K inoculated wires was observed after treatment with the three cleaning chemistries 
when compared to the positive controls (Figure 42). The image analysis confirmed that 
the largest levels of protein remaining post decontamination treatment was found on the 
wires treated with Hamo 100 and less was observed on the wires treated with Klenzyme 
and Enzol (92%, 99% and 98% reduction when compared to the controls, respectively) 
(Figure 42). Similar amounts of prion-associated amyloid were observed on the wires 
treated with Hamo 100 and Klenzyme with a lower level of contamination observed on 
the wires  treated with  Enzol  (71%, 81% and 88% reduction when compared to  the 
controls,  respectively)  (Figure  42).  The  levels  of  residual  lipid  contamination  were 
similar after treatment with all three cleaning chemistries, with slightly less observed 
after Enzol treatment (82%, 85% and 89% reduction when compared to the controls, 
respectively) (Figure 42).  
 
  Secondly, the contamination pre and post decontamination treatment on 22L-
inoculated  wires  was  analysed.  The  clearest  observation  when  comparing  the 
micrographs of the 263K and the 22L-inoculated wires is that the wires contaminated 
with  22L-infected  brain  homogenate  harboured  considerable  higher  levels  of 
contamination, both pre and post decontamination, highlighted by increased staining 
intensities of the three fluorophores. Representative micrographs of scans of the whole 
wires show that the control wires (no decontamination) clearly contained the highest 
levels of protein, lipid and prion-associated amyloid contamination when compared to 
the three cleaning chemistries (Figure 40 and Figure 41). The wires decontaminated 
with Hamo 100 demonstrated the highest levels of protein and prion-associated amyloid 
contamination  post  treatment  when  compared  to  the  other  two  cleaners;  however, 
increased residual contamination was observed compared to the 263K-inoculated wires 
(Figure  40).  The  micrographs  again  show  that  Hamo  100  was  poorly  effective  at 
removing  the  larger  protein  deposits  (Figure  40).  The  wires  decontaminated  with 
Klenzyme  and  Enzol  demonstrated  very  similar  levels  of  prion-associated  amyloid 
contamination  post  treatment;  however,  the  wires  decontaminated  with  Enzol 
demonstrated lower levels of protein compared to Klenzyme treated wires (Figure 40). 
Decontamination with Hamo 100 and Klenzyme again demonstrated similar volumes 
and staining of lipid deposits remaining post treatment (Figure 41). However, the wires 
decontaminated with Enzol showed residual contamination completely the opposite of  
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the  263K-contaminated  wires  with  larger  lipid  deposits  remaining  post  treatment 
compared to the other two cleaning chemistries (Figure 41).  
 
The  most  obvious  observation  when  comparing  the  263K  and  22L 
contamination of the surgical stainless steel wires is that the 22L-infected homogenate 
attached more readily to the wires surface than the 263K-infected homogenate. Almost 
a 4-fold increase in contamination was observed on the 22L-positive controls compared 
to the 263K-positive controls, this clearly lead to increased residual contamination post 
decontamination  treatment.  However,  the  same  significant  trend  of  remaining 
contamination compared between the three cleaning chemistries was observed. Again, 
wires treated with Hamo 100 demonstrated the highest levels of residual protein with 
slightly lower levels observed on the Klenzyme and Enzol treated wires (86%, 96% and 
98%  reduction  when  compared  to  the  controls,  respectively)  (Figure  43).  A  slight 
decrease  in  prion-associated  amyloid  contamination  was  observed  across  the  three 
different  treatments  (89%, 91% and 96% reduction when compared to the controls, 
respectively) (Figure 43). The levels of residual lipid contamination was the opposite of 
that observed with the 263K contaminated wires with the lowest levels of lipid found on 
the  wires  after  Hamo  100  treatment  with  the  highest  levels  observed  after  Enzol 
treatment (91%, 86% and 85% reduction when compared to the controls, respectively) 
(Figure 43).  
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Figure 38 – Micrographs of protein and amyloid contamination on stainless steel wires post 263K contamination 
Representative micrographs of protein (SR (A)) and prion-associated amyloid (ThT (B)) contamination on surgical stainless steel wires inoculated with 263K-
infected brain homogenate. The micrographs highlight contamination both pre (control) and post (Hamo 100, Klenzyme, Enzol) decontamination treatment. Scale 
bar = 100 µm.    136 
 
 
Figure 39 – Micrographs of lipid and amyloid contamination on stainless steel wires post 263K contamination 
Representative micrographs of lipid (NR (A)) and prion-associated amyloid (ThT (B)) contamination on surgical stainless steel wires inoculated with 263K-infected 
brain homogenate. The micrographs highlight contamination both pre (control) and post (Hamo 100, Klenzyme, Enzol) decontamination treatment. Scale bar = 100 
µm. 
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Figure 40 – Micrographs of protein and amyloid contamination on stainless steel wires post 22L contamination 
Representative micrographs of lipid (SR (A)) and prion-associated amyloid (ThT (B)) contamination on surgical stainless steel wires inoculated with 22L-infected 
brain homogenate. The micrographs highlight contamination both pre (control) and post (Hamo 100, Klenzyme, Enzol) decontamination treatment. Scale bar = 100 
µm.   138 
   
 
Figure 41 – Micrographs of lipid and amyloid contamination on stainless steel wires post 22L contamination 
Representative micrographs of lipid (NR (A)) and prion-associated amyloid (ThT (B)) contamination on surgical stainless steel wires inoculated with 22L-infected 
brain homogenate. The micrographs highlight contamination both pre (control) and post (Hamo 100, Klenzyme, Enzol) decontamination treatment. Scale bar = 100 
µm.  
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Figure 42 – Image analysis of protein, lipid and amyloid contamination on stainless 
steel wires post 263k contamination 
Image analysis of protein (SR, top), lipid (NR, bottom) and prion-associated amyloid (ThT, top 
and  bottom)  residual  contamination,  both  pre  and  post  decontamination  with  Hamo  100, 
Klenzyme  or  Enzol,  on  surgical  stainless  steel  wires  inoculated  with  263K-infected  brain 
homogenate. Error bars represent SEM (n = 6-20 wires) ** = p ≤ 0.01 and *** = p ≤ 0.001 
when compared to the positive controls.  
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Figure 43 – Image analysis of protein, lipid and amyloid contamination on stainless 
steel wires post 22L contamination 
Image analysis of protein (SR, top), lipid (NR, bottom) and prion-associated amyloid (ThT, top 
and  bottom)  residual  contamination,  both  pre  and  post  decontamination  with  Hamo  100, 
Klenzyme  or  Enzol,  on  surgical  stainless  steel  wires  inoculated  with  22L-infected  brain 
homogenate. Error bars represent SEM (n = 6-15 wires) ** = p ≤ 0.01 and *** = p ≤ 0.001 
when compared to the positive controls.  
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5.3.4 N2a infectivity and SB/ThT analysis of decontamination efficacy  
 
  Previously,  the  sensitivity  of  the  N2a  wire  passage  infectivity  assay  with 
SB/ThT analysis for the detection of wire-bound infectivity was determined. The N2a 
wire  infectivity  assay  was  then  utilised  to  determine  residual  infectivity  on  22L-
inoculated surgical SS wires post decontamination treatment with Hamo 100, Klenzyme 
and Enzol for the comparison with the presence of protein, lipid and prion-associated 
amyloid, discussed in section 5.3.3, and with published infectivity data from animal 
bioassays  assessing  the  same  cleaning  chemistries  with  263K-infected  brain 
homogenate.   
 
  All of the wires pre (positive controls) and post decontamination were originally 
inoculated in  10% 22L-infected brain  homogenate or 10%-NBH for the un-infected 
controls. The levels of amyloid accumulation was visualised using SB/ThT staining at 
each passage as described previously. A cut-off threshold of detection of 1000 pixels 
was chosen to take account for some areas of background fluorescence associated with 
the spheroid clumping of the N2a cells that were being picked up by the image analysis 
even after setting the pixel  intensity threshold using the control  images. The image 
analysis results of SB/ThT signal clearly demonstrated a significant increase over the 8 
weekly passages post wire removal that followed a similar trend as wires inoculated 
with 10
-4 diluted 22L-infected brain homogenate (Figure 45). The example micrographs 
show that there is an accumulation of large ThT-positive plaques at the 7
th passage point 
(49 days) post wire removal in the positive controls (Figure 44). The N2a #58 cell 
samples  that  had  been  in  contact  with  22L-inoculated  wires  decontaminated  with 
Klenzyme and Enzol both showed similar amyloid accumulation kinetics over the 8 
weekly passages post wire removal. A lag phase of low levels of amyloid accumulation 
was observed over the first three passages (21 days) post wire removal, followed by a 
significant increase in ThT-positive amyloid accumulation from passages 3 – 8 (21 – 56 
days) post wire removal (Figure 45). Representative micrographs demonstrate smaller 
ThT-positive plaques, compared to the plaques observed in the positive controls, found 
in  the  N2a  cells  that  had  been  in  contact  with  22L-inoculated  wires  treated  with 
Klenzyme (Figure 44). The same smaller plaques were also observed in N2a cells that 
had been in contact with Enzol treated wires. Very low levels of ThT staining was  
  142 
observed in the N2a cells that had been in contact with wires treated with Hamo 100; 
although  a  significant  (p  ≤  0.001)  increase  in  ThT  signal  was  observed  at  p5  this 
dropped from  passage 6  – 8 post wire removal (significance of p ≤  0.01) and was 
deemed  below  the  threshold  level  of  detection  set  at  1000  pixels  (Figure  45).  The 
representative micrographs in Figure 44 demonstrate the diffuse background staining of 
the cells that had been in contact with 22L-inoculated wires treated with Hamo 100; the 
same  diffuse  staining  was  observed  in  the  un-infected  controls.  All  samples 
demonstrated a slight drop in ThT signal between passage 1 and 2 as this was the first 
time cells were split post-wire removal (Figure 45).        
 
 
 
 
Figure 44 – Example micrographs from the wire decontamination infectivity study 
Representative micrographs of SB/ThT stained prion-associated amyloid accumulation in N2a 
cells after 7 passages following introduction of 22L-inoculated surgical stainless steel wires 
both pre (A) and post decontamination with Klenzyme (B), Hamo 100 (C) and un-infected NBH 
controls (D). Scale bars = 10µm 
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Figure 45 – Amyloid content in N2a cells after inoculation with 22L contaminated wires pre and post decontamination. 
Image analysis of SB/ThT-positive staining of prion-associated amyloid accumulation in N2a cells post inoculation with surgical stainless steel wires contaminated 
with 22L-infected brain homogenate both pre and post decontamination with Hamo 100, Klenzyme and Enzol. Error bars represent SEM (n = 50). ** = p ≤ 0.01 and 
*** = p ≤ 0.001 when compared to the uninfected controls.  
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  The wire infectivity titre study described in section 5.3.2 of this chapter was 
used to determine the log reductions in infectivity observed from the wires that had 
been treated with one of the three cleaning chemistries and analysed using the N2a/22L 
SB/ThT wire infectivity assay. Briefly, the ThT pixel counts from passages 4 – 8 for 
each initial dilution of 22L in the wire titre study (Section 5.3.2) were used as standard 
values at those given time points. A standard curve for each passage point was produced 
using the ThT pixel standards taken from passage 4 – 8. The ThT pixel counts from 
each cleaner at each passage point were then plotted against the linear regressions of the 
standards at the corresponding time point. The values determined corresponded to the 
predicted  initial  dilutions  of  22L  on  the  inoculated  wires  post  decontamination  in 
relation to the amyloid accumulation in the N2a cells at that given time point. The initial 
22L dilution value from each passage point was then pooled for each cleaner and the 
mean was  determined.  These initial  22L dilution  values were then compared to  the 
positive control values to determine the log reduction in infectivity produced by each 
cleaner.  This  procedure  was  used  so  that  the  changes  in  lag  phase  observed  in  the 
amyloid accumulation between the cells that had been in contact with wires treated 
using different treatments were taken into account and not the just the final ThT signal 
observed at the 8
th passage.  
 
The log reduction in infectivity in the N2a/22L SB/ThT experiments was then 
compared to infectivity data from 263K hamster bioassay data summarised in Table 5. 
The  log  reductions  in  infectivity  for  Hamo  100  and  Klenzyme  using  the  animal 
infectivity  bioassays  were  5.6  and  3.5,  respectively  (Table  5).  However,  the  log 
reduction for Enzol was not given but with the very low incubation period is thought to 
be similar or less than that observed with Klenzyme (Yan et al. 2004). No transmission 
to  the  hamsters  was  observed  after  Hamo  100  treatment,  however,  complete 
transmission  was  observed  after  Klenzyme  and  Enzol  treatment  (Table  5).  The  log 
reductions determined in the N2a/22L SB/ThT assay were 7.9, 2.5 and 2.5 after Hamo 
100, Klenzyme and Enzol treatment, respectively (Table 5). The working pH of each 
cleaner was also included as one argument in prion research is that the pH of the cleaner 
is crucial for optimal prion degradation and therefore reduction in infectivity.    
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Table 5 – Comparison of infectivity data and cleaner pH 
A comparison of the log reduction in prion infectivity after decontamination in Hamo 100, 
Klenzyme or Enzol, detected using animal bioassay (AB) or the SB/ThT detection after N2a 
infectivity  assay.  The  incubation  time  between  animal  inoculation  and  death  and  the 
transmission  rate  is  included.  The  cleaning  chemistries’  working  pH  is  summarised  for 
comparison to infectivity. 
1(Fichet et al. 2004, Fichet et al. 2007b), 
2 (Yan et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Hamo 100  Klenzyme  Enzol 
AB log reduction  5.6
1  3.5
1  -
 
AB Incubation (days)  >365
1   143 (±12)
1  95 (±0.4)
2 
AB Transmission (%)  0
1  100
1  100
2 
SB/ThT log reduction  7.9  2.5  2.5 
Cleaner pH  12.9  7.6  9  
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5.4 Discussion  
 
  Prion infectivity assays used to analyse prion decontamination protocols require 
the  detection  of  prion  infectivity  remaining  on  surfaces  post  decontamination. 
Therefore, the majority of infectivity assays, both animal and cell-based, use surgical 
grade stainless steel wires as models of surgical instrument surfaces (Edgeworth et al. 
2009, Edgeworth et al. 2011b, Fichet et al. 2004, Fichet et al. 2007b, Flechsig et al. 
2001, Yan et al. 2004, Zobeley et al. 1999). The wires are inoculated with the prion 
strain in question and then either incorporated into the animal brain in animal bioassays 
or into the cells in cell-based assays to induce prion propagation and fundamentally 
detection of infectivity.  
 
  The  previous  two  chapters  of  this  report  demonstrated  the  optimisation  of  a 
sensitive SB/ThT in situ detection method for the analysis of amyloid accumulation in 
N2a #58 cells as a marker of prion infectivity. However, the assay described in these 
chapters  assessed  infectivity  from  the  direct  inoculation  of  22L-infected  brain 
homogenate  into  the  cells  which  poses  difficulties  when  analysing  the  efficacy  of 
decontamination protocols, especially in relation to surgical surfaces. Therefore, this 
chapter focused on the adaptation of the N2a/22L SB/ThT assay for the detection of 
surface-bound  infectivity  by  introducing  the  infectious  material  to  the  cells  on 
inoculated wires as is demonstrated in the aforementioned published infectivity assays. 
Firstly, 5 mm lengths of surgical SS wires are used for implantation in the animal brain 
during  animal  infectivity  assays  or  incorporated  into  cells  in  cell-based  assays; 
therefore, this was kept consistent within this assay (Edgeworth et al. 2011b, Flechsig et 
al. 2001). However, the number of inoculated wires required for optimal and consistent 
amyloid propagation needed to be determined. A large number of wires (20 per sample) 
are required in current cell based infectivity assays (Edgeworth et al. 2009, Edgeworth 
et al. 2011b) which was again clearly demonstrated in the N2a cells where 20 wires per 
35 mm dish of cells were required for an optimal and consistent amyloid accumulation. 
Amyloid accumulation was observed in the cells that had been in contact with the lower 
wire numbers; however, the accumulation was very inconsistent between different fields 
of view suggesting that fewer infected cells from the fewer wires led to an inconsistent 
spread of amyloid across the tissue culture dish. Furthermore, loss of accumulation was  
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observed over the 7 passages when the initial prion dose was lowered by 2-log and only 
10 wires were used; again suggesting that fewer wires lead to fewer infected cells which 
would be further diluted with the cell splits at each passage point.  
 
  Following the determination of the number of 22L-inoculated wires required to 
induce prion infection in the N2a cells; the sensitivity of the SB/ThT assay was again 
assessed for the detection of prion infectivity from wire-bound prions. As was observed 
with the brain homogenate infectivity studies from the previous chapter, the sensitivity 
of the wire infectivity assay demonstrated amyloid accumulation in the N2a cells from 
wires that had been inoculated with a 10
-10 dilution of 22L-infected brain homogenate. 
This again matched the sensitivity of the SSBA, SCEPA assay described previously 
(Edgeworth et al. 2009, Edgeworth et al. 2011b). However, the SB/ThT assay allows 
the in situ detection of amyloid accumulation which can help to visualise the changes in 
plaque  size  and  distribution  observed  between  the  different  samples  and  infectious 
material titres. Generally it was observed that the lower the initial 22L infectious dose 
that was introduced to the N2a cells, the smaller and more distributed the plaques were 
over the latter passages. In the higher dose samples the plaques had polymerised to form 
larger plaques that were easier to detect. Furthermore, assessing amyloid accumulation 
at  every  passage  point  allows  a  picture  to  be  produced  of  the  kinetics  of  amyloid 
accumulation  over  time,  which  can  be  compared  between  different  samples.  It  was 
observed that the lower the initial prion dose was, the longer the lag phase would be 
until the detection of a significant increase in ThT-positive amyloid signal. This lag 
phase is also observed when using the ASA protocol, that again utilises ThT signal as a 
marker of prion propagation (Colby et al. 2007). Furthermore, the SB/ThT assay does 
not require PK digestion which imitations have been described previously in this report. 
 
   Prior  to  analysing  the  efficacy  of  three  commercially  available  cleaning 
chemistries in regards to remaining infectivity using the N2a/22L SB/ThT assay, the 
residual contamination on surgical grade SS wires was assessed. The SR/ThT assay was 
the chosen method as it allows the sensitive detection of residual contamination without 
the need to remove the residual biofouling from the surface under examination prior to 
analysis (Herve et al. 2009, Herve et al. 2010, Howlin et al. 2010). Furthermore, the 
SR/ThT dual stain assay was adapted to incorporate NR staining to allow the sensitive  
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detection  of  residual  lipid  contamination.  Due  to  the  association  that  lipid  rafts 
potentially aid the infectivity of the prion protein we wanted to determine if there was a 
correlation  of  residual  lipid  contamination  with  remaining  infectivity  (Reviewed  in 
Taylor et al. 2006, Wadia et al. 2008). The analysis of residual contamination of both 
263K and 22L-infected brain homogenate was compared on stainless steel wires as a 
comparison of prions strains from two different species as 263K is used in the animal 
bioassays and 22L was used in the N2a/22L SB/ThT assays.  
 
   Both of the infected brain homogenates were normalised to 1 mg/ml prior to 
wire inoculation to allow for the comparison of the attachment of biofouling to the 
wires  surfaces.  The  biggest  difference  that  was  observed  when  comparing  the 
attachment of protein, lipid  and prion-associated amyloid between the two different 
homogenates is that around 4-fold higher levels of attachment were observed with the 
22L-infected homogenates. Although higher levels of contamination were observed in 
the 22L controls, higher percentage reductions after the three cleaning treatments were 
also  observed  compared  to  the  263K-inoculated  wires.  However,  the  remaining 
contamination was still greater with the 22L-inoculated wires, which is a factor to take 
into consideration regarding variations in the infectivity of different prion strains.  
 
  The three cleaning chemistries all demonstrated significant decreases in protein, 
lipid and prion-associated amyloid contamination with both of the homogenates tested. 
The wires treated with Hamo 100 demonstrated slightly, but not significantly higher 
levels of protein when compared to the other two cleaners, with Enzol demonstrating 
the lowest levels of residual protein. Enzol treatment also demonstrated the greatest 
reduction  of  prion-associated  amyloid  remaining  when  compared  to  the  other  two 
cleaners that demonstrated similar levels with both homogenates. Analysis of residual 
lipid contamination demonstrated different trends with the two different homogenates. 
Hamo 100 treatment demonstrated the lowest levels of residual lipid from the 22L-
infected homogenate and Enzol the highest, whereas the opposite was found with the 
263K-infected homogenate. These results were similar to the efficacy of these cleaning 
chemistries  with  regards  to  residual  ME7  infected  homogenate  protein  and  prion-
associated amyloid on SS wires (Howlin et al. 2010) and tokens (Herve et al. 2010). 
However, the opposite was found when a technique utilising thermostable adenylate  
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kinase  (tAK)  activity  mixed  in  browns  soil  (Steris
©)  which  demonstrated  a  higher 
reduction  in  tAK  activity  post  alkaline  treatment  (Hamo  100)  than  compared  to 
enzymatic  treatment  (Klenzyme,  Enzol)  (Ungurs  et  al.  2010).  Of  course,  reduced 
activity could have been due to tAK enzyme inactivation rather than actual removal of 
the enzyme protein per se. Browns soil is only associated with protein contamination 
and does  not  contain any prion  related material  so  it is  unknown and hazardous to 
suggest  how  residual  protein  contamination  correlates  with  prion  attachment  or 
decontamination  efficacy.  Furthermore,  WB  analysis  of  residual  PrP
res  post  PK 
digestion demonstrated that alkaline treatment removed all PrP
res from test surfaces, 
however  no  or  low  levels  of  PrP
res  removal  has  been  previously  observed  with 
enzymatic treatments (Fichet et al. 2004, Fichet et al. 2007b, Howlin et al. 2010). 
 
  One of the most important questions in prion decontamination research is how 
does  residual  contamination  correlate  with  infectivity  and  how  does  different  prion 
strain infectivity vary? Therefore, the N2a/22L SB/ThT assay was used to compare the 
infectivity  remaining  on  22L-inoculated  wires  post  decontamination  with  the  three 
cleaning chemistries tested previously. It was clearly demonstrated that no infectivity 
was present on the wires treated with Hamo 100 with a log reduction in infectivity of 
~7.9.  This  correlates  with  the  263K  hamster  bioassays  which  also  demonstrate  no 
transmission to the animals post Hamo 100 treatment and a log reduction in infectivity 
of ~ 5.6 (Fichet et al. 2004, Fichet et al. 2007b). The higher log reduction in infectivity 
observed in the N2a/22L SB/THT assay is most likely due to the higher sensitivity of 
this assay compared to the 10
-7 limit of detection of the animal bioassays. However, 
these results  contradicted the results  obtained using the SSBA SCEPA  assay  which 
demonstrated remaining tissue culture infectivity units (TCIU) in the N2a PK1 cells 
after Hamo 100 treatment, whereas, no TCIU were found after enzymatic treatment with 
Prionzyme  (Edgeworth  et  al.  2011b).  The  contradictions  between  these  two  assays 
could be caused by the different prion strains tested (22L or RML) or by the different 
methods  used  for  detection  (detection  of  amyloid  or  PrP
res).  This  highlights  the 
importance of understanding both the prion strain analysed and the detection methods 
used. Rather than relying on one infectivity assay, the amalgamation of two cell-based 
infectivity  assays  with  different  methods  of  detection  could  be  more  beneficial  in 
understanding the remaining prion infectivity post decontamination.  
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The infectivity remaining on the SS wires post decontamination with Klenzyme 
and  Enzol  demonstrated  the  same  trend,  with  a  lag  in  amyloid  accumulation  onset 
compared  to  the  controls  using  the  N2a/22L  SB/ThT  assay.  A  log  reduction  in 
infectivity of ~2.5 was observed with both cleaners which were again comparable to the 
~3.5 demonstrated for Klenzyme treatment in the hamster 263K model and the low 
incubation time observed for Enzol treatment (Fichet et al. 2004, Yan et al. 2004). The 
lower reduction in infectivity observed in the N2a/22L SB/ThT assay can be explained 
by the higher attachment of residual 22L contamination observed post decontamination 
in the SR/ThT and NR/ThT assay when compared to the 263K-infected homogenate. 
 
  No correlation was observed when comparing residual protein, lipid and prion-
associated  amyloid  contamination  with  infectivity.  In  fact,  the  highest  protein 
contamination was observed after Hamo 100 treatment; however Hamo 100 was the 
only cleaner that demonstrated a total loss of infectivity. It could be argued that slightly 
lower levels of lipid contamination were observed after Hamo 100 treatment of the 22L 
homogenate, however, this was not the case for the 263K homogenate and the same 
results were obtained using the 263K hamster infectivity bioassays. A correlation can be 
observed when comparing PrP
res deposition with WB detection post decontamination. 
Both the enzymatic cleaners demonstrated high levels of PrP
res post treatment whereas 
the alkaline cleaner demonstrated no PrP
res (Fichet  et  al.  2004,  Fichet  et  al.  2007b, 
Howlin  et  al.  2010).  However,  as  mentioned  before  the  SSBA  SCEPA  assay 
demonstrated remaining PrP
res based infectivity post decontamination with the alkaline 
cleaner which again does not correlate with these results. The only correlation between 
cleaner properties and reduction in infectivity that was observed within our N2a/22L 
SB/ThT assay and the 263K hamster models is that higher pH of the cleaner leads to 
reduced/no infectivity. Although this is difficult to confirm with the small number of 
cleaners tested. However, this has also been observed post treatment with other cleaning 
protocols that utilise high pH; for example, NaOH (~ pH 13) (Fichet et al. 2004, Fichet 
et al. 2007b, Flechsig et al. 2001, Yan et al. 2004) and more recently gaseous hydrogen 
peroxide treatment (~ pH 11.5) (Fichet et al. 2007a). Further research is required to 
determine whether this affect is caused by the actual pH of the cleaner or the available 
alkalinity of the various cleaning chemistries.   
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  This chapter has demonstrated the sensitivity of the wire based N2a/22L SB/ThT 
infectivity assay. This assay has also been utilised to analyse the remaining infectivity 
post  decontamination  using  three  commercially  available  cleaning  chemistries. 
Furthermore, this assay correlated with currently used animal infectivity bioassays. It 
has been previously demonstrated that wires are easier to decontaminate than larger 
tokens;  thus,  questioning  whether  wires  are  a  good  model  of  surgical  instruments 
(Lipscomb et al. 2006a). The N2a/22L SB/THT assay has the potential to be adapted to 
analyse infectivity from a number of different surface types which is not possible in 
animal bioassays. The N2a/22L SB/ThT assay for wire-bound infectivity could also be 
utilised to test further decontamination protocols described previously such as gaseous 
hydrogen peroxide and DLC coated surfaces (Fichet et al. 2007a, Secker et al. 2012b). 
Furthermore, post contamination conditions such as drying times could also be analysed 
with regards to residual infectivity (Secker et al. 2011). This chapter also demonstrates 
that relying on the analysis of residual contamination post decontamination does not 
always correlate with remaining infectivity. Furthermore, the prion strain tested does 
not always correlate in regards to remaining contamination or infectivity. Therefore the 
incorporation of the SB/ThT detection methods with the propagation of different prion 
strains in different cells lines could further increase the potential of this assay especially 
in relation to the analysis of CJD infectivity which would not be possible in human 
subjects.  
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Chapter 6 
 
Improvements in NSC culture 
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6.1 Introduction 
 
This report has demonstrated the sensitivity and specificity of the N2a #58 cells 
and SB/ThT staining for the detection of prion infectivity pre and post decontamination. 
However,  limitations  in  the  detectability  of  infectivity  of  different  prion  strains  are 
observed when utilising many of the animal cell lines for prion propagation. The major 
limitation of murine neuroblastoma cells in relation to prion infectivity is that they are 
only  susceptible  to  infection  from  a  minimal  number  of  murine  prion  strains;  for 
example, 22L, Fukuoka-1, 139A and Chandler for the N2a #58 cells, as summarised in 
Chapter 1 of this report (Nishida et al. 2000, Nuvolone et al. 2009). Furthermore, N2a 
cells  primarily  require  genetic  manipulation  to  express  increased  levels  of  PrP
c  to 
increase their susceptibility to prion infection. Thus, questioning the relevance of these 
cell models in relation to disease propagation using natural PrP
c levels associated with 
animal  or  human  brains.  Neural  stem  cells  (NSC)  have  the  potential  to  be  more 
constructive as a realistic model of prion infectivity as their multi-potent nature allows 
them to differentiate into neuronal cells that naturally express higher levels of PrP
c. 
Therefore  they  offer  the  potential  for  sensitive  prion  propagation  without  artificial 
genetic manipulation. The detection of a 10
-4 22L infection has already been determined 
in these cells using WB analysis (Milhavet et al. 2006). However, the SB/ThT detection 
protocol has already demonstrated a much greater sensitivity in the N2a #58 cells that 
could be utilised with the NSC’s. Furthermore, the number of prion strains that NSC’s 
will be susceptible to is currently unknown and could potentially be more than the N2a 
cells, offering excellent scope for further development (Milhavet et al. 2006, Nuvolone 
et al. 2009).  
 
Therefore, the SB/ThT detection method, described previously, was utilised for 
the detection of amyloid accumulation from a 10
-4 22L infection within a neuron rich 
culture of differentiated NSC’s. However, it was quickly observed that a number of 
cells that die during the differentiation process accumulate around the live cells and 
readily autofluoresce hindering the SB/ThT staining process. The cell loss observed 
could also affect the validity of the NSC assay as a loss of cells could potentially cause 
decreased prion propagation in comparison to in vivo propagation.  
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Some natural cell loss is observed in NSC proliferation as there is a mixture of 
cells types produced within the progeny; not all daughter cells become stem cells, some 
of the cells become transient and some will spontaneously differentiate and not survive 
the prolonged culture conditions in the proliferation media (Reviewed in Galli et al. 
2003). Furthermore, the differentiated cells will die at the point where the proliferating 
neurospheres are passaged for expansion due to the lack of culture nutrients required for 
the maturation of the differentiated cells (Reviewed in Galli et al. 2003). Two main 
reasons  hypothesised  for  the  increased  loss  of  cells  at  the  point  of  induced 
differentiation in in vitro NSC cultures are the lack of nutrients or trophic support upon 
the removal of the mitotic factors (bFGF/EGF) or that culture conditions do not mimic 
pathological conditions (Niidome et al. 2006). DMEM/F12 media supplemented with 
N2 supplement is replaced at the point of differentiation with Neurobasal media for the 
improved culture of neuronal  cells.  However, the DMEM/F12 media  contains  more 
nutrients  than  the  Neurobasal  media  and  the  N2  supplement  contains  insulin,  apo-
transferrin, sodium selenite, progesterone and putrescine that are all removed at the 
point of differentiation. Furthermore, almost all cell culture is carried out at normal 
oxygen levels or normoxia (~21% O2); however, not all regions of the body that cells 
are derived from contain these levels of oxygen. In the brain the levels of O2 range from 
0.5 – 7%, therefore the normoxia conditions used are in fact hyperoxic for these cells 
and mild hypoxic conditions are “in situ normoxia” for brain derived cells (Reviewed in 
Ivanovic 2009, López-Barneo et al. 2001).       
 
Improvements in the in vitro culture of NSC needed to be addressed prior to 
utilising  the  cells  for  prion  propagation  assays.  Therefore,  this  chapter  studied  the 
improvements  in  NSC  culture  conditions  in  relation  to  media  supplementation  and 
atmospheric conditions. Furthermore, the percentage of neuronal and glial cells post 
differentiation in the different conditions was assessed so that the improved conditions 
did not alter the percentage of these cells types as a neuron rich culture is more ideal for 
optimal prion propagation.    
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6.2 Material and methods 
 
Details of the materials and methods for this section can all be found within 
Chapter 2 of this report. Briefly, NSC’s (2.1.2) were cultured according to the protocol 
described in section 2.2.2. The NSC’s were then subjected to a 22L (2.1.3 and 2.3.1) 
infection at the point of induced differentiation following the N2a time course assay 
described in section 2.3.2. The prion propagation was analysed with SB/ThT staining 
and EF microscopy described in sections 2.4.2 and 2.4.5, respectively. The NSC culture 
conditions were then addressed as described in section 2.5 comparing normoxia and 
hypoxia (2.5.1) environments and improved supplementation (2.5.2). Cell type analysis 
and live dead staining was carried out as described in section 2.6. All EF images were 
captured and analysed as described in sections 2.4.5. Statistical analysis was carried out 
as described in section 2.7.   
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6.3 Results 
 
6.3.1 Dead cells hinder SB/ThT analysis 
 
Firstly, during the analysis of the 10
-4 22L propagation in the NSC’s using the 
SB/ThT analysis, a large number of bright spots were observed in both the control and 
infected cell samples (Figure 46). The problem associated with the SB/ThT staining on 
the  infected  NSC’s  was  hypothesised  to  be  caused  from  the  autofluorescence  or 
accumulation of ThT fluorescence in the chromatin of dying/dead cells observed 1 – 2 
days post differentiation of the NSC’s. The dead cells show up clearly as they shrink 
and glow readily under the ThT filter block parameters. The presence of the bright spots 
observed  in  both  the  uninfected  controls  and  the  10
-4  22L-infected  NSC’s  made  it 
impossible to determine the ThT-positive amyloid staining and therefore analyse the 
22L infectivity (Figure 46).  
 
 
 
Figure 46 – NSC micrographs demonstrating dead cell fluorescence issue 
Example micrographs of the SB/ThT staining on A) the 10
-4 22L-infected NSC’s and B) the 
uninfected  NSC  controls  demonstrating  the  hindrance  of  the  bright  auto/background 
fluorescence associated with the shrunken dead cells (highlighted by the arrows) observed  in 
both samples. Scale bars = 10 µm.  
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  The bright spots of ThT fluorescence was confirmed to be caused by dead cells 
by comparing the morphology and location of dead cells stained with propidium iodide 
(PI) in comparison to live cells stained with SYTO 9 (S9, Figure 47, A and B). The PI 
stained dead cells showed the same morphology as the shrunken dead cells fluorescing 
within the ThT detection parameters. Furthermore, the location of the PI stained dead 
cells surrounding the cell bodies of the S9 stained live cells correlated with the location 
observed  with  the  bright  spots  of  ThT-associated  fluorescence  (Figure  47,  C). 
Therefore, improvements in the culture conditions were required to be able to utilise the 
NSC’s and SB/ThT detection for the analysis of prion infectivity.  
 
 
 
Figure 47 – Micrographs of SYTO 9/PI staining to confirm presence of dead cells 
Example micrographs of live/dead staining to demonstrate and confirm the location of the dead 
NSC’s observed with the SB/ThT staining. A) Propidium iodide (PI) staining of the dead cells 
highlighted by the arrows. B) SYTO 9 staining of all cells, both live and dead. C) Image A and 
B merged to show the location of the dead cells accumulating around the live cells as observed 
in the SB/ThT stained samples. Scale bars = 10 µm.   
 
6.3.2 Differentiation confluency 
 
Firstly, before addressing the culture conditions  the  confluency  at  which the 
NSC’s were differentiated was analysed to determine if the NSC’s were differentiated at 
too higher confluency and therefore cell loss was increased by the excess cells. The 
NSC’s were grown to different visual confluences ranging from 40 - 90%, by estimating 
the percentage coverage of cells in the tissue culture dishes, at which point the mitotic 
factors were removed, media changed to the NB differentiation media and the cells were  
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left to differentiate for 7 days. Over the 7 days differentiation the cells were checked on 
a daily basis with phase contrast microscopy to visualise the quality of the cells in 
culture and subsequently the amount of floating dead cells. No visual difference in the 
quantity of cell death was observed when the confluency prior to differentiation was 
altered; suggesting that the confluency levels between 40 – 90% had no relation to the 
increased number of dead cells observed in the original NSC cultures.  
 
6.3.3 Hypoxia environment for NSC culture 
 
Following the discovery that the confluency range analysed had no effect on the 
level of cell death, the adaptation of the culture conditions was potentially the way to 
improve the culture quality. Firstly, changing the levels of oxygen that the cells were 
incubated in to try and closer mimic the physiological conditions from the cells origin 
was analysed. Originally the cells were cultured at normoxia (~21% O2) which could 
have caused stress within the cells as this is not physiological conditions However, in 
this study the NSC’s were seeded into increasing oxygen concentrations starting at 1% 
O2 until a concentration was reached in which the cells were growing comfortably and 
consistently.  The  cells  were  observed  using  phase  contrast  microscopy  daily  and 
observations were recorded. The cells died within the first 24 hours post seeding when 
grown in the lower oxygen concentration (1 – 4% O2). Between 4 and 6% O2 the cells 
would stay alive for up to 2 weeks but the proliferation would be extremely slow and 
the cells  would  aggregate  in  one  group, then  within 2  – 3 days  cell  apoptosis  was 
observed,  suggesting  this  level  of  O2  was  too  low  for  cell  survival.  The  optimal 
concentration  where  the  cells  would  proliferate  to  100%  confluency  within  7  days 
consistently was at 8% O2. Therefore, for the rest of the hypoxia experiments this was 
the oxygen concentration used. The numbers of cells after 7 days culture in normoxia 
and  hypoxia  was  tested  to  determine  the  efficiency  of  proliferation  within  these 
environments (Figure 48). A significant increase in the number of cells after 7 days 
proliferation was observed in the cells grown in hypoxia (43 ± 6) compared to the cells 
grown in normoxia (24 ± 3) (Figure 48). This suggests that the cells proliferate more 
rapidly when grown in the lower oxygen environment.   
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Figure 48 – Cell counts of NSC’s cultured in a normoxia or hypoxia environment  
Cell counts of the NSC’s using SYTO 59 to label all cell nuclei from cells grown in either 
normoxia (~21% O2) or hypoxia (8% O2) for seven days post seeding. Error bars represent the 
SEM (n = 10), ** = p ≤ 0.01 when compared to normoxia.  
 
 
Nestin  immuno  labelling  of  the  undifferentiated  dividing  cells  was  used  to 
visualise the percentage of neuronal progenitor cells and subsequently highlight which 
environment is associated with more spontaneous differentiation within the proliferating 
cells. Image analysis was used to quantify the percentage of nestin-positive cells in all 
of the samples as a comparison (Figure 49). The percentage of nestin-expressing cells 
was increased, but not significantly, in the cells grown in 8% O2 (88% ± 6.9) compared 
to the cells grown in normoxia (80% ± 5.9). The representative micrographs in Figure 
49 also demonstrate the similar levels of nestin positive cells, but also the increased cell 
numbers observed when cultured in the 8% O2 environment compared to the normoxia 
cultured cells. 
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Figure 49 – Comparison of the percentage of nestin-positive cells grown in the 
different atmospheric conditions 
The percentage of nestin-positive cells present after 7 days culture in different atmospheric 
conditions.  The  representative  micrographs  demonstrate  example  images  of  nestin  (green) 
immuno labelled cells and SYTO 59 (red) nuclei staining of NSC’s cultured in A) normoxia and 
B) 8% O2 for 7 days post seeding. Error bars represent SEM (n = 10). Scale bars = 10 µm. 
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6.3.4 Varying culture supplements post differentiation in the different                                 
atmospheric conditions      
 
Another  hypothesis  for  the  occurring  cell  loss  was  the  media  change  and 
removal of the mitotic factors at the point of differentiation, thus removing a lot of the 
nutrients that the cells were receiving during the proliferation stages. This would cause 
the cells to become shocked and ultimately die. Therefore, alongside comparing the 
normoxia and hypoxia culture environments, one of two supplements (0.1% bFGF and 
0.1% FBS) was introduced to the cells for two days post differentiation to wean the 
cells  of the original nutrients. The cells  were incubated for 7 days  before cell type 
analysis was performed. During this period phase contrast images were taken every 2 
days  to  compare  the  differences  in  cell  morphology.  The  micrographs  at  5  days 
demonstrated  clear  differences  in  the  cell  morphology  between  the  three  different 
environments  (Figure  50).  The  bFGF  supplemented  cells  demonstrating  the  most 
differences showing a higher number of cells and vacuoles associated with cell death; 
however it is impossible to comment on the levels of differentiation without cell type 
immuno-labelling (Figure 50). There did not appear to be any difference in appearance 
of the cells when comparing the unsupplemented media with FBS.  
 
 
Figure 50 – Phase contrast images of differentiated NSC’s culture in different 
conditions  
Example inverted phase contrast micrographs of live NSC’s five days post differentiation with 
no supplement (None) or supplemented with 0.1% basic fibroblast growth factor (bFGF) or 
0.1% fetal bovine serum (FBS) for 2 days post differentiation. Scale bars = 10 µm.  
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6.3.4.1 Cell type analysis post differentiation in the different culture 
conditions 
 
Phase contrast microscopy of the live cells during differentiation demonstrated 
variations in the cell morphology between the different culture conditions. Therefore, 
immuno labelling was utilised to determine the percentage of progenitor cells (Nestin-
positive), astrocytes (GFAP-positive) and neurones (β-III-Tubulin-positive) present in 
the different supplemented culture conditions and environments.  
 
After  altering  the  culture  condition,  the  levels  of  undifferentiated  progenitor 
cells remaining post differentiation was analysed. This can be used to determine the 
number of dividing cells remaining post induced differentiation; thus, demonstrating the 
differences in the levels of differentiation between the different culture conditions. No 
significant increase in the percentage of nestin-positive cells post differentiation was 
observed between the cells cultured within the different culture conditions, all ranging 
between 20 – 30% (Figure 51). However, a slight increase, but not significant, in nestin-
positive cells was observed in the cells grown in the normoxia (24 – 30%) atmosphere 
when compared to the hypoxia (20 – 22%) (Figure 51). The representative micrographs 
demonstrate  the  similar  faint  nestin-positive  staining  observed  in  the  conditions 
containing the highest and lowest percentage of nestin-positive cells (Figure 51).     
 
GFAP  immuno-labelling  was  used  to  analyse  and  compare  the  levels  of 
astrocytic cells post differentiation in the different supplemented culture conditions and 
atmospheric environments. A significant increase in the percentage of GFAP-expressing 
cells  was  observed  in  the  cells  grown  with  FBS  supplementation  in  normoxia  and 
hypoxia (44% ± 5 and 44% ± 3, respectively), no supplementation in hypoxia (54% ± 4) 
and bFGF supplementation in hypoxia (67% ± 7) when compared to the cells grown in 
normoxia with bFGF supplementation (Figure 52). The highest percentage of GFAP-
expressing cells was observed in the cultures grown in hypoxia with the addition of 
bFGF post differentiation. This was significantly higher than the cells grown with no 
supplementation in the normoxia environment and the cells supplemented with FBS in 
the normoxia and hypoxia environments. The lowest percentage of GFAP-expressing  
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cells  was  observed  in  the  cells  grown  in  the  normoxia  environment  with  again  the 
addition of bFGF (21% ± 5) (Figure 52). The representative micrographs in Figure 52 
demonstrate the clear difference of GFAP-positive cells in the conditions containing the 
lowest and highest percentage of astrocytic cells.     
 
Class III β-Tubulin immuno-labelling was utilised to analyse and compare the 
levels of neuronal cells cultured within the different oxygen conditions and the different 
supplements post differentiation. Similar percentages of neurons were observed in the 
cultures  grown  in  the  hypoxic  environment  with  no  supplements  (74%  ±  4), 
supplemented with bFGF (68% ± 5) or  supplemented with FBS (82% ± 3) (Figure 53). 
A significant decrease in the percentage of β-III-Tubulin-expressing cells was observed 
in the cultures grown in normoxia with no supplements post differentiation (60% ± 4) or 
supplemented  with  bFGF  (45%  ±  6)  (Figure  53).  The  lowest  percentage  of  β-III-
Tubulin-expressing cells was observed in the normoxia environment supplemented with 
bFGF post differentiation. The highest percentage of β-III-Tubulin-expressing cells was 
observed in the cultures grown in hypoxia and normoxia supplemented with FBS (79% 
± 5 and 82% ± 3, respectively) (Figure 53). Generally the level of β-III-Tubulin staining 
was lower in the cells grown in normoxia apart from the cells supplemented with FBS 
which had close to the same expression as the hypoxia cultured cells (Figure 53). The 
representative  micrographs  demonstrate  the  different  percentages  of  neuronal  cells 
present in the conditions that cultured the lowest and highest percentages of neuronal 
cells.  
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Figure 51 – Comparison of the percentage of nestin-positive cells cultured in the 
different culture conditions 
The percentage of nestin-positive cells after 7 days differentiation with different supplements 
and cultured within different atmospheric conditions (Normoxia (Dark grey bars) and Hypoxia 
(Light  grey  bars)).  The  representative  micrographs  demonstrate  example  images  of  nestin 
(green) immuno-labelled cells and SYTO 59 (red) nuclei staining of NSC’s supplemented with; 
A) 0.1% fetal bovine serum (FBS) and cultured in a hypoxia normoxia and B) 0.1% basic 
fibroblast  growth  factor  (bFGF)  and  cultured  in  normoxia  post  differentiation.  Error  bars 
represent SEM (n = 10). Scale bars = 10 µm. 
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Figure 52 - Comparison of the percentage of GFAP-positive cells cultured in the 
different culture conditions 
The percentage of GFAP-positive cells after 7 days differentiation with different supplements 
and cultured within different atmospheric conditions (Normoxia (Dark grey bars) and Hypoxia 
(Light  grey  bars)).  The  representative  micrographs  demonstrate  example  images  of  GFAP 
(green) immuno-labelled cells and SYTO 59 (red) nuclei staining of NSC’s supplemented with; 
A) 0.1% basic fibroblast growth factor (bFGF) and cultured in normoxia and B) 0.1% basic 
fibroblast  growth  factor  (bFGF)  and  cultured  in  hypoxia  post  differentiation.  Error  bars 
represent SEM (n = 10). * = p ≤ 0.05, *** = p ≤ 0.001 when compared to Normoxia/bFGF and 
† = p ≤ 0.05 when compared to Hypoxia/bFGF. Scale bars = 10 µm.  
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Figure 53 – Comparison of the percentage of β-(III) Tubulin-positive cells cultured 
in the different culture conditions 
The  percentage  of  β-(III)  Tubulin-positive  cells  after  7  days  differentiation  with  different 
supplements and cultured within different atmospheric conditions (Normoxia (Dark grey bars) 
and Hypoxia (Light grey bars)). The representative micrographs demonstrate example images of 
β-(III) Tubulin (green) immuno-labelled cells and SYTO 59 (red) nuclei staining of NSC’s 
supplemented with; A) 0.1% basic fibroblast growth factor (bFGF) and cultured in normoxia 
and B) 0.1% fetal bovine serum (FBS) and cultured in hypoxia post differentiation. Error bars 
represent SEM (n = 10). * = p ≤ 0.05 when compared to Normoxia/bFGF and 
+ = p ≤ 0.05 when 
compared to Normoxia/None. Scale bars = 10 µm. 
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6.3.4.2 Comparison of the ratio of live: dead cells between the different 
culture conditions 
 
Finally, the cell loss observed in the cultures kept under all of the conditions was 
quantified by labelling all cells with SYTO 9 and cells with compromised membranes 
(i.e.  dead  cells)  with  propidium  iodide.  The  ratio  of  live  to  dead  cells  was  then 
compared between cells grown within the different conditions and supplementation. A 
significant increase in the ratio of live to dead cells was observed in the cells cultured in 
hypoxia with no supplementation (3.5 ± 0.4) and the cells cultured in normoxia and 
hypoxia with the FBS supplementation (3.9 ± 0.5 and 4.1 ± 0.4, respectively) when 
compared to the cells cultured in the other three conditions (Figure 54). The lowest 
ratios  of live to  dead cells  was  observed in  the cells  cultured at  normoxia with  no 
supplementation and the cells cultured in normoxia and hypoxia supplemented with 
bFGF (1.8 ± 0.2, 1.4 ±  0.1 and 1.7 ± 0.1, respectively) (Figure 54). The highest ratio of 
live  to  dead  cells  was  observed  in  the  cells  cultured  in  normoxia  or  hypoxia 
supplemented with FBS post differentiation. Twice as many live cells to dead cells were 
observed  in  the  FBS  supplemented  cells  when  compared  to  the  original  culture 
conditions of normoxia cultured cells with no supplementation post differentiation. The 
representative micrographs demonstrate the live/dead staining in the hypoxia cultured 
cells  and  the  three  supplemented  conditions.  From  these  it  is  clear  to  see  that  the 
number of red (dead) cells is greatly increased in the bFGF supplemented cells. The 
other clear observation from these micrographs is the increase in the number of live 
(green) cells present in the FBS supplemented cells, so not only is there a higher ratio of 
live to dead cells there are also a larger number of live cells present post differentiation 
compared to the other conditions (Figure 54).   
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Figure 54 – Comparison of the ratio of live: dead cells when cultured in the 
different culture conditions 
The percentage ratio of live: dead NSC’s after 7 days differentiation with different supplements 
and cultured within different atmospheric conditions (Normoxia (Dark grey bars) and Hypoxia 
(Light  grey  bars)).  The  representative  micrographs  demonstrate  images  of  SYTO  9  (green) 
labelling  all  cells  and  PI  (red)  nuclei  staining  of  dead  NSC’s  supplemented  with;  A)  no 
supplements, B) 0.1% basic fibroblast growth factor (bFGF) and C) 0.1% fetal bovine serum 
(FBS) and cultured in hypoxia post differentiation. Error bars represent SEM (n = 10). * = p ≤ 
0.05 when compared to Normoxia/bFGF, 
+ = p ≤ 0.05 when compared to Normoxia/None and † 
= p ≤ 0.05 when compared to Hypoxia/bFGF. Scale bars = 50 µm. 
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6.4 Discussion  
 
The importance of cell-based assays for the detection of prion infectivity has 
been widely  discussed  within this  report. The  main advantage of neural  stem  cells, 
against other discussed cells, for the propagation of PrP
Sc is their multi-potent ability. 
This allows them to differentiate, with the addition of different supplements in vitro, 
into three important cell types of the CNS; neurons, astrocytes and oligodendrocytes 
(Morrison 2001). Neuronal cells are the most susceptible cells in the body to infection 
from PrP
Sc because they naturally contain higher levels of PrP
c. Therefore they would 
be  an  ideal  model  for  prion  infectivity  as  they  require  no  genetic  manipulation  to 
increase PrP
c expression and are therefore, a closer model of prion infections in vivo 
than the modified neuroblastoma assays presented in the previous chapters. The other 
potential advantage of the NSC assays is that the different prion strains that the cells are 
susceptible to infection from are unknown and could potentially be more or different to 
the strains observed in the mouse N2a assays.  
 
The  use  of  NSC’s  for  the  propagation  of  the  infectious  prion  alongside  the 
sensitive  SB/ThT  detection  method  demonstrated  in  the  N2a  cells  could  produce  a 
highly sensitive and diverse prion infectivity assay. This was first tested with a 10
-4 22l 
infection in the NSC’s. However, an issue arose when the NSC’s were differentiated in 
that a considerable amount  of cell death was  observed.  Furthermore, the  dead cells 
readily autofluoresce under the same spectral range as ThT, thus hindering the detection 
of  the  amyloid  accumulation.  This  was  clearly  confirmed  with  live/dead  staining, 
highlighting the accumulation of the dead cells around the live cell bodies. Therefore, it 
was determined that the NSC culture conditions needed to be carefully revised and 
improved, so firstly, the SB/ThT staining would not be hindered and secondly, the level 
of cell death did not invalidate the assay.  
 
The confluency that the cells were differentiated at was first believed to be the 
problem so the level of cell confluency was altered to see if this altered the amount of 
cell death previously observed. However, changing the confluency showed no visual 
change in the quality of the cultured cells. The next hypothesis was that the atmospheric  
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conditions that the NSC’s were cultured in were not optimal for cell growth. Standard 
cell culture conditions use 37
oC, 5% CO2 and 20% O2. Whilst this temperature mimics 
the body temperature and the CO2 is the same as arteriole CO2, the levels of O2 in 
different regions of the body are not always at atmospheric levels (~21%) (Studer et al. 
2000). It has been documented that the partial pressures of O2 in the brain range for 10 – 
40 mm Hg PO2 which translates to between 3 – 7% O2 (Masamoto et al. 2009, Wion et 
al. 2009). Levels of O2 in the cerebral cortex of rat brain of around 27.6 mm Hg or 2.5 – 
5.3%  O2  have  also  been  documented  (Masamoto  and  Tanishita  2009,  Studer  et  al. 
2000).  This  information  suggests that  cortical NSC culture should be carried out  at 
lower  oxygen  levels  than  the  standard  cell  culture  conditions  to  closer  mimic  the 
physiological conditions that the cells were derived from (Reviewed in Ivanovic 2009). 
Therefore, the NSC’s were cultured in increasing oxygen levels from 1-8% to determine 
the lowest oxygen concentration that gave optimal cell proliferation. The optimal cell 
growth was observed at 8% O2 which is higher than previously documented studies that 
use 5% but is closer to physiological conditions than atmospheric oxygen (Clarke et al. 
2009, Studer et al. 2000). The efficiency of cell proliferation over 7 days increased by 
almost double in the cells cultured in the hypoxia environment when compared to the 
cells cultured at normoxia, which correlated with previous studies (Clarke and van der 
Kooy 2009, Studer et al. 2000). The percentage of nestin-positive cells was very similar 
in both hypoxia and normoxia prior to differentiation suggesting no obvious difference 
in  the  percentage  of  progenitor  cells  and  therefore  the  level  of  spontaneous 
differentiation observed between the two culture conditions. These results confirmed 
that the hypoxia environment improved the NSC culture prior to differentiation.  
 
Following these observations the two atmospheric conditions were compared for 
the quality of NSC differentiation with the added addition of one of two supplements 
(bFGF  or  FBS)  for  two  days  post  differentiation.  Firstly  the  percentage  of  nestin-
positive cells remaining post differentiation was analysed to determine the number of 
progenitor cells remaining. A similar percentage of undifferentiated cells were observed 
within  all  of  the  culture  conditions  with  slightly  lower  percentages  observe  in  the 
hypoxia cultured cells when compared to the normoxia grown cells. This suggested that 
the hypoxia environment also supported slightly higher levels of differentiation within 
the cultured cells. The percentage of GFAP-expressing cells was used to determine the 
number of astrocytes in all of the conditions seven days post differentiation. The highest  
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percentage  of  astrocytic  cells  was  observed  in  the  cells  cultured  in  the  hypoxic 
environment  with  no  or  bFGF  supplementation.  This  suggests  that  the  hypoxia 
environment improved the levels of differentiation towards the lineage of astrocytic 
cells compared to the original culture conditions. The higher percentage of astrocytic 
cells could also be a marker of stress, which may be observed in the hypoxia cultured 
bFGF  supplemented  cells  as  this  condition  gave  rise  to  an  excess  of  cells  post 
differentiation. Lastly the percentage of β-III-Tubulin-expressing cells was used as a 
marker for the percentage of neuronal cells in all of the conditions. The percentage of 
neurons in all of the culture conditions was observed to be higher than the percentage of 
astrocytes. This was hypothesised as the supplementation of the NB media with B27 
factor  is  a  common  method  utilised  to  fabricate  culture  conditions  that  favour  the 
differentiation of the NSC progenitor cells into neuronal cells (Milhavet et al. 2006). 
Furthermore, B27 supplements also contains molecules which reduce oxidative stress 
and therefore help to promote cell survival (Hall et al. 2008). An increased percentage 
of neuronal cells were observed in the hypoxia cultured cells which is most likely to be 
caused by the lower levels of reactive oxygen species observed in the mild hypoxic 
environments (Fan et al. 2008, Ivanovic 2009, Niidome et al. 2006). In addition, the 
FBS supplementation increased the percentage of neurons observed in the normoxia 
environment. This could be caused by numerous growth factors that are observed in 
FBS  (Even et al. 2006), but without Mass spectrometry analysis of the composition of 
the FBS used in our experiment it would be difficult to comment directly. Potentially, 
there could be a key role for the presence of insulin-like growth factor-1 (IGF-1) found 
in FBS as it has a similar structure to insulin which is commonly used to improve cell 
viability  within  culture  (Singh  et  al.  1997).  Furthermore,  the  highest  percentage  of 
neuronal cells was observed in the cultures that contained over 40% astrocytic cells. 
Astrocytic  cells  have  demonstrated  a  neuroprotective  role  and  will  protect  neurons 
especially in vitro culture which is most likely the reason for this observed correlation 
(Brown 1999, Chen et al. 2001, Liu et al. 2012). 
 
More importantly was the comparison of the ratios of live to dead cells between 
the different culture conditions as it was the dead cells that were hindering the SB/ThT 
staining. The highest ratio of live to dead cells was observed in the hypoxia conditions 
with no supplement and FBS supplementation and the normoxia environment with FBS 
supplementation. This suggests again that the lower levels of reactive oxygen species  
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(ROS) observed in mild hypoxia environments helps to decrease cell death and that the 
increased growth factors introduced from the FBS is also improving the viability of the 
cells. The lowest ratios of live to dead cells was observed in the cells supplemented with 
bFGF and cultured in both normoxia and hypoxia environments. This is likely to be 
caused  by  the  introduction  of  bFGF  post  differentiation  initially  inhibiting 
differentiation  and  increasing  cell  confluency.  When  the  supplement  was  removed, 
increased cell death and less differentiation was observed suggesting this supplement 
does not enhance the culture conditions post differentiation. The lack of trophic support 
or nutrients in in vitro culture of neuronal progenitor cells was also observed with a 
mouse multi-potent cell line MEB5 which are similar to mouse NSC’s (Niidome et al. 
2006). Furthermore, in this study they also demonstrated that molecules that block the 
levels  of  ROS  present  in  the  cell  culture  environment  protected  the  cells  and 
subsequently lowered the levels of cell death (Niidome et al. 2006). This is also true for 
the hypoxia environments used within our culture systems. The lower levels of cell 
death associated with the cells grown in the lower oxygen environment in our work 
could be associated with the documented lower levels of ROS present in mild hypoxic 
environments, thus correlating with the results obtained using molecules that block ROS 
production (Fan et al. 2008, Ivanovic 2009, Niidome et al. 2006). Therefore a mixture 
of the wrong O2 concentrations and the lack of nutrients for differentiated cell survival 
were the contributing factors to the cell death primarily observed.  
 
This  study  highlights  the  importance  of  understanding  the  physiological 
conditions of different cell types so that the optimal culture conditions can be used. 
Growing the cells in hypoxia has improved the efficiency of NSC proliferation and cell 
viability  and  improved  the  number  of  neurons  post  differentiation,  thus  potentially 
improving the infectivity potential of the NSC cultures. The supplementation of the 
cells with FBS improved the culture conditions with regards to all of the cell markers 
analysed and the ratio of live to dead cells in both normoxia environments. However, a 
mixture of hypoxic conditions to improve proliferation of the undifferentiated NSC’s 
and  FBS  supplementation  post  differentiation  to  improve  differentiation  and  cell 
viability is the optimal conditions for the NSC culture. These conditions can then be 
used  in  future  work  to  analyse  SB/ThT  analysis  of  prion  propagation  without  the 
hindrance of the original, sub-optimal culture conditions.   
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Final discussion and future work 
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7.1 Discussion and future work  
 
The aim of this project was to design and develop a cell-based infectivity assay 
system that incorporated sensitive in situ staining for the microscopic detection of prion 
infectivity that has the potential to be adapted to analyse a wide range of prion stains. 
Furthermore, this assay was designed to focus on the assessment of surgical instrument 
decontamination  procedures  in  relation  to  remaining  prion  infectivity.  This  in  situ 
staining procedure aimed to be transferable between cell lines that are susceptible to 
prion infection from prion strains of different species and ultimately be able to detect 
infectivity from CJD contaminated instruments and biological samples.   
 
The  first  important  question  to  address  when  developing  a  novel  cell  based 
infectivity assay is the cell line used. Cell lines vary in their susceptibility to infection 
from different prion strains due to the effect of the “species barrier” and their ability to 
establish a consistent infection that is not lost during cell division and passage steps. 
The variations in cell line susceptibility to different prion strains has been discussed 
previously  in  this  report  (Summarised  in  Nuvolone  et  al.  2009).  Furthermore,  it  is 
important  to  establish  a  balance  between  a  steady  consistent  propagation  and 
uncompromised cell viability. This is because an accumulation of PrP
Sc that is too rapid 
will  cause  cell  death  and  therefore  loss  of  infected  cells  and  subsequently  loss  of 
detectable material. Consequently, it is important to use a cell line that will amplify 
PrP
Sc to a level in which the prion propagation is at a steady state but not engulfing the 
cells (Ghaemmaghami et al. 2007, Mahal et al. 2007).  
 
Neuroblastoma cell subclone N2a #58 has already been established as a cell line 
that  is  susceptible  to  prion  infection  from  three  murine  scrapie  prion  strains;  22L, 
Fukuoka-1 and 139A (also known as chandler of RML) (Mange et al. 2002, Nishida et 
al. 2000). Therefore, N2a #58 cells were initially utilised to develop and determine the 
sensitivity of this novel staining procedure in relation to prion decontamination. Mouse 
adapted scrapie prion isolate 22L was the prion strain used to infect the cells as it has 
been established to reliably infect the N2a #58 cells at higher doses (Mange et al. 2002, 
Nishida et  al. 2000). Thioflavin T was chosen as the fluorophore to identify prion- 
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associated amyloid as a marker of prion propagation and subsequently infectivity within 
the N2a cells. Thioflavin T has been established in a number of techniques to detect 
prion associated-amyloid upon SS surfaces and surgical instruments and has previously 
shown 2-log greater sensitivity when compared to WB detection of PK resistant PrP
Sc 
(Herve et al. 2009, Herve et  al. 2010, Howlin et al. 2010, Lipscomb et al. 2007a). 
Furthermore, ThT is also utilised in the amyloid seeding assay (ASA) to detect the 
amplification of PrP
Sc in solution via increased ThT fluorescence using a fluorescent 
plate reader (Colby et al. 2007). Furthermore, the ASA was incorporated into the RT-
QUIC assays to combine the improved quaking conversion of PrP
Sc with the sensitive 
amyloid based detection of prion amplification  (Atarashi et al. 2008, Atarashi et al. 
2011a, Atarashi et al. 2011b). The majority of current cell-based prion infectivity assays 
rely on the immuno-detection of PK digested PrP
Sc known as PrP
res; however, more 
recently it has been established that a high percentage (~80% of disease associated prion 
material) is sensitive to PK digestion, denoted sPrP
Sc (D'Castro et al. 2010, Gambetti et 
al.  2008,  Kuczius  and  Groschup  1999,  Pastrana  et  al.  2006,  Thackray  et  al.  2007). 
Therefore, there is considerable doubt as to whether these assays are able to detect the 
true  remaining  infectivity  of  this  infectious  agent  or  whether  the  disease  associated 
material  is  lost during  digestion. As a result,  ThT was  chosen in  this  novel  in  situ 
staining procedure to avoid the loss of disease-associated material associated with PK 
digestion and provide an alternative method of detection.        
 
Chapter  3  of  this  report  introduced  the  in  situ  ThT  detection  of  amyloid 
accumulation in the N2a cells from initial 22L doses ranging from a 10
-4 – 10
-9 dilution 
of 10% 22L-infected brain homogenates propagated over 14 days post inoculation with 
no cell passaging. Initial experiments observed high autofluorescence and non-specific 
binding associated with ThT in the assay. One step to partially address this was a final 
acetic acid wash within the protocol as it has been previously discussed that increased 
pH  reduces  non-specific  binding  of  ThT  to  nucleic  acids  (Khurana  et  al.  2005). 
Furthermore,  initial  assays  also  noted  a  significant  amount  of  autofluorescence 
associated with tissue lipids. Work aimed to address this issue and, subsequently, Sudan 
black was used to quench lipid-associated autofluorescence. The incorporation of Sudan 
black to the ThT staining protocol increased the sensitivity of amyloid accumulation 
detection from a 10
-6 22L infection with the ThT alone, to a 10
-9 22L infection with the 
SB/ThT staining. This also demonstrated a >3 log increase in sensitivity when directly  
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compared to the WB detection of PrP
Sc content of the 22L-infected N2a lysates form the 
35  mm  cell  culture  dishes.  However,  variability  in  the  propagation  and  amyloid 
accumulation was observed between different experiments especially within the lower 
dose samples. This was thought to be associated with the 100% confluency of the N2a 
cells observed between 8-10 days post infection. Therefore, PrP
Sc propagation between 
8-14  days  was  inconsistent  and  subsequently  the  cell  loss  due  to  contact  inhibition 
observed at 14 days post infection made the results un-comparable. 
 
The majority of cell assays for the detection of prion infectivity incorporate cell 
splits or passages to improve the sensitivity of the assay by essentially allowing the cells 
increased time in contact with the infectious material. This subsequently increases the 
chance for prolonged PrP conversion and ultimately increased infection (Archer et al. 
2004, Edgeworth et al. 2009, Edgeworth et al. 2011b, Klohn et al. 2003, You et al. 
2010). Furthermore, the increased turnover of cells producing PrP
c that will potentially 
come into contact with infectious material will closer mimic the natural turnover of PrP
c 
within an in vivo environment associated with animal infectivity assays. Cell passages 
are  required  for  cell  lines,  such  as  the  N2a  cells,  that  do  not  survive  well  at  high 
confluency.  However,  RK13  epithelial  cells  (genetically  modified  to  encode  prion 
proteins from different species) have demonstrated the sensitive detection of a number 
of prion strains from different hosts within two experimental cycles (Arellano-Anaya et 
al. 2011). The RK13 cells survive well at high confluency for >3 weeks with weekly 
media changes, allowing an increased time for prion propagation without the need for 
cell splits (Arellano-Anaya et al. 2011). However, these cells also need to be genetically 
modified to improve prion susceptibility and rely on WB detection of PrP
res.  
 
When introducing cell passages into prion infectivity assays it is important to 
split the cells at the optimal point to allow consistent propagation without the loss of 
cell susceptibility over time and ultimately a decrease in PrP
Sc (Ghaemmaghami et al. 
2007, Mahal et al. 2007). Therefore, in Chapter 4, the time-course infections in the N2a 
cells were adapted to incorporate cell passages to improve sensitivity and decrease the 
variability observed in the time-course experiments. Firstly, the optimal day for cell 
passage to compromise between adequate prion propagation for a steady accumulation 
and cell culture consistency was found to be every ten days post initial infection. The  
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sensitivity of the passage-based N2a/22L infectivity assays with SB/ThT assessment 
was demonstrated to detect a final 10
-10 dilution of original 10% 22L-infected brain 
homogenate. Furthermore, the reliability of this assay was improved as the variability 
associated with the time-course experiments was decreased. However, some variability 
observed in the samples is important as it highlights the variations in the uniformity of 
amyloid distribution between the different samples, taken into account by the capture of 
random fields of view. The sensitivity of this assay was greater than the sensitivity of a 
number of the cell-based assays relying on WB based detection, ranging from 10
-4 – 10
-7 
dilutions  of  the  original  infected  brain  homogenates  (Archer  et  al.  2004,  Arellano-
Anaya et al. 2011, You et al. 2010). This assay also demonstrated ~3 log increase in 
sensitivity when compared to the animal infectivity bioassays (Fichet et al. 2004, Fichet 
et al. 2007b, Yan et al. 2004). Moreover, the passage assays matched the sensitivity of 
the  SCEPA  SSBA  used  for  the  detection  of  prion  infectivity  from  prion-inoculated 
wires (Edgeworth et al. 2009, Edgeworth et al. 2011b). 
 
The first two research chapters of this report introduced the sensitive SB/ThT 
staining of amyloid accumulation within N2a #58 cells inoculated with 22L=infected 
brain homogenate. An adaptation in the way infectious material is introduced to the 
cells has to be made, as it is difficult to assess decontamination protocols directly on 
infectious  brain  homogenate.  Furthermore,  reduction  of  prion  infectivity  has  to  be 
assessed in relation to the decontamination of surgical instruments via the analysis of 
prion attachment to model surgical surfaces. Therefore both animal bioassays and cell 
based infectivity assays which are used for the assessment of decontamination protocols 
introduce the infectious material from inoculated surgical grade SS wires both pre and 
post decontamination  (Edgeworth  et  al.  2009, Edgeworth  et  al.  2011b,  Fichet  et  al. 
2007a,  Fichet  et  al.  2007b,  Flechsig  et  al.  2001,  Lawson  2008,  Yan  et  al.  2004). 
Therefore, Chapter 5 concentrated on the adaptation of the N2a/22L SB/ThT assay by 
using inoculated wires to assess decontamination protocols.  
 
Importantly, and crucially for inter-assay comparisons, the length and diameter 
of the wires (5mm length, 0.16mm diameter) used was comparable to the size of wire 
used  within  the  majority  of  cell  and  animal-based  assays  (Edgeworth  et  al.  2009, 
Edgeworth et al. 2011b, Fichet et al. 2004, Fichet et al. 2007b, Flechsig et al. 2001).  
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The numbers of inoculated wires introduced to each 35 mm dish was assessed to give a 
consistent  and  optimal  propagation  detected  with  the  SB/ThT  staining  and  was 
determined to be 20 wires per 35mm dish. Importantly, this is also the number of wires 
used in other assays (Edgeworth et al. 2009, Edgeworth et al. 2011b, Flechsig et al. 
2001).  The  sensitivity  of  the  assay  for  the  detection  of  wire-bound  22L  infectivity 
matched the sensitivity of the passage assays, detecting as low as a 10
-10 dilution of 
22L-infected  homogenate.  Consequently,  this  data  indicates  again  that  this  assay  is 
more sensitive than animal bioassays and is comparable in sensitivity with the SSBA 
and SCEPA detection methods (Edgeworth et al. 2009, Edgeworth et al. 2011b, Fichet 
et al. 2004, Yan et al. 2004). 
  
The  N2a/22L  SB/ThT  assay  was  then  utilised  to  assess  the  decontamination 
efficacy  of  three  commercially  available  cleaning  chemistries  in  relation  to  their 
reduction of infectivity. Amyloid accumulation was observed in the cells that had been 
in contact with 22L-inoculated wires that had been decontaminated with Klenzyme and 
Enzol; however, there was a delay in infection onset of three weekly passages post-wire 
introduction. The cells that had been in contact with 22L-inoculated wires that had been 
treated  with  Hamo  100  demonstrated  no  amyloid  accumulation  and  suggested 
infectivity  levels  below  the  detection  range  of  this  assay.  The  log  reductions  in 
infectivity  were  determined  for  these  three  cleaning  chemistries  and  interestingly 
correlated well with those observed in the animal bioassays (Fichet et al. 2004, Fichet et 
al. 2007b, Yan et al. 2004). The increased log reduction observed for Hamo 100 could 
be explained by the increased sensitivity of the SB/ThT assay. However, the complete 
loss of infectivity observed post-Hamo 100 treatment was not observed in the SSBA 
with  SCEPA  (Edgeworth  et  al.  2011b).  This  observation  could  be  explained  by 
variations in the prion strain used or the differences in markers used in the detection 
protocols (Edgeworth et al. 2011b). This highlights the importance of understanding the 
scientific credentials of the prion strain analysed and the limitations of the detection 
method used.  
 
To partially address this issue the SR/ThT assay for the sensitive detection of 
protein  and  prion-associated  amyloid  pre-  and  post-decontamination  was  utilised  to 
compare the attachment of 22L and 263K (used in the animal bioassays) infected brain  
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homogenates to the surgical SS wires. Furthermore, the SR/ThT staining was adapted to 
produce the NR/ThT staining for the detection of residual lipid contamination as an 
association between prion infectivity and lipid content has been previously hypothesised 
(Reviewed in Gale 2007). The most important observation from these experiments was 
the >4-fold increase in protein, prion-associated amyloid and lipid attachment to the 
stainless steel wires inoculated with the 22L-infected brain homogenate when compared 
to  the  263K-inoculated  wires.  The  brain  homogenates  were  normalised  prior  to 
inoculating the wires so that both strain inoculants were at the same concentration. This 
observation was either a result of the different prion strains or could be caused by the 
different nature of the proteins present in hamster brain (263K) and mouse brain (22L).  
 
Although a greater percentage of removal using all of the cleaning chemistries 
was associated with the 22L-inoculated wires, the increased initial bio-burden meant a 
higher  concentration  of  residual  contamination  still  remained  on  the  22L-inoculated 
wires compared to the 263K-innoculated wires. This could explain the slightly lower 
log  reductions  in  infectivity  demonstrated  by  Klenzyme  and  Enzol  treatment  when 
analysed using the N2a/22L SB/ThT analysis compared to the 263K hamster bioassays. 
The  lowest  concentrations  of  protein  and  prion-associated  amyloid  contamination 
observed  on  both  the  263K  and  22L-inoculated  wires  was  observed  post-Enzol 
treatment,  followed  closely  by  the  Klenzyme  treatment  and  the  highest  remaining 
contamination was observed after the Hamo 100 treatment. This was the same trend 
observed with the residual lipid contamination on the 263K-inoculated wires; however, 
the opposite was observed for the residual lipid contamination on the 22L-inoculated 
wires. No correlation was observed with the remaining contamination on the wires and 
the log reduction in infectivity associated with the animal bioassays or the N2a/22L 
SB/ThT assay. This could be explained by the nature of the cleaners. The most efficient 
cleaners (Klenzyme and Enzol) are enzymatic chemistries and could be removing and 
breaking up the large plaques to form smaller aggregates but are ineffective at breaking 
up  the  aggregates  to  smaller  single  prion  molecules.  In  agreement  with  this  is  that 
several studies have already documented that the intermediate small aggregates of about 
14 – 28 prion molecules are the most infectious units (Gale 2007, Silveira et al. 2005). 
Conversely, Hamo 100 alkaline treatment may not be as efficient at removing the gross 
contamination  but  due  to  its  alkaline  nature  may  be  more  likely  to  break  up  the 
aggregates to small monomers or trimers, which have demonstrated “virtually absent”  
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infectivity (Gale 2007, Silveira et al. 2005). Alternatively, the alkaline cleaner could be 
denaturing the prion proteins but not removing them. The only correlation that was 
observed  with  the  cleaning  chemistries  was  that  cleaners  with  the  highest  pH;  like 
Hamo  100  and  NaOH  demonstrate  the  greatest  reductions  in  infectivity.  Again  no 
correlation was observed for the lipid staining and infectivity. The pixels of the lipid 
stain may not really give us an idea of the mass of remaining lipid as the process of 
producing  a  stained  lipid  standard  to  compare  the  pixel  numbers  to  mass  was  not 
achieved within this study. Furthermore, the types of lipid that Nile red binds to is fairly 
unknown. However, it has been documented that Nile red binds to intercellular lipid 
droplets,  whereas  the  lipids  associated  with  PrP  are  more  likely  to  be  membrane 
phospholipids or sphingolipids (Gale 2007, Greenspan et al. 1985). 
 
This chapter demonstrated the sensitivity of the N2a/22L SB/ThT assay for the 
in situ detection of prion infectivity post decontamination. This assay could now be 
utilised  to  analyse  various  other  cleaning  chemistries  and  novel  decontamination 
protocols. Furthermore, the decontamination parameters discussed in the wet vs. dry 
study  (Secker et al.  2011, Appendix A)  and the novel  DLC surfaces  (Secker et al. 
2012b) could be assessed for remaining infectivity as the original work was carried out 
with SR/ThT which within this report has demonstrated no correlation with remaining 
infectivity. It has previously been reported that wires are not ideal models of surgical 
instruments  as  they  do  not  portray  a  worst  case  scenario;  furthermore,  it  has  been 
demonstrated that larger tokens are more difficult to clean (Lipscomb et al. 2006a). The 
N2a/22L SB/ThT assay could be adapted to determine residual infectivity on different, 
more complex surfaces that would not be possible to test in small rodent brains in the 
animal infectivity bioassays. Cell culture assays could potentially assess the remaining 
infectivity on a whole instrument if grown to a lawn of cells within a large culture tray. 
Furthermore, the N2a/22L SB/ThT assay could be adapted to assess prion infectivity 
within blood products by incorporating previously reported magnetic beads for prion 
capture  that  could  then  be  introduced  to  the  cells  and  subsequently  initiate  prion 
propagation (Miller and Supattapone 2011). The most important adaptation of this assay 
would be replacing the N2a cells with different cells that are susceptible to different 
prion  strains  without  the  need  of  transfection  and  ultimately  cell  lines  for  the 
amplification and detection of CJD infectivity.  
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Consequently,  the  final  research  chapter  of  this  report  began  to  adapt  the 
N2a/22L  SB/ThT  assay  for  the  use  of  NSC’s  as  opposed  to  the  N2a  cells.  This  is 
because, once differentiated, the high levels of PrP
c expressed on neurons negate the 
need for transfection to artificially increase PrP
c levels. This makes the NSC’s a more 
representative and relevant model to wild-type prion infections as the amplification is 
induced by the endogenous PrP
c. However, it was observed that an increase in cells 
undergoing apoptosis at the point of differentiation hindered the SB/ThT staining and 
thus reduced the potential of these cells, in the first instance, to be used in an infectivity 
assay without addressing the culture conditions.  
 
It was observed during this work that two main conditions were affecting the 
quality of the NSC’s within culture. Firstly, sub-optimal oxygen concentrations were 
being used and secondly, it was noted that there was a lack of trophic support at the 
point of differentiation. The culture of NSC’s at 8% O2 doubled the rate of proliferation 
of the undifferentiated NSC progenitor cells without changing the levels of spontaneous 
differentiation when compared to the cells grown at normoxia. Furthermore, the cells 
cultured in 8% O2 differentiated into a higher percentage of neurons than astrocytes 
when compared to the cells cultured at normoxia. This is likely to further increase the 
cells susceptibility to prion infection because neuronal cells naturally express increased 
levels of PrP
c. The 8% O2 cultured NSC’s supplemented with FBS also demonstrated 
around half the number of dead cells when compared to the normoxia cultured cells. 
FBS  supplementation  also  increased  the  percentage  of  neurons  in  culture  when 
compared to the bFGF supplemented cells and those with no supplementation at all. The 
improvements observed in this chapter can be easily explained as the lower oxygen 
concentrations used closer mimic the “in vivo normoxia” of the lower oxygen levels 
observed in the cortical region where the NSC’s are derived from. The improved culture 
in this environment is likely caused by a lower level of ROS build up associated with 
the mild hypoxic conditions, therefore decreasing the cell death usually associated with 
increased ROS levels (Galli et al. 2003, Ivanovic 2009, Niidome et al. 2006). The FBS 
supplementation most likely improves the cultures by replacing the lost nutrients from 
the  point  of  differentiation  and  therefore  lowering  the  levels  of  trophic  support 
deprivation (Niidome et al. 2006). However, it is difficult to pinpoint what in the FBS is 
aiding the cell culture as there is an amalgamation of growth factors present in FBS that 
varies from batch to batch (Even et al. 2006). This chapter highlighted the importance of  
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optimising cell culture conditions and not always relying on standard procedures. This 
also demonstrated that an understanding of the in vivo physiological conditions that cell 
types  are  derived  from  is  crucial  and  should  be  translated  into  the  in  vitro  culture 
conditions. Not only will this affect the quality of culture it will also affect many of the 
in  vivo  processes  and  actions  of  these  cells;  for  example,  the  levels  of  ROS  or 
complement molecules that would affect the comparability of in vitro models in relation 
to in vivo results.  
   
Future work with the NSC’s in the new culture conditions will now look to 
develop them for the analysis of prion infectivity using the SB/ThT analysis system 
with  22L  infection  without  the  hindrances  associated  with  the  original  culture 
conditions. Once established, the infectivity of various prion strains will then be tested 
within  the  NSC’s  to  determine  which  prion  strains  the  NSC’s  are  susceptible  to. 
Furthermore, the SB/ThT analysis will be incorporated into different cell lines that have 
or  could  demonstrate  susceptibility  to  CJD  infection;  such  as  SH-SY5Y  human 
neuroblastoma or GT-1 hypothalamic cells (Ladogana et al. 1995, Oesch et al. 1985). 
This would allow the production of a sensitive, in situ method for the detection of CJD 
infectivity before and after decontamination treatment.  
 
Although the current levels of iCJD and vCJD are in decline there is still a 
potential  threat  of  a  further  outbreak  of  vCJD  leading  to  an  increase  in  iCJD.  The 
number of asymptomatic carriers is currently unknown. However, it can be estimated by 
the  most  recent  appendices  studies  that  the  number  of  carriers  is  around  1/2000. 
Furthermore, the effect of genetic background on disease progression is still questioned 
but  it  has  been  demonstrated  in  humanised  mice  that  MV  heterozygous  and  VV 
homozygous  polymorphisms on codon 129 of the PRNP  gene lead to  far increased 
incubation periods prior to disease progression. Moreover, the risk of prion transmission 
to  humans  from  other  prion  diseases  such  as  CWD  has  not  yet  been  confirmed. 
Therefore, with the potential of the increased numbers of asymptomatic carriers with 
potentially prolonged disease progression and the increased risk of iCJD from surgical 
procedures  and  blood  transfusions;  the  importance  of  addressing  decontamination 
protocols with these improved infectivity assays is crucial to negate the potential future 
risks.  Furthermore, due  to  the  generic amyloid  staining of ThT which  is  not  solely  
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specific  to  prion  diseases,  the  SB/ThT  could  also  be  utilised  to  detect  amyloid 
accumulation  within  Alzheimer's  disease  if  the  suggested  transmissibility  of  AD  is 
confirmed (Kane et al. 2000, Morales et al. 2011, Rosen et al. 2012). The potential 
impact  of transmissible  AD on public health would  be huge so  any assay  with  the 
potential to detect AD transmission and analyse decontamination protocols would be of 
great benefit.         
     
In final summary, this report has introduced the N2a/22L SB/ThT as a sensitive 
in situ infectivity assay for the assessment of the prion infectivity remaining on surgical 
surfaces post decontamination. Rather than having a single cell based infectivity assay 
for the detection of prion infectivity, an amalgamation of the SCEPA assay and the 
SB/ThT assay would be most beneficial for a greater understanding of prion infectivity. 
The  SCEPA  assay  would  analyse  the  end-point  infectivity  in  relation  to  PrP
res 
accumulation, whereas the SB/ThT would analyse the kinetics of amyloid build up over 
several passages to demonstrate the delay in amyloid accumulation and furthermore, the 
variations in plaque size observed between different time points and different samples. 
Ultimately the limitations of these two assays would be addressed when both assays are 
utilised in unison. Furthermore the introduction of the SB/ThT to different cell lines 
could produce a sensitive assay for the detection of CJD infectivity from instruments or 
blood samples which would aid in the detection of potential iCJD sources and improve 
decontamination  protocols  to  negate  the  potential  risk  of  a  future  iCJD  or  vCJD 
outbreak.    
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